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Introduction
Chronic inflammatory bowel diseases (IBD) comprising Crohn’s disease (CD) and ulcerative 
colitis (UC) are characterized by chronic relapsing inflammation of the gastrointestinal tract. 
The combined prevalence of CD and UC is estimated at 100 – 200 / 100.000 in developed 
countries. The pathogenesis of IBD is only partially understood but concordance rates in 
twins and siblings suggest that a genetic predisposition, apart from environmental and im-
munological factors, contributes to the pathogenesis of IBD. In the past decade, tremendous 
progress has been achieved in unraveling the genetic etiology of IBD. By conducting genome 
wide scans, several susceptibility loci for IBD have been identified. In 2001 the CARD15 gene 
encoding for the NOD2 protein on chromosome 16 (IBD1) has been found to be strongly asso-
ciated with CD susceptibility.1  NOD2 is part of the innate immune system and is an intracellu-
lar pathogen-associated molecular pattern (PAMP) receptor that recognizes specific bacterial 
membrane components. Two missense mutations (R702W and G908R) and one frameshift 
insertion mutation (L1007fsinsC) in the leucine rich repeat region of the protein are inde-
pendently associated with ileal CD in Caucasian patients. The L1007fsinsC mutation causes 
a truncated protein, suggesting that a defect in bacterial recognition might be involved in 
CD.  The exact mechanism how mutations in CARD15 are involved in IBD susceptibility is still 
only partially understood and studies thus far give conflicting data. Although the discovery 
of CARD15 as a susceptibility gene has not led to clinical consequences, important progress 
and insight in the pathogenesis of IBD has been made. Actually, the discovery of the CARD15 
gene in IBD has been one of the success stories in genetic research in complex genetic dis-
eases and it has helped researchers to focus at signaling pathways of bacterial products in 
both epithelial and immune cells in the gut. Since CD and UC have many different phenotypic 
presentations and genome wide scans detected several linkage regions, IBD is considered a 
polygenic disease. Therefore many additional candidate-gene studies have been performed 
in the last decade. 
CODE Study
For genetic research in complex genetic disorders as IBD it is important to have large ho-
mogenous cohorts of well described patients. In 2001 the CODE study (Chronische Ontsteking 
van de Darm en Erfelijkheid: Chronic Inflammation of the Gut and Inheritance) started in 
the University Medical Center Groningen. DNA has been, and is still being collected to form 
a large cohort of mainly Caucasian patients and family members from the Northern part of 
the Netherlands. Since the immigration rate in the Northern part of the Netherlands has 
been relatively low, this cohort can be considered a founder population. It is therefore suit-
able for genetic research and in particular for haplotype analysis, since it is assumed that the 
present population descends from a limited number of founders that results in evolutionary 
conserved haplotypes. Previously, several association studies have been performed in this 
cohort. For CARD15 the R702W and the 1007fsinsC mutation were independently associated 
with CD and not with UC. For different subsets of CD, association was found for an early age 
of onset, ileal localization, familial occurrence of IBD and penetrating or stricturing disease 
behavior.2  In another study in collaboration with the University Medical Center Nijmegen and 11
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the Erasmus Medical Center Rotterdam association analysis was performed for IBD and Toll 
Like Receptor 4 (TLR4). TLR4 is, like NOD2, part of the innate immune system and is involved 
in NF-κB regulation. Haplotype analysis showed an association of CD and UC with TLR4, but 
in contrast with prior publications, no association could be found for the Asp266Gly and the 
Thr399Ile polymorphisms and IBD.3 Furthermore a candidate gene study was carried out for 
association of IBD and the Multi Drug Resistant 1 (MDR1) Gene, but no association could be 
found with IBD, CD, UC or different subsets of patients. 4
Genotypes vs. Phenotypes
An important aspect in studying IBD genetics is the consequent description of disease phe-
notypes.  Since IBD is considered a multigenic disorder, different genes are probably involved 
in different subsets of phenotypes. It is therefore mandatory to have internationally accepted 
classification systems for IBD. An accepted and frequently used system is the Vienna clas-
sification.5 It includes age of onset, disease localisation and disease behaviour. A number of 
studies, including a study from the CODE cohort has validated this classification. However, 
several considerations have led to an update of the Vienna classification system during an 
expert meeting in Montreal in 2005. The main modifications were the introduction of an 
early age of onset category (< 16 years), the possibility of co-classification of upper gastroin-
testinal involvement and the inclusion of perianal disease as a disease modifier instead of 
being a form of penetrating disease. For the current thesis the original Vienna classification 
has been used. 
Pharmacogenetics
Pharmacogenetics is another research subject in IBD genetics. There has been much interest 
in the pharmacogenetics of azathioprine metabolism. Azathioprine is a purine analogue that 
is frequently used in the treatment of Crohn’s disease but its use is hampered by the frequent 
occurrence of side-effects. Polymorphisms in the thiopurinemethyltransferase (TPMT) gene, 
which metabolizes azathioprine to 6-mercaptopurine and 6-methyl-mercaptopurine, and 
inosine triphosphate pyrophospatase (ITP-ase) deficiency which leads to accumulation of the 
metabolite 6-thio-ITP, have been found to be responsible for a subset of the side-effects of 
azathioprine therapy.  Introduction
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Aims and outline of the thesis
This thesis aims to gain insight in the genetic background of IBD.
The first part of this thesis focuses on specific genetic associations with IBD. Therefore, a 
detailed review of the current literature on IBD-genetics is given in Chapter 2. Since the 
discovery of the association of CARD15 and IBD, many additional genes have been studied. 
Several of these genes are potentially truly associated, but results have been conflicting for 
many of the associations found. Next to specific genetic associations, current research on the 
functional role of mutations in CARD15 in IBD is also reviewed. 
The initial part of the thesis comprises two studies investigating novel candidate genes 
for IBD susceptibility.  In chapter 3 the association between IBD and Interleukin Receptor 
associated Kinase-M (IRAK-M) is studied. IRAK-M is a NF- κB -mediated, negative regulator 
of Toll-like receptor (TLR) signaling and is localized on chromosome 12q14, a susceptibil-
ity locus for IBD. It was hypothesized that a functional mutation in a negative regulator 
of TLR signaling might induce impaired endotoxin tolerance and increased inflammatory 
responses. Therefore IRAK-M is a good candidate gene for association analysis with IBD. 542 
patients with IBD (309 CD and 233 UC) and 305 controls were studied. Phenotypic details 
of all CD patients according to the Vienna classification were available. UC patients were 
phenotyped according to an accepted classification including extend of the disease, age 
of onset, need for colectomy, extraintestinal manifestations and the occurrence of malig-
nancy. Two single nucleotide polymorphisms (SNPs) and six microsattelite markers were 
evaluated by association analysis and Haplotype Sharing Statistics. Results were stratified 
for CARD15 mutations R702W, G908R and 1007fsinsC.  
In Chapter 4 the genetic association between RUNX3 and IBD is studied. RUNX3 is a mem-
ber of the runt domain family of transcription factors. It is known that loss of RUNX3 
function is associated with a spontaneous colitis in knockout mice. It is a member of the 
TGF- ß signaling pathway, which is a potent inhibitor of inflammation in IBD. Impaired 
activation of RUNX3 might result in decreased activity of the TGF- ß pathway and decreased 
inhibition of inflammation in IBD.The gene encoding for RUNX3 resides on chromosome 
1p36, which is a susceptibility locus for IBD. Therefore RUNX3 is a good candidate gene for 
susceptibility for IBD.  Four SNPs and four microsattelite markers were studied for RUNX3 
in the CODE cohort.  Furthermore, mutations in SLC22A4 and 5 encoding for the organic 
cation transporters 1 and 2 (OCTN1/2) were found to be associated with CD in previous 
publications and an association was found between polymorphisms in SLC22A4, resulting 
in a disrupted binding site for RUNX in rheumatoid arthritis.6 For that reason, association 
analysis for 6 SNPs in SLC22A4/5 (including the known polymorphisms 207 G→C, 1672 C→
G) and IBD and interaction with RUNX3 was studied. All results were stratified for CARD15 
status. In addition to the genetic association analysis RUNX3 and OCTN1 expression was 
analyzed in colonic and ileal, inflamed and non-inflamed mucosal tissue samples of 30 
IBD patients and 6 controls. 13
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The second part of the thesis comprises three studies aimed at the confirmation of previously 
described genetic associations with IBD and describes specific genotype-phenotype interac-
tions. Next to CARD15, SLC22A4/5 and TLR4, several other genes have been identified to be as-
sociated with IBD susceptibility. Simultaneously with the identification of SLC22A4/5, genetic 
variations in DLG5 (Drosophila Discs Large Homologue 5) on chromosome 10q23 showed as-
sociation with CD.7 DLG5 is important in maintaining epithelial stability and genetic variants 
could result in an impaired intestinal permeability.  Additionally, two recent important stud-
ies identified two novel CD associated genes by performing the first genome wide association 
studies.8 9  An uncommon coding SNP in the gene encoding for the interleukin-23 receptor 
(IL23R) conferred strong protection against CD. It was also shown to be associated with UC in 
non-Jewish patients. The other SNP in the autophagy-related 16-like 1 gene (ATG16L1) was 
shown to be associated with CD.
It is supposed that genetic susceptibility has a more prominent role in the aetiology of early-, 
than of late-onset IBD, since early-onset patients were less exposed to environmental factors 
than late-onset patients. As a result, a higher frequency of IBD associated mutations is ex-
pected. In chapter 5 polymorphisms of CARD15, TLR4, SLC22A4/5 and DLG5 are analyzed in 
a cohort of 103 pediatric onset and 696 adult onset IBD patients and controls. Prevalence of 
mutations in the pediatric cohort was compared with the prevalence in adult-onset IBD and 
controls. Specific genotype-phenotype associations were studied. 
Since it is of pivotal importance that genetic associations are confirmed in independent 
cohorts from different countries, chapter 6 describes a replication study for the two most 
strongly associated SNPs in IL23R and ATG16L1 in our cohort of IBD patients. We were also 
interested in discovering whether these two genes are more generally involved in other com-
mon chronic disorders of the gastrointestinal tract and we therefore included a cohort of 
celiac disease patients from the Netherlands. 
It is not only mandatory that previously found associations are confirmed in independent co-
horts, these cohorts also need to have sufficient power to detect specific genotype-phenotype 
interactions. For SLC22A4/5 and DLG5 there have been conflicting results in the literature, but 
many studies are hampered by small sample size or the lack of adequate uniform phenotypic 
descriptions. As mentioned before, for genetic research in complex genetic disorders as IBD it 
is important to have large homogenous cohorts of well described and uniformly phenotyped 
patients. For that reason a large nationwide collaborative project was initiated. Results are 
described in chapter 7. DNA samples and phenotypic details of IBD patients from seven Uni-
versity Medical Centers in the Netherlands (University Medical Center Groningen; Academic 
Medical Center, Amsterdam; VU University Medical Center, Amsterdam; Leiden University 
Medical Center; Radboud University Nijmegen Medical Center; Erasmus Medical Center, Rot-
terdam and the University Medical Center Utrecht ) were collected. 2937 patients (1696 CD, 
1099 UC and 142 with indeterminate colitis) and 1484 healthy controls were included. Phe-
notypic details were available for 2090 patients (1315 CD / 775 UC).  We performed an associa-
tion analysis for DLG5, SLC22A4/5 and ATG16L1 with IBD, CD, UC en different subsets of CD and 
UC. Interaction between these genes was studied.Introduction
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The last part of the thesis focuses on azathioprine toxicity. In daily clinical practice it was 
noted that azathioprine toxicity occurred more often in IBD compared to other diseases for 
which azathioprine is frequently used. Particularly azathioprine induced pancreatitis had 
been rarely observed in other diseases than Crohn’s disease in clinical practice as well as in 
the literature. To investigate this clinical observation, a retrospective case-note review has 
been performed analyzing azathioprine toxicity and necessity of withdrawal in 1564 patients 
with a liver or renal transplantation, systemic lupus erythematosus, Wegener’s granuloma-
tosis, autoimmune hepatitis, rheumatoid arthritis ulcerative colitis or Crohn’s disease. Aza-
thioprine use and toxicity in the University Medical Center Groningen were also compared to 
the use in IBD patients in a large community hospital (Martini Hospital Groningen).  Results 
are described in chapter 8. The fact that azathioprine induced acute pancreatitis was more 
prevalent in Crohn’s disease compared to other diseases, led to the exploration of an associa-
tion of azathioprine induced pancreatitis and circulating pancreatic antibodies, which are 
highly specific for CD compared to UC and other autoimmune diseases. 
Finally the results of the studies in this thesis are summarized and future perspectives for 
genetic research in IBD are given in chapter 9. 15
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Abstract
Tremendous progress has been achieved in unraveling the genetic etiology of inflammatory 
bowel diseases (IBD) comprising ulcerative colitis (UC) and Crohn’s disease (CD). It has led to 
the discovery of mutations in NOD2/CARD15 associated with ileal CD. It is only partially un-
derstood how mutations in NOD2/CARD15 lead to CD. Mouse models, in vitro data and stud-
ies in humans offer conflicting data whether there is a loss or gain of function of NOD2 in CD. 
Through the conductance of genome wide scans and hypothesis driven candidate gene stud-
ies several additional genes have been identified. Only few of these genes are currently being 
recognized as potential disease causing or disease modifying genes. Promising candidate 
genes include Toll like receptor 4 (TLR4), Multi Drug Resistance 1 (MDR1), NOD1 (CARD4), HLA 
DRB1*103, DLG5 as well as the IBD5 locus including members of the organic cation trans-
porter cluster 1 and 2. For future genetic research accurate phenotyping of patients is very 
important and large population based cohorts are needed. Although genetic research has 
not yet led to better prediction of the disease course, development of malignancy or patient 
selection for medical therapy, remarkable progress has been made in the understanding of 
the pathogenesis of IBD. Eventually, genetic research may be able to classify different disease 
phenotypes on a more detailed molecular basis and may provide important contributions in 
the development of new therapeutic approaches. 2
19
Introduction
In the past decade, tremendous progress has been achieved in unraveling the genetic eti-
ology of inflammatory bowel diseases (IBD) comprising ulcerative colitis (UC) and Crohn’s 
disease (CD). By conducting genome linkage studies, several susceptibility loci for IBD have 
been identified termed IBD1 to IBD7 (figure 1).1-12 Through fine mapping of these susceptibil-
ity loci as well as by hypothesis driven candidate gene studies, the CARD15 gene encoding 
for the NOD2 protein on IBD1 has been found to be strongly related to CD susceptibility.13 14   
Since IBD is considered a multigenic disorder, many other candidate genes have been studied 
in addition to CARD15. None of these genes has been as consistently replicated as CARD15 
and probably other disease susceptibility genes will not be discovered as straightforward 
as CARD15, due to low penetrance and complex gene-gene and gene-environment interac-
tion. Promissing candidate genes include Toll like receptor 4 (TLR4), Multi Drug Resistance 1 
(MDR1), NOD1 (CARD4), HLA DRB1*103, DLG5 as well as the IBD5 locus including members of 
the organic cation transporter cluster 1 and 2.15-21
Figure 1
Inflammatory Bowel Diseases (IBD) associated genes and susceptibility loci for IBD on the human 
genome, termed IBD1 to IBD7.
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In addition to the search for new IBD susceptibility genes, one of the main research themes 
in IBD focuses on the function of NOD2 in CD. Although many questions have been answered, 
it still remains unknown whether there is loss or gain of protein function in patients carrying 
mutated NOD2.22 
We will summarize current topics in IBD genetics, focussing on NOD2 functionality and novel 
candidate genes.
Innate immunity
Since the discovery of NOD2 in CD susceptibility, the innate immune system has been studied 
extensively. Current research, regarding the innate immune system in IBD, is focussing on 
NOD2 functionality and new candidate genes for IBD susceptibility.
Function of  NOD2
NOD2 is composed of two N-terminal caspase recruitment domains (CARDs), a nucleotide 
binding and oligomerisation domain and ten C-terminal leucine rich repeats (LRRs) (figure 2). 
It is mainly expressed in macrophages, neutrophils and dendritic cells as well as in intraepi-
thelial Paneth cells that are located in the crypts of Lieberkühn in the ileum.23 24 NOD2 is part 
of the innate immune system and is a pathogen associated molecular pattern (PAMP) recep-
tor that recognizes muramyl dipeptide (MDP) which is a part of bacterial peptidoglycanes. 
The three variants associated with IBD are all located in the LRR region which is the binding 
site for MDP. They consist of two missense mutations (R702W and G908R) and one frameshift 
insertion mutation (L1007fsinsC).25 26 The L1007fsinsC mutation causes a truncated protein, 
suggesting that a defect in bacterial recognition might be involved in CD. Interestingly, a muta-
tion in NOD2 located in the central nucleotide binding domain instead of the LRR region is 
associated with Blau’s syndrome, a rare autosomal dominant disorder with granulomatous 
arthritis, uveitis and skin rash, implying different pathological pathways.27 CD is characterized 
by an increased activity of NF-κB and NOD2 has been shown to have a role in the activation 
of NF-κB. However, the precise mechanism, how mutations in NOD2 and subsequently activa-
tion of NF-κB leads to susceptibility of IBD is still only partially understood.28 Studies in NOD2 
deficient mice have given contradictory results and one seemingly simple question whether 
there is loss or gain of function in CD associated NOD2 variants remains to be answered.29-31
In a recent study with insertion of mutated NOD2 alleles in mice, Maeda et al. showed that 
mutant mice had increased activation of the NF- κB pathway, increased secretion of IL-1β 
and were more susceptible to bacteria-mediated experimental colitis, suggesting a gain of 
function.29 On the other hand, a study by Watanabe and co-workers showed that NOD2 func-
tions as a negative regulator of TLR2-mediated T helper type 1 response. NOD2 deficient mice 
showed increased TLR2-driven activation of NF- κB, particularly of the NF- κB subunit c-Re1, 
whereas intact NOD2 signaling inhibited TLR2-driven activation of NF- κB.30 In an additional 
study, NOD2 deficient mice had decreased expression in intestinal Panethcells of cryptdins, 
which are mouse homologues of human α-defensins.These α-defensins are important mem-2
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bers of the innate immune system. NOD2 deficient mice were susceptible to bacterial infec-
tion via the oral route but not through intravenous or intraperitoneal exposure, suggesting 
an important role for NOD2 as a regulator of bacterial immunity in the intestine.31 Indeed, re-
duced expression of α-defensins is observed in Paneth cells in subjects with CD, which is even 
more pronounced in patients with NOD2 mutations.32 33 Loss of function of NOD2 may lead to 
enhanced mucosal invasion of bacteria resulting in an increased inflammatory response. 
Still, mouse models, in vitro data and studies in humans offer conflicting data and many 
additional studies are currently being undertaken to give an answer to the question how 
mutations in the LRR region of NOD2 lead to CD. 
NOD1 and Toll Like Receptors
Since the identification of NOD2 in CD susceptibility, many further candidate gene studies 
were performed in genes involved in the innate immunity. The most promising results, al-
though data have been conflicting and not solidly reproduced, suggest an association of 
NOD1/CARD4 and TLR4 with IBD.15 17
NOD1 is expressed in the epithelium of the small and large intestine and is fairly similar to 
NOD2, but differs by the presence of only one CARD. Its LRR functions as a pattern recognition 
receptor for diaminopimelic acid present in gram-negative bacterial peptidoglycans. Activa-
tion of NOD1 activates NF- κB and enhances apoptosis.34
In addition, the gene encoding for NOD1 (CARD4) is located on chromosome 7p14, previously 
recognized as an IBD susceptibility locus.10 Though a previous study did not show an associa-
tion with IBD, NOD1 has recently been implied in IBD susceptibility.17 35  McGovern et al. found 
that the deletion allele of a complex functional insertion-deletion polymorphism was associ-
ated with early age of onset IBD and extraintestinal manifestations.17  The same study showed 
that haplotypes in the terminal exons of CARD4 were also significantly associated with IBD. 
Again, these data need further confirmation.
The Toll Like Receptors are important members of the innate immunity. Different TLRs recog-
nize selectively PAMPs of different classes of microorganisms.36 TLR4 recognizes lipopolysac-
Figure 2
Structure of the NOD2 protein with the three variants in the LRR region associated with CD.
Abbreviations: CARDs, caspase activating recruitment domains; NBD, nucleotide binding domain; 
LRR, leucine rich region.
R702W G908R L1007fsinsC
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N CCurrent affairs in IBD genetics 
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charidases which are components of the cellular wall of gram negative bacteria. TLR4 is up-
regulated during intestinal inflammation in macrophages, dendritic cells and epithelial cells 
in IBD.37 Upon binding with LPS it forms a complex with CD14 at the surface of monocytes and 
neutrophils leading to NF- κB activation and the release of inflammatory cytokines.38 39 The 
Asp299Gly mutation is located in the extracellular LRR domain of TLR4 and is associated with 
decreased responsiveness to endotoxins in humans.40  This mutation has been found to be 
associated with CD in two studies and with IBD in one Belgian study.41-43 A second mutation 
Thr399Ile which is in strong LD with Asp299Gly has also been implied with IBD susceptibil-
ity.44 These results have not been confirmed in several other studies.15 45 In a study by our own 
group, association with the TLR4 region was found by haplotype analysis of microsatellite 
markers surrounding the gene but not with Thr399Ile or Asp299Gly.15  This finding implies 
that the Thr399Ile and Asp299Gly polymorphisms could be merely in LD with other disease 
associated variants  in the TLR4 region, instead of being causative themselves.  
A recent study found no genetic association of TLR1, TLR2 and TLR6 with disease susceptibil-
ity but an association between variants of these TLRs and a specific phenotype of extensive 
colonic disease in CD or UC was established.46
The HLA region
The HLA region on the short arm of chromosome 6p (IBD3) was identified as a disease suscep-
tibility locus in several genome wide scans as well as in a recent meta-analysis of 10 genome 
wide scans 4 6 9 12 47 This area harbors a total of 224 highly polymorphic genes, many of which 
appear to have immunoregulatory functions.48 HLA proteins present peptides to T-Cell recep-
tors and are divided in class I and II HLA proteins. The HLA class II proteins play a central 
role in the immune response, are expressed on specialized immune cells and consist of an 
α-chain and a ß-chain that form a groove by which the antigen peptide is presented to the T 
cell receptor.49 The three genes encoding for these α- and ß-chains are HLA-DP, HLA-DQ and 
HLA-DR which are highly polymorphic. HLA class II genes have been extensively studied in 
association studies for IBD.50 
A meta-analysis of data published until 1998 showed a positive association with UC of HLA 
DR2, DR9 and DRB*103 and a protective association with DR4. For CD, HLA-DR7, DRB3*0301 
and DQ4 showed a positive association whereas HLA DR2 and DR4 showed a protective as-
sociation.52 The association with HLA- DRB*103 has been confirmed in European cohorts and 
seems to be associated with extensive disease in UC and in CD with pure colonic involvement. 
HLA- DRB*103 seems to be a potentially important contributor to colonic involvement of 
IBD. However, the rare variant of HLA- DRB*103 has a very low frequency in the general pop-
ulation thereby minimizing its possible clinical value.53 54 Polymorphisms for HLA-DRB1*1502 
which are found in populations with variable ethnic background have been associated with 
UC.57-59 HLA DRB*07 has been consistently replicated in CD patients with ileal localisation. 
Interestingly, patients carrying the risk associated allele for HLA DRB*07 did not carry any of 
the three NOD2 mutations, stressing the fact that there is a great genetic heterogeneity in CD, 2
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even within specific phenotypes such as ileal localisation.55 56  
Tumour Necrosis Factor-α (TNFα) is a proinflammatory cytokine that plays an important role 
in the inflammatory processes involved in IBD.60 61 The importance of TNFα is highlighted 
by clinical efficacy of treatment with anti-TNFα monoclonal antibodies in CD.62 63 TNF poly-
morphisms have been extensively studied in the HLA class III region. Several polymorphisms 
in the promoter region are known, but functional data are lacking and genetic association 
studies have been very inconsistent.64 65 Another interesting finding, although not in the 
HLA region, is the recently found association with the Tumour Necrosis Factor superfamily 
member 15 (TNFSF15) on chromosome 9q33 in a Japanese and a UK cohort. The function 
of TNFSF15 remains to be elucidated but it is involved in NF-κB activation and induction of 
apoptosis.66    67 
In conclusion, several genes in the HLA complex are involved in IBD susceptibility, but results 
of genetic research have been conflicting because of the high density of genes in this region, 
a high degree of LD resulting in highly conserved haplotypes and complex gene-gene interac-
tions with genes outside the HLA region.51
Novel candidate genes
IBD5
A genome wide screen in affected Canadian families identified linkage with a region at chro-
mosome 5q31-q33 (IBD5) with a length of approximately 250 kb conferring susceptibility for 
CD with early age of onset.9 20 This region contains a number of potentially interesting genes, 
including several genes encoding for immunoregulatory cytokines. However, identifying the 
causative gene(s) in the IBD5 locus has been hampered by the high extent of LD in the region. 
Recently, two functionally relevant mutations in the carnitine / organic cation transporter 
(OCTN) genes on the IBD5 locus were shown to be associated with CD.21 The T substitution of 
C1672 in exon 9 of the SLC22A4 gene encoding for OCTN1 and a G to C substitution at position 
-207 in the promoter region of  SLC22A5 gene encoding for OCTN2, were identified. Together 
these polymorphisms form a 2 allele risk haplotype associated with CD susceptibility.  Gene-
gene interaction with mutations in the CARD15 gene is suggested.68 
These results have been replicated in a German population even though the association was 
much weaker than in the original study of Peltekova et al.69 This is in concordance with the 
findings that the IBD5 locus as a whole is less important in European populations compared 
to the original Canadian cohort.70 Other studies did not find an association between OCTN 
polymorphisms and CD, though in one study an increased risk in a subgroup with perianal 
Crohn’s disease has been found.71 72  
Relatively little attention has been given to these genes before, due to the lack of a sensible 
explanation for a role in the pathogenesis of IBD. In the paper by Peltekova et al. preliminary 
functional experiments were performed demonstrating that the two single nucleotide poly-
morphisms (SNPs) impair function of the OCTNs, resulting in reduced carnitine transport, but 
convincing functional data remain scarce.Current affairs in IBD genetics 
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In addition to the lack of solid replication studies and functional data, it is also difficult to un-
derstand how two mutations in two adjacent genes produce IBD susceptibility. It still remains 
to be seen whether the SLC22A4 and SLC22A5 genes encoding for OCTN1 and OCTN2 are the 
causative genes for IBD susceptibility at the IBD5 locus or that they are merely haplotype tag-
ging SNPs in strong linkage disequilibrium with other disease associated genes. Larger popu-
lation based cohorts and functional data are needed to answer this important question.
DLG5
Recently the DLG5 gene (Drosophila Discs Large Homologue 5) has been recognized as a novel 
susceptibility gene for CD and IBD.19 DLG5 is important in maintaining the epithelial structure 
and genetic variants could result in impaired intestinal permeability.73
Stoll et al identified DLG5 by refining their previously defined linkage region on chromosome 
10q23. It is worth mentioning that this region has not been confirmed in other genome wide 
scans. Genetic variants in DLG5 were identified by using a positional cloning strategy. Two 
haplotypes were involved in IBD and CD susceptibility. A SNP 113 G→A, resulting in an ami-
noacid substitution R30Q, was positively associated with IBD and CD patients in a case control 
study. A second haplotype, identified by several other tagging SNPs was protective for IBD. 
Gene-gene interaction with CARD15 in CD was detected by a significant difference in associa-
tion of the 113A variant in patients carrying the risk alleles for CARD15 compared to patients 
not carrying these alleles. Only one published study has been able to reproduce these results. 
74 Initial enthusiasm has been discouraged by several studies from Europe and Japan, failing 
to show any association for DLG5 with IBD. 75-78 In the same way as for OCTN, large population 
based case-control studies are needed to elucidate the role of DLG5 in IBD susceptibility.
MDR1
P- glycoprotein-170 (Pgp170) is encoded by the multi drug resistance gene (MDR1). It was 
initially recognized to be responsible for resistance to cytotoxic drugs in cancer cells. It is an 
ATP binding cassette (ABC) transporter which is highly expressed in the intestinal epithelium. 
There is mounting evidence that Pgp170 is an important factor in host-bacterial interactions 
and in maintaining intestinal homeostasis.79 Mice lacking the MDR1 gene spontaneously de-
velop colitis which is histologically similar to UC.80 In combination with the fact that MDR1 is 
located on chromosome 7q22 which was identified as an IBD susceptibility locus in one UK 
cohort MDR1 appears to be a good candidate gene.10
Two exonic SNPs C3435Tand G2677T/A are involved in altered activity and expression of 
PgP170. Schwab et al. found the T allele and TT genotype of the C3453T SNP to be associated 
with UC and not with CD.16 This association with UC has been confirmed in a Slovenian and 
Scottish cohort and with IBD in a mixed North American population.81-83 This is in contrast 
with two other studies that could not replicate these positive findings.84 85  In a large case-
control study of Dutch patients in our own center, we did not find an association with the 
MDR1 gene and IBD, UC or CD, neither on a single locus and haplotype association analysis 
nor with the haplotype sharing statistics.86 
Although the MDR1 gene holds promise as being involved in IBD susceptibility, there is doubt 
whether the previously found associations are true positive results.2
25
Conclusions and future perspectives
Research in the genetic background of IBD is a rapidly evolving field and has helped un-
ravelling pathophysiological processes involved in complex multifactorial diseases as IBD. 
Important progress and insight in the pathogenesis of IBD has been made by the discovery of 
NOD2/CARD15. In fact, the discovery of the CARD15 gene in IBD has been one of the success 
stories in genetic research in complex genetic diseases. The exact mechanism how NOD2 is 
involved in IBD susceptibility is unknown to date, but genetic research has helped us to focus 
research at signaling of bacterial products in both epithelial and immune cells in the gut. 
Furthermore, numerous candidate gene studies have been performed which has resulted in 
several positive and negative associations for IBD. Many of these studies are hampered by 
small sample sizes and hence the lack of power to detect low penetrant genes or complex 
gene-gene interactions. Only few of the identified genes are currently being recognized as 
potential disease causing or disease modifying genes. To establish true positive associations, 
large population based case-control studies and functional studies are needed in the future. 
It is therefore encouraging that collaboration between centers and countries is initiated in 
IBD genetics. 
In addition to susceptibility for IBD, genetic variations may account for disease expression 
including disease location, clinical behaviour and response to therapy. For that reason, one 
important “current affair” in IBD genetics is the reliable phenotyping of patients. Since the 
successful connection of NOD2 with ileal CD and the increasing number of serological mark-
ers associated with different subsets of IBD, it is recognized that different phenotypes of CD 
or UC patients are characterized by different molecular and serological markers.87 88 For future 
research, it is therefore of utmost importance that patients are accurately phenotyped ac-
cording to a well defined clinical classification scheme. The Vienna classification is frequently 
used for genetic studies in CD and includes age of onset (A), disease localisation (L) and dis-
eases behaviour (B).89 A number of studies have validated this classification; however, several 
considerations have led to an update of the Vienna classification system during an expert 
meeting in Montreal in 2005.90 91 The main modifications were the introduction of an early 
age of onset category (< 16 years), the possibility of co-classification of upper gastrointestinal 
involvement and the inclusion of perianal disease as a disease modifier instead of being a 
form of penetrating disease. The latter is an important modification because it is recognized 
that there is no clear association between perianal disease and intra-abdominal penetrating 
disease.92 The aim of rigorous phenotyping is to include serological and genetic markers into 
the clinical classification system to stratify patients and eventually to predict disease course 
and response to medical therapy. 
Although genetic research has not yet led to better prediction of the disease course, devel-
opment of malignancy or patient selection for medical therapy, remarkable progress has 
been made in the understanding of the pathogenesis of IBD. Genetic research holds a strong 
promise for the future of IBD research. Eventually, genetic research may be able to classify 
different disease phenotypes on a more detailed molecular basis and may provide important 
contributions in the development of new therapeutic approaches. Current affairs in IBD genetics 
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Abstract
Background: Inflammatory bowel diseases (IBD) have a complex genetic background. The 
Interleukin Receptor associated Kinase-M (IRAK-M) is a NF- κB -mediated, negative regula-
tor of Toll-like receptor (TLR) signaling. A functional mutation in a negative regulator might 
induce impaired endotoxin tolerance and increased inflammatory responses. IRAK-M is situ-
ated on chromosome 12q14, a susceptibility locus for IBD, what makes it a good candidate 
gene. We analyzed a large cohort of IBD patients for the association of IBD with IRAK-M.
Methods: 542 patients with IBD (309  Crohn’s disease (CD), 233  Ulcerative Colitis (UC)) and 
305 controls were studied. Two single nucleotide polymorphisms (V147I and V270I) and six 
microsatellite markers were evaluated by association analysis and the Haplotype Sharing 
Statistic. Results were stratified for CARD15 mutations R702W, G908R and 1007fsinsC.
Results: No significant differences in IRAK-M allele frequencies were observed between IBD, 
UC, CD or subgroups of CD or UC and controls. Five of 36 UC patients (13.9%) with an IBD 
associated CARD15 mutation were carrier versus 2/167(1.2%) in non-carriers (OR13.1, 95%CI 
1.0-164.5). No interaction was observed for CD.
Conclusion: No evidence was found for an association between IBD, CD, UC or subsets of 
CD and UC and IRAK-M. However, interaction was found between IRAK-M and CARD15 in UC 
patients. In CARD15 mutant patients the production of IRAK-M upon stimulation might be 
impaired. Further studies are needed to test if an impaired negative regulation of the TLR-
signaling pathway might be partly responsible for the development of IBD.3
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Introduction
Crohn’s disease (CD) and ulcerative colitis (UC) are the major forms of chronic inflamma-
tory bowel diseases (IBD) and are characterized by chronic relapsing inflammation of the 
gastrointestinal tract. The combined prevalence of CD and UC is estimated at 100 – 200 / 
100.000 in developed countries.1 2
Concordance rates in twins and siblings suggest that a genetic predisposition contributes to 
the pathogenesis of IBD.3-5 Inflammatory bowel diseases do not follow a simple Mendelian 
mode of inheritance and the penetrance and expression of IBD is variable.6  Both CD and 
UC are considered complex genetic disorders. Genetic linkage analyses, through genome 
wide screens, have identified a number of susceptibility loci and led to the discovery of 
the association of CD with the caspase activation recruitment domains gene on chromo-
some 16q.7-9
The main factor in the pathogenesis of IBD is a dysregulated immune response to intralu-
minal antigens. CARD15 is an intracellular component of the innate immune system and 
is involved in the recognition of microbial products consisting of pathogen-associated mo-
lecular patterns (PAMPs) and activation of Nuclear Factor kappa B (NF- κB). Besides statis-
tical evidence of a genetic association with IBD, CARD15 has also been shown to have a 
functional role in activating NF- κB.10 The precise mechanism how functional mutations in 
the NOD2/CARD15 gene and subsequently an impaired activation of NF- κB leads to suscep-
tibility of IBD is still only partially understood. 
Toll-like receptors (TLRs) are, like CARD15, important components of the innate immune 
system. TLRs have extracellular leucine-rich-repeat domains that recognize PAMPs and acti-
vate adaptive immunity.11 Chronic repeated stimulation of TLRs by PAMPs causes an “endo-
toxin tolerance”.12 This process involves of different mechanisms, including TLR4 downregu-
lation and decreased NF- κB activation.13-15 The interleukin-receptor associated kinase-M 
(IRAK-M, IRAK-3) is a NF- κB dependent, negative regulator of Toll-like receptor signaling 
pathway. Genetically engineered IRAK-M knockout mice have an impaired endotoxin toler-
ance and showed increased inflammatory responses to bacterial infection.16 17 The gene 
coding for IRAK-M is on chromosome 12q14.2, and co-localizes with a susceptibility locus 
for IBD (IBD2), that was identified by a two-stage genome-wide search for inflammatory 
bowel diseases.18 
The function of IRAK-M as a negative regulator of TLR signaling, inducing an impaired 
endotoxin tolerance and an inflammatory response, in combination with it’s localization 
at the IBD2 locus makes IRAK-M a good candidate gene for susceptibility for inflammatory 
bowel disease. Therefore, we studied the association of IRAK-M with IBD and with specific 
UC and CD phenotypes and the interaction with CARD15 in a cohort of patients from the 
northern part of the Netherlands. IRAK-M and IBD
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Methods
Patients and controls
Patients were recruited from the outpatient department of the University Medical Center Gro-
ningen, the Netherlands. Patients fulfilling diagnostic criteria for CD an UC were eligible for 
the study. These criteria are based on accepted clinical, endoscopic, radiological and histo-
logical findings.19 For CD patients, phenotypic details were obtained according to the Vienna 
Classification.20 For UC patients, phenotypes were described according to age of onset, extend 
of disease (proctitis, leftsided, or extended), necessity of colectomy and the occurrence of ma-
lignancy and extraintestinal manifestations. Duration of follow up was defined as the interval 
between diagnosis and the moment of case note review. The Medical Ethics Committees of 
the University Medical Center Groningen approved of the study. Written informed consent 
was obtained from all participating subjects. All DNA samples and data in this study were 
handled anonymously and individuals were aware that they would not be informed about 
individual test results. When DNA of parents was available the non-transmitted haplotypes 
of each parent were used as a control. When DNA of a child and a spouse was available, both 
haplotypes of the spouse were regarded as a control. In case of missing data, all available 
family members (i.e. parents, sibs or children of the patients) were used to reconstruct the 
missing data.
Genotyping and SNP selection
DNA was extracted from 20 ml EDTA-blood following standard procedures and was stored 
at -80 oC. Two known single nucleotide polymorphisms (SNP) and six microsatellite mark-
ers in and around the gene encoding for IRAK-M were genotyped. One SNP in exon 5, V147I   
(rs1152888) and a SNP in exon 8, V270I (rs11465972) were studied. One microsattelite marker 
was the known D12S288, located 27 kb downstream of IRAK-M. The other five microsatellite 
loci were found on the genomic sequence segment comprising the IRAK-M gene, with a mar-
gin of 40 kb downstream and upstream, and downloaded from the NCBI’s public database. 
Marker details are given in Table 1.  For CARD15 the three known mutations R702W, G908R, 
and 1007fsinsC were evaluated. 
Primers to amplify the polymorphic loci were selected using on-line Primer3 software.21 SNP 
genotyping was carried out by using TaqMan PCR primer/probe sets, designed through Ap-
plied Biosystems’ Assay by Design service (http://myscience.appliedbiosystems.com/, Foster 
City, USA). SNP assay reactions were performed in 5 μl volumes and contained 25 ng DNA, 
1x TaqMan Universal PCR Master Mix (Applied Biosystems), 100 nM of each primer and 900 
nM of each probe. Cycling conditions on the ABI prism 7900 HT (Applied Biosystems) were 2 
minutes 50°C, 10 minutes 95°C followed by 40 cycles of 15 seconds 92°C and 1 minute 60°C. 
End-point fluorescence was measured immediately after cycling. Alleles were assigned using 
SDS 2.0 software (Applied Biosystems). 
For each microsatellite marker polymerase chain reaction (PCR), 0.5 units Taq DNA polymer-
ase (Amersham Pharmacia Biotech, Uppsala, Sweden) was used to amplify the fragments. 
Reaction mixtures contained 0.2 mM dNTP (Roche Diagnostics, Mannheim, Germany), 2.5 
mM MgCl2, 10 mM Tris-HCl (pH 9.0), 50 mM KCl (Amersham Pharmacia Biotech) and 0.25 μM IRAK-M and IBD
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of each primer (with one primer 5’ labeled with a fluorochrome 6-FAM or HEX (Sigma, Mal-
den, the Netherlands). Cycling was done on a PTC-225 thermal cycler (MJ Research, Waltham, 
MA) and a PrimusHT (MWG Biotech, Ebersberg, Germany). A standard protocol was used for 
amplification. Post PCR multiplexing was performed by combining 2-10 μl (based on signal 
strength) of the PCR products. A 2.3 μl sample of the pooled fragments was mixed with 2.5 μl 
MilliQ and 0.2 μl ET-400R size standard (Amersham Pharmacia Biotech) and separated on a 
MegaBACE 1000 capillary sequencer (Amersham Pharmacia Biotech) according the manufac-
turers protocol. Results were analyzed using Genetic Profiler version 2.0 (Amersham Pharma-
cia Biotech). Scoring of the alleles was blinded for affection status and family structure.
Statistical methods
After genotyping the markers, Hardy-Weinberg equilibrium was tested among the unrelated 
unaffected individuals of the sample and inheritance errors were determined. If a marker 
showed deviation from Hardy-Weinberg equilibrium or the fraction of erroneous inheritance 
exceeded 5%, the marker was discarded from further analyses.
As our sample includes a large cohort of trios, haplotypes could be constructed. The non-
transmitted haplotypes of the parents or the haplotypes of the spouse of the patient served 
as control haplotypes. 
The allele frequencies of patients and controls were compared to test for association us-
ing the chi-square test or the Fisher’s exact test when appropriate. Differences between the 
haplotypes of patients and the control haplotypes were also analyzed by Haplotype Sharing 
Statistics (HSS), which analyses length of haplotype similarity. The validity of this method has 
been demonstrated elsewhere by applying it extensively to simulated data as well as empiri-
cal data.22-27 Haplotype analysis assumes that in genomic regions flanking disease mutations, 
haplotypes of patients will be more similar to each other and more extended than haplotypes 
of controls.
As a test of Linkage Disequilibrium (LD) in order to prove the presence of conserved haplo-
types, the D’ for multi-allelic markers was used.28 The significance of the observed D’ value 
was determined by the fraction of 1,000 randomizations (for which alleles were randomly 
redistributed over the haplotypes independently for all loci) that revealed a larger D’ value 
than the observed one.
A multiple testing correction was performed for the number of complementary subgroups 
of patients using a Bonferroni correction. For allele and genotype associations, all patients 
were included. For the HSS, which require phase to be derived, only those with at least one 
participating family member were used.
Results
A total of 542 patients with IBD (309 with CD and 233 with UC) and 305 controls were in-
cluded. Clinical characteristics of patients with CD and UC were available from 520 patients 
(table 2 and 3). For haplotype analysis 403 trios or duos were available. The percentage of 3
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Table 2. Characteristics of patients with Crohn’s disease.
Total number      309
Sex (m/f)       108 / 201
Age at diagnosis (years)
  Mean (range)      30.9 (6.7 – 73.9)
  Median        27.4
Follow up (years)
  Mean (range)      11.9 (0.4 – 49.4)
  Median        9.0
Disease localization 
  Ileal         80    (25.9%)
  Colon        64     (20.7%)  
  Ileocolon      165    (53.4%)
Disease behavior
  Non-stricturing, non penetrating  100     (32.4%)
  Stricturing      75    (24.3%)
  Penetrating      134     (43.3%)
Perianal        89    (28.8%)
Extraintestinal manifestations    43     (13.9%) 
Family history of IBD      65    (21.0%) 
Table 3. Characteristics of patients with ulcerative colitis.
Total number      233
Sex (m/f)       122 / 111
Age at diagnosis (years)
  Mean (range)      33.0 (20 – 46.0)
  Median        31.4
  Below40       166    (71.2%)
Follow up (years)
  Mean (range)      13.7 (4.9 - 22.5)
  Median        11.9
Disease localization ¶
  Proctitis      16    (6.8%)
  Leftsided      75     (32.2%)  
  Pancolitis      120    (51.5%)
Extra-intestinal manifestations    39    (16.7%) 
Family history of IBD      39    (16.7%) 
History of surgical intervention    50    (21.4%)
¶  Data unavailable for 22 (9,4%) patientsIRAK-M and IBD
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Figure 1. Linkage disequilibrium.
LD across IRAK-M and flanking genomic region. D’ values for LD are shown for each pair of markers. 
The upper line depicts localization of markers across the genomic region. Most markers are in LD.
unknown alleles due to inheritance errors or PCR failure was 2.9%. Most markers were in LD 
(figure 1). SNP V270I in the encoding region for IRAK-M appeared not to be polymorphic in 
our sample; therefore this SNP was not informative for further analysis. All markers proved 
to be in Hardy-Weinberg equilibrium and to show a correct inheritance pattern in more than 
97% of the trios. 
Association analysis and Haplotype Sharing Statistic IRAK-M
No significant differences in the distribution of IRAK-M allele frequencies between the pa-
tients with IBD, CD or UC and controls were observed. Analysis of clinical subgroups of CD 
and UC patients did not reveal any significant differences. SNP V147I had a frequency for 
allele A of 5.6% for controls compared to 5.7% for IBD, 5.6% for CD and 5.9% for UC. A protec-
tive effect of allele 160 at marker F was observed for colonic localization and for stricturing 
behavior in CD. 11.3% of the controls, but only 1.4% of the patients with stricturing behavior 
and 1.7% of the patients with a colonic localization carried allele 160 homozygously. This 
effect did not reach statistical significance (p=0.11 for stricturing disease versus controls and 
p=0.21 for colonic localization versus controls). 
Similar to the association analysis, the HSS revealed no difference in haplotype sharing be-
tween patients and controls for IBD. Analysis of the subgroups with UC and CD and the differ-
ent phenotypes of patients with CD did not show any difference with the HSS either. 
Interaction IRAK-M and CARD15
The prevalence of one of the three risk associated mutations in CARD15 was 27.1% in IBD, 
34,1% in CD, 17.4% in UC and 18.3% in controls. For CD patients no interaction between 3
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CARD15 and IRAK-M was observed. For UC, interaction was observed between microsattelite 
marker C and CARD15 status (Figure 2). Five of 36 UC patients (13.9%) with a CARD15 mutation 
were carrier versus 2/167 (1.2%) not carrying an IBD associated mutation in CARD15. (OR 13.1, 
95% confidence interval 1.0-164.5). 
Discussion
We studied the association of IRAK-M with IBD and with specific CD phenotypes in a large 
cohort of patients from the northern part of the Netherlands. No evidence was found for 
an association between IBD, CD, UC or different subsets of CD and the IRAK-M gene region, 
indicating that mutations in IRAK-M are not involved in IBD susceptibility.
The pathogenesis of inflammatory bowel diseases still remains elusive. Mutations in the en-
coding gene for CARD15 are associated with susceptibility for CD, but how these mutations are 
involved in the pathogenesis of IBD is poorly understood. CARD15 is present in the cytoplasm 
of monocytes and epithelial cells and patients with CARD15 mutations will have less NF- κB 
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Figure 2. Allelic Association of IRAK-M and IBD in CARD15 Carriers.
Association of IRAK-M and IBD, CD and UC, in carriers one of the three IBD associated mutations in 
CARD15 (R702W, G908R, and 1007fsinsC), versus non-carriers. IRAK-M and IBD
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activation upon stimulation with muramyl dipeptides (MDP). On the one hand, this impaired 
NF- κB activation could lead to a defective immune response against luminal bacteria.29  
On the other hand, it is suggested in a recent study that CARD15 functions as a negative 
regulator of TLR 2-mediated T helper type 1 responses.30 CARD15 (-/-) mice showed increased 
TLR 2-driven activation of NF- κB, particularly of the NF- κB subunit c-Re1, whereas intact 
NOD2 signalling inhibited TLR 2-driven activation of NF- κB. This is the first study that shows 
increased NF- κB activation and inflammatory responses in CARD15 knockout mice, rather 
than less activation as shown in earlier models. This could explain why there is an increased 
susceptibility for CD in patients lacking functional CARD15.
IRAK-M is known as a negative regulator of the TLR signaling pathway.16 IRAK-M is probably 
involved in a negative feedback loop, where TLR mediated activation of NF- κB will yield IRAK-
M, which blocks further TLR activation, making the cell less responsive for TLR signaling.31 The 
encoding gene is situated on chromosome 12q14, a region which was previously identified 
as a susceptibility locus (IBD2) for IBD.18  We hypothesized that a mutation of such a negative 
regulator could explain the increased NF- κB activation as seen in CARD15 wildtype and even 
in CARD15 mutant patients. Gene products with these features are good candidate genes for 
susceptibility for IBD. 
We studied a large cohort of IBD patients and family-based controls from the northern part of 
the Netherlands. Two known SNPs and six microsatellite markers spanning the entire IRAK-M 
encoding region were used. We failed to show an association of IRAK-M with IBD or with the 
clinical subsets CD or UC, both at a single locus level as well at a haplotype level. No association 
with different phenotypes in CD or UC was found either. Power analysis showed that an associa-
tion with an odds ratio of >1.75 should have been detected in our study population. Neverthe-
less, due to small size of the different subsets a smaller effect could have been missed. 
No interaction of IRAK-M and CARD15 was observed in CD patients or different subsets of CD pa-
tients. However, carriership of one or more of the three IBD associated mutations in CARD15 in 
combination with microsattelite marker C showed an increased risk for UC compared to patients 
not carrying a CARD15 mutation. Since CARD15 has not been shown to be involved in UC suscep-
tibility before, it remains doubtful whether this is a true association or a false positive result. 
Marker F revealed an interesting protective association for stricturing or colonic disease in 
Crohn’s disease but this was not statistically significant. Marker F is situated 40kb downstream 
of the coding region for IRAK-M in an area coding for LOC390340, a protein similar to phos-
ducin-like 3 with no known function to date. Because of the weak association and the lack of 
a functional explanation, no further investigations were done in this region. 
In conclusion, in this Dutch cohort we could not find an association between IBD and IRAK-M 
at the SNP and haplotype level. We did find an association of IRAK-M and Ulcerative Colitis 
in carriers of a CARD15 mutation compared to non-carriers, however this was based on small 
numbers. The lack of a genetic association does not rule out that in CARD15 mutant patients 
the production of IRAK-M upon MDP stimulation is impaired, resulting in increased TLR signal-
ing. Further studies on the regulation of TLR signaling in CARD15 mutant patients and on the 
role of IRAK-M in IBD are needed to test this hypothesis. A defect in the negative regulation 
of TLR signaling, inducing an impaired endotoxin tolerance and an increased inflammatory 
response might be partly causative in IBD. 3
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The Runt-Related  
Transcription Factor 3 
(RUNX3) is associated with 
ulcerative colitis and shows 
epistasis with Solute Carrier 
Family 22, members 4 and 5 
(SLC22A4/5)
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Abstract
Background: Inflammatory bowel diseases (IBD) –comprising Crohn’s disease(CD) and ulcer-
ative colitis(UC)– are intestinal inflammatory disorders with a complex genetic background. 
Mice deficient for the runt-domain-transcription factor 3 (Runx3) develop spontaneous coli-
tis. Human RUNX3 resides in a susceptibility locus for IBD. We studied the association of 
RUNX3 in a cohort of IBD patients and analyzed the interaction with SLC22A4/5. RUNX3 and 
OCTN1 mRNA expression was assessed in inflamed and non-inflamed mucosa from patients 
and controls.
Methods: 543 IBD patients (309 CD/234 UC) and 296 controls were included. Four Single 
Nucleotide Polymorphisms (SNPs) and four microsatellite markers were studied for RUNX3. 
Five SNPs (including SNP-207G→C and SNP1672C→T) were analyzed for SLC22A4/5. RUNX3 
and OCTN expression in mucosal tissue from 30 patients (14UC/16 CD) and 6 controls was 
determined by Q-PCR.
Results: We demonstrate significant association between RUNX3-SNP rs2236851 and UC (OR 
1.61;CI 1.11-2.32,p=0.020). Carriership is associated with pancolitis (OR 1.86;CI 1.08-3.21). 
SLC22A4/5-SNPs rs272893 and rs273900 are associated with CD (OR 2.16;CI 1.21-3.59 and OR 
2.40;CI 1.43-4.05). We find epistasis for carriership of a risk-associated allele in RUNX3 and 
SLC22A4/5 for UC patients versus CD patients(OR 3.83;CI 1.26-11.67). RUNX3 mRNA expression 
is increased (p<0.05) and OCTN1 expression is decreased (p<0.05) in inflamed colonic mu-
cosa of IBD patients compared to their non-inflamed mucosa and controls.
Conclusions:  We provide the first evidence that RUNX3 is associated with UC and shows 
epistasis with SLC22A4/5. Additionally, we show a correlation between increased RUNX3 and 
decreased OCTN1 expression in inflamed mucosa of IBD patients. 4
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Introduction
Chronic inflammatory bowel diseases (IBD) comprising Crohn’s disease (CD) and ulcerative 
colitis (UC) are characterized by chronic relapsing inflammation of the gastrointestinal tract.1 
The combined prevalence of CD and UC is estimated at 100 – 200 / 100,000 in developed 
countries. Concordance rates in twins and siblings suggest that a genetic predisposition con-
tributes to the pathogenesis of IBD.  The CARD15 gene on chromosome 16 was identified as 
the first susceptibility gene for IBD by performing genome-wide linkage studies. Three mu-
tations (R702W, G908R, and 1007fsinsC) are independently associated with CD in Caucasian 
patients. Since IBD are complex genetic diseases with many different phenotypes, multiple 
genes are likely involved in different subsets of patients.
Functional mutations in Solute Carrier Family 22 members 4 and 5 (SLC22A4 and SLC22A5) 
on chromosome 5q31 (IBD5) encoding for the Organic Cation Transporters 1 and (OCTN1/2) 
have been reported to be associated with CD. The risk haplotype consisting of the mutations 
1672T→C in SLC22A4 and -207G→C in SLC22A5 had a higher frequency among CD patients 
(54%) than among controls (42%).7 8 An epistatic effect of the risk haplotype with the CARD15 
gene was also reported. However, this has not been confirmed in a consecutive study.9 
Besides genome-wide linkage studies, IBD candidate genes can also be selected from gene 
knock-out studies in mice. Disruption of single genes in mice may lead to the development of 
spontaneous colitis or an increased sensitivity to chemically-induced colitis, with similar phe-
notypes as observed for IBD. Mice that lack the Runt-related transcription factor 3 (Runx3) de-
velop such a phenotype.10 RUNX3 forms the runt domain family of transcription factors with 
RUNX1 and RUNX2, which share the same highly conserved runt domain. RUNX3 is involved 
in T-cell differentiation and functions as a tumour suppressor gene in gastric cancer.11 12  It 
is highly expressed in dendritic cells (DCs) where it is involved in the Transforming Growth 
Factor-ß (TGF- ß) signaling pathway. The RUNX proteins appear to have a potential role in 
autoimmune diseases like rheumatoid arthritis, systemic lupus erythematosis and psoriasis 
although very little is known how these transcription factors are involved in these disorders. 
13 The gene encoding for RUNX3 resides on the chromosomal region 1p36, which has been 
found to be a susceptibility locus for IBD.14 15  Moreover, RUNX3 and TGF- ß are downregulated 
in peripheral blood cells of CD patients, which might suggest involvement of this pathway 
in the human pathogenesis of IBD16  In view of these considerations RUNX3 seems a good 
candidate gene for susceptibility for IBD. More specifically, regarding the development of a 
colitis similar to UC in knockout mice, it might be associated with ulcerative colitis.  
Interestingly, a polymorphism in the RUNX binding site in SLC22A4 was linked to rheumatoid 
arthritis.17 Since this binding site is the same for all three members of the RUNX family, inter-
action between SLC22A4/5 and RUNX3 might be involved in IBD susceptibility. 
We studied 543 IBD patients, in most cases participating with family members to form trios, 
for association of RUNX3 and SLC22A4/5 with IBD. Genetic epistasis between the two genes 
and separately with CARD15 was analyzed. In addition, in vitro data on RUNX3 and OCTN 
mRNA expression in normal and inflamed colonic mucosa from patients with IBD are pre-
sented.RUNX3, SLC22A4/5 and IBD
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Methods
Patients and controls
For the genetic association study, a cohort of 543 IBD patients (309 CD and 234 UC) from the 
University Medical Center Groningen was used.18 Diagnosis of IBD was established by accept-
ed clinical, endoscopic and histopathological criteria.1  For 183 (108 CD and 75 UC) patients 
DNA of both parents was also available. Patients with CD were phenotyped using the Vienna 
classification.19 Patients with UC were phenotyped according to disease localization (proctitis, 
leftsided or pancolitis), extraintestinal manifestations, the development of malignancy or the 
need for colectomy. Clinical characteristics of patients with CD and with UC are presented in 
tables 1 and 2 respectively.
Mucosal tissue samples were available for 30 patients with IBD (14 UC and 16 CD) and for 
6 controls referred for endoscopy for analysis of abdominal pain, without endoscopic and 
microscopic abnormalities at colonoscopy. 20 Characteristics of patients and controls  are pre-
sented in table 3. Intestinal mucosal biopsy specimens were obtained, during endoscopy 
from inflamed and non-inflamed areas in the terminal ileum and throughout the colon of 
Table 1. Clinical characteristics of patients with Crohn’s disease included in the genotyping cohort.
  Total number      309
  Sex (m/f)       108 / 201
  Age at diagnosis (years)
  Mean (range)      30.9   (6.7 – 73.9)
  Median      27.4
  Below 40       227   (73.5%)
  Follow up (years)
  Mean (range)      11.9  (0.4 – 49.4)
  Median      9.0
  Disease localization 
  Ileal         80  (25.9%)
  Colon        64   (20.7%)  
  Ileocolon      165  (53.4%)
  Disease behavior
  Non-stricturing, non penetrating  100   (32.4%)
  Stricturing      75  (24.3%)
  Penetrating      134   (43.3%)
  Upper GI tract      24  (7.8%)
  Peri-anal       89  (28.8%)
  Extra-intestinal manifestations    43   (13.9%) 
  Family history of IBD    65  (21.0%) 
  History of surgical intervention   186  (60.2%)4
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Table 2. Clinical characteristics of patients with ulcerative colitis included in the genotyping 
cohort.
  Total number      234
  Sex (m/f)       122 / 112
  Age at diagnosis (years)
  Mean (range)      33.0   (20 – 46.0)
  Median      31.5
  Below 40       167   (71.4%)
  Follow up (years)
  Mean (range)      13.7   (4.9 - 22.5)
  Median      11.9
  Disease localization †
  Proctitis      16  (6.8%)
  Leftsided      76   (32.5%)  
  Pancolitis      120  (51.3%)
  Extra-intestinal manifestations    39  (16.7%) 
  Family history of IBD    39  (16.7%) 
  History of surgical intervention   50  (21.4%)
†  Data unavailable for 22 (9,4%) patients.
Table 3. Clinical characteristics of patients included in the mucosal biopsies cohort.
    Male/Female  Mean Age  Medication 
        (years)    (without / with)     
 
   CD (n=16)        3 / 13    40    7 / 9  Azathioprine (4),    
              Steroids (5), 
              Mesalazine (2).
   UC (n=14)        6 / 8    48    7 / 7  Azathioprine (3),    
              Steroids (3) 
              Mesalazine (7).
   Controls (n=6)               5 / 1    41    6 / 0  None     
 RUNX3, SLC22A4/5 and IBD
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patients with active CD or UC. In controls, biopsies were obtained from the terminal ileum, 
ascending colon, transverse colon, and rectum. The study was approved by the institutional 
ethics review committee and all patients gave informed consent.
Genotyping
DNA was extracted from 20 ml EDTA-blood following standard procedures and was stored at 
-80 oC. Primers to amplify the polymorphic loci were selected using Primer3 software.21 SNP 
genotyping and microsatellite marker polymerase chain reaction (PCR) were performed as 
described previously.18 
No informative Single Nucleotide Polymorphisms (SNPs) were found in the exonic regions 
of RUNX3. Therefore, four SNPs in intronic regions were determined for RUNX3 (rs2236848, 
rs2282719, rs2236851 and rs742230). In addition, four microsatellite loci were found on 
the genomic sequence segment comprising the RUNX3 gene in the NCBI’s public database. 
These microsattelite markers are named RX3-01, RX3-02, RX3-03 and RX3-04 in the present 
study.  For SLC22A4/5 the previously found associated polymorphisms rs2631367 (-207 G→C), 
rs1050152 (1672 C→G), the polymorphism disrupting the RUNX1 binding site rs3792876 as 
well as three additional SNPs (rs272893 rs273900 and rs274551) were analyzed. 16 19  Details of 
Table 4. Marker data for genetic analysis RUNX3 and SLC22A4/5.
Marker Name MS/SNP*  Position Type
RUNX3
RX3-01 MS -75 kb (CA)n FP†:GAGCAAGATCCTGCCACTACA
RP: ATATGCCCTGTTGTCCCTCT
RX3-02 MS -12 kb (CA)n FP: GCCAAGGGCATCACTAGGTA
RP: CAGGGGTCACGAATATCCAG
rs2236848 SNP G→A
rs2282719 SNP T→G
rs2236851 SNP G→A
RX3-03 MS Intra 20kb (TTCA)n FP: ACCAAGCTGAAAATGCCTTG
RP: TCTGGTCCATCAAAGCGAGT
rs742230 SNP C→T
RX3-04 MS +30 kb (CATC)n FP: AATCGTCAGCCCATTCATTC
RP: CATTGCTGCCCCTCACTACT
SLC22A4/5
rs3792876 SNP C→T
rs2728932 SNP C→T
rs1050152 SNP 1672 G→C
rs273900 SNP C→T
rs2631367 SNP -207 G→C
* SNP Single nucleotide polymorphism, MS Microsatellite
† FP Forward Primer; RP Reverse Primer4
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all markers are given in table 4. 
SNP rs274551 in SLC22A4 appeared not to be in Hardy-Weinberg equilibrium and was ex-
cluded from further analysis. The percentage of unknown alleles due to PCR failure or inheri-
tance errors was 1.8% for RUNX3 and 1.6% for SLC22A4/5. Data for the three known mutations 
R702W, G908R, and 1007fsinsC in CARD15 were available from a previous study.22 
RNA Isolation and Quantitative PCR
The collection of mucosal biopsies, isolation of total RNA and conditions for quantitative 
PCR to determine mRNA expression were described before.20 RUNX3 and OCTN1 expression 
was determined using the assay-on-demand kit on the ABI PRISM 7700 (Applied Biosystems, 
Foster City, California, USA). Each sample was analyzed in duplicate. 18S levels were used as 
endogenous control. 
Statistical methods
After genotyping, Hardy-Weinberg equilibrium was tested among the unrelated unaffected 
individuals of the sample and inheritance errors were determined. If a marker showed devia-
tion from Hardy-Weinberg equilibrium or the fraction of erroneous inheritance exceeded 5%, 
the marker was discarded from further analyses. As our sample includes a large number of 
patients and family members, haplotypes could be constructed. For haplotype analysis 403 
trios or duos were available. The non-transmitted haplotypes of the parents or the haplo-
types of the spouse of the patient served as control genotypes.
For the microsatellite markers, allele frequencies in patients and controls were compared 
to test for association using the chi-square test or the Fisher’s exact test when appropriate. 
For SNPs, the genotype frequencies were compared. Frequencies of haplotypes of SNPs were 
estimated by the expectation-maximization (EM)-algorithm and differences between patients 
and controls were analyzed by means of the likelihood ratio test. In trios consisting of the 
patients and both parents (n=183), association was also examined by the Transmission / 
Distortion test (TDT). 
Odds ratios (ORs) and 95% confidence intervals (CI) were estimated using binary logistic re-
gression (SPSS 12). Binary logistic regression was also used to determine gene-gene interac-
tion effects with inclusion of the main effects of each gene in the model. Differences between 
the haplotypes of patients and the control haplotypes were analyzed by Haplotype Sharing 
Statistics (HSS), which analyses length of haplotype similarity. The validity of this method has 
been demonstrated elsewhere. 18 23  
As a test of Linkage Disequilibrium (LD) in order to prove the presence of conserved haplo-
types, the D’ for multi-allelic markers was used. The significance of the observed D’ value was 
determined by the fraction of 10,000 randomizations (for which alleles were randomly redis-
tributed over the haplotypes independently for all loci) that revealed a larger D’ value than 
the observed one. A multiple testing correction was performed for the number of subgroups 
of patients using a Bonferroni correction. This applies not only to the p-values but also to the 
confidence intervals of the OR. For allele, genotype and haplotype associations, all patients 
were included. For the HSS, which require phase to be derived, only those with at least one 
participating family member were used.RUNX3, SLC22A4/5 and IBD
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Results
Association of  RUNX3 and IBD
SNP rs2236851 in RUNX3 was significantly associated with UC (p=0.020, OR 1.61 CI 1.11-2.32). 
The T-allele was present in 40.2% of the UC patients compared to 33.8% of  CD patients and 
in 29.5 % of the controls. This association was confirmed by the TDT (allele T was 34 times 
transmitted and 14 times not transmitted, p=0.004) and HSS (p=0.012). (Fig 1.) Carriership 
of rs2236851 in UC was associated with pancolitis (OR 1.86 CI 1.08-3.21) and a tendency to 
association with an early age of onset (OR 1.59 (CI 0.98-2.57)).
For microsatellite marker RX-02, an association was found for colonic localization of CD 
(p=0.022). For the microsattelite marker RX3-01 an association with IBD was found (p=0.045). 
This association seemed to be stronger in CD (p=0.051) than in UC (p=0.17). With respect to 
subgroups of CD, RX3-01 was associated with an early age of onset (p=0.039) and ileocolonic 
localization (p=0.026).  
All markers for RUNX3, except for all pairs with intra-genic marker RX3-03 and the pairs 
RX3-02 with rs2236851 and rs2236848 with RX3-04, were in LD with each other. For all other 
combinations, the p-value of the observed values of D’ obtained by randomization were 
smaller than 0.05 and for the SNP combinations even smaller than 0.003, implying strong 
LD within the gene. 
Association of  SLC22A4/5 and IBD
Results of the association analysis for SLC22A4/5 are shown in figure 2. SNPs rs272893 and 
rs273900 were significantly associated with CD (p=0.008 and 0.004 respectively) but not with 
UC. For homozygotes the ORs for CD of were 2.16 (1.21-3.59) for rs272893 and 2.40 (1.43-
4.05) for rs273900 compared to controls. Heterozygotes were not at increased risk. Both SNPs 
were associated with an age of onset >40 yrs (p=0.0016/0.0007), ileocolonic localization 
(p=0.006/0.002), upper GI tract localization (p=0.007/0.003), non-stricturing non-penetrating 
behavior (p=0.020/0.011), and extra-intestinal manifestations (p=0.001 and <0.001). These 
SNPs are almost in complete LD with each other (r2=0.97). The TDT revealed no significant 
distortion to UC patients or to CD patients in general for either SNP (Figure 2). Haplotype as-
sociation analysis supported the results found by single locus association, but did not show 
higher levels of significance. 
We did not find any association for SNP rs2631367 (-207 G→C) and SNP rs1050152 (L503F) 
with UC, CD or subgroups of CD. The previously described risk haplotype TC was observed in 
our population in 41.1% of CD patients, 45.9% of UC patients and 44.4% of controls. 
All SNPs in SLC22A4/5 were in strong LD with each other. For all combinations of SNPs, the 
p-value of the observed values of D’ obtained by randomization were smaller than 0.001. 
Interaction of  SLC22A4/5, RUNX3 and CARD15.
Among patients with homozygosity for one or both associated SNPs rs272893 or rs273900 in 
SLC22A4, 14 out of 25 UC patients (56%) were carriers of rs2236851 in RUNX3 compared to 14 
out of 51 (27.5%) of CD patients and 8 out of 26 (30.8%) of controls. Binary logistic regression 
analysis revealed an OR of 3.83 for UC patients versus CD patients to carry the combination 4
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Figure 1.
Genetic association of RUNX3 and 
IBD,  CD  and  UC  of  543  patients 
(309  CD,  234  UC)  compared  to 
healthy  controls.  SNP  rs2236851 
is associated with UC (OR 1.61 CI 
1.11-2.32)  but  not  with  CD  (1A). 
This  association  was  confirmed  by 
TDT (1B) and haplotype sharing sta-
tistics (1C).
A
B
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Figure 3. 
Expression  of  RUNX3  (A)  and 
OCTN1 (B) mRNA quantified by real 
time RT-PCR. RUNX3 expression is 
evenly distributed throughout the co-
lon and the ileum. OCTN1 expression 
is increased in the ileum compared to 
the  colon  (p<0.00001).  Total  RNA 
was  isolated  from  biopsies  from  co-
lonic and ileal tissue from 6 controls. 
Relative expression levels (∆Ct) were 
normalized to 18S.Data are expressed 
as means ± SD.
Abbreviations: Asc -Ascending colon;
Trans - Transverse colon
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Figure 2. 
Genetic  association  of  Slc22a4/5  and 
IBD,  CD  and  UC  of  543  patients  (309 
CD,  234  UC)  compared  to  healthy  con-
trols. SNPs rs272893 and rs273900 were 
associated with CD (OR 2.16 (1.21-3.59) 
and 2.40 (1.43-4.05)) on allelic association 
analysis.SNPs rs1050152 (1672C→T) and 
rs26313667 (-207G →C) were not associ-
ated with IBD, CD or UC.
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of homozygosity for allele A at rs272893 and/or allele T at rs273900 (i.e. risk factor for CD) and 
carriership of allele T at rs2236851 (i.e. risk factor for UC) (p=0.018, CI 1.26-11.67) (Table 5). 
No difference was observed between IBD patients and controls (OR=1.05 (CI 0.38-2.86)). 
No significant interaction was found for the associated SNP rs2236851 in RUNX3 and SNP 
rs3792876 which disrupts the RUNX binding site in SLC22A4. No evidence for epistasis of 
CARD15 with SLC22A4/5 or for CARD15 with RUNX3 was found in IBD, UC or CD or in subsets 
of UC or CD patients.
RUNX3 and OCTN1 mRNA expression in inflamed and non-inflamed intestinal 
mucosa 
RUNX3 and OCTN1 mRNA expression in the colon and ileum of healthy controls is presented 
in figure 3a and 3b respectively. RUNX3 mRNA expression is evenly distributed throughout 
the colon and the ileum. OCTN1 expression is higher in the ileum compared to the colon 
(p<0.00001), while the expression level is constant throughout the colon. 
Expression levels of RUNX3 mRNA in inflamed colonic mucosa of CD and UC patients were 
increased compared to controls (Figure 4). This difference was not observed in inflamed ileal 
mucosa in CD patients compared to controls. RUNX3 expression levels are increased in in-
flamed colonic mucosa compared to non-inflamed colonic mucosa in UC patients (p=0.01). 
OCTN1 expression is decreased in inflamed colonic mucosa compared to non-inflamed co-
lonic mucosa (p=0.08) (figure 4a and 4b). In CD, RUNX3 is upregulated in inflamed intesti-
nal mucosa (ileal and colonic localization combined) compared to non-inflamed mucosa 
(p=0.04) and OCTN1 down regulated (p=0.008). 
Table 5. Output of the binary logistic regression analysis for interaction of RUNX3 and SLC22A4/5 in 
Ulcerative Colitis (UC) versus Crohn’s Disease (CD), showing an increased risk for UC in patients who 
have homozygosity for SLC22A4/5 Allele A at rs272893 and/or SLC22A4/5 allele T at rs273900 to-
gether with carriership of RUNX3 allele T at rs2236851. Significance is corrected for multiple testing.
p-value OR 95.0% C.I.
  lower upper
SLC22A4/5 *   0.0082 0.36 0.17 0. 77
RUNX3 ¶ †  0.73 1.07 0.72 1.61
SLC22A4/5 and RUNX3 * ¶ †  0.018 3.83 1. 26 11.67
* SLC22A4/5 defined as homozygosity for the risk allele of rs272893 and/or rs273900 
¶  RUNX3 defined as carrying the risk allele of rs2236851 
† Corrected for multiple testingRUNX3, SLC22A4/5 and IBD
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Figure 4.
Expression of RUNX3 (fig 4a) and OCTN1 (fig 4b) mRNA quantified by RT-PCR. RUNX3 mRNA 
is increased in inflamed colonic mucosa compared to non-inflamed mucosa in UC (p=0.01) and in CD 
(not significant). RUNX3 mRNA is not increased in inflamed ileal mucosa compared to non-inflamed 
ileal mucosa in CD. OCTN1 mRNA is decreased (but not statistically significant) in inflamed colonic 
mucosa compared to inflamed colonic mucosa in UC and CD and in inflamed ileal mucosa compared 
to non-inflamed ileal mucosa in CD. Total RNA was isolated from biopsies from uninflamed and in-
flamed colonic or ileal tissue from 30 IBD patients (14 UC and 16 CD) and 6 controls. Relative expres-
sion levels (∆Ct) were normalized to 18S. Data are expressed as means ± SD.
A
B
Abbreviations: UC - Ulcerative colitis; CD - Crohn’s Disease; Non infl - Non inflamed; Infl - inflamed4
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Discussion
In this study, we applied a candidate gene approach to analyze the genetic association be-
tween the genes RUNX3 and SLC22A4/5 with IBD, UC, CD or subsets of CD and UC. 
This is the first report showing an association of genetic variation in RUNX3 with ulcerative 
colitis. Carriership of the T-allele of SNP rs2236851 was associated with UC with an OR of 1.61, 
which was supported by  HSS and TDT. The association was most significant for extensive UC. 
As a TGF-ß1 target, the RUNX3 protein is involved in TGF-ß1 mediated inhibition of T-cell 
proliferation and differentiation, as well as down regulation of macrophage activation and 
dendritic cell maturation. The important role of adequate TGF-ß1 signaling is apparent in 
TFG-ß1 knockout mice, which die soon after birth. Transgenic mice expressing dominant 
negative TGF-ßRII chains which are unresponsive to TGF-ß1 signaling develop severe colitis 
and pulmonary inflammation.24 25 Furthermore Runx3 knockout mice developed indolent 
non ulcerative colitis characterized by epithelial hyperplasia, leukocyte infiltration, forma-
tion of B cell clusters and increased production of IgA.  
SNP rs2236951 is located in an intron of the RUNX3 gene and at present it is unclear how this 
may be related to UC susceptibility. This is, however, not a unique finding, since an intronic 
SNP in RUNX1 has previously been shown to be associated with rheumatoid arthritis.17 Fur-
thermore, several studies have reported that important transcriptional regulatory elements 
are located in intronic regions.26 Involved mechanisms might be hypermethylation of the 
promoter region of RUNX3 or mislocalization of the protein into the cytoplasm, as observed 
in gastric cancer, which can both result in decreased activity of RUNX3.28 Whether this par-
ticular SNP has a causative role in UC susceptibility or it is in LD with other functional muta-
tions in the RUNX3 gene needs further investigation. 
Endoscopical and histological inflamed colonic mucosa of wild type RUNX3 patients showed 
upregulated RUNX3 mRNA expression compared to non-inflamed colonic mucosa of the 
same patient or controls. In contrast, inflamed ileal mucosa did not show an upregulated 
RUNX3 mRNA suggesting region-specific upregulation. This corresponds with the association 
of RUNX3 SNP rs2236851 with UC and of microsattelite marker RX-02 with CD with colonic 
localization.  
We could not confirm the association of the SLC22A4/5 -207 G→C and 1672 G→C variants 
with IBD, CD or UC.8 The previously described risk haplotype TC was not associated with an 
increased risk for UC, CD or different phenotypes of CD. Interestingly, we did find an associa-
tion for homozygosity for two other SNPs rs272893 and rs273900 with ORs of 2.19 and 2.36 
respectively for CD compared to controls. This effect was even more obvious in CD patients 
with an early age of onset, ileocolonic localization, non-stricturing non-penetrating behavior, 
extra-intestinal manifestations and, although numbers are small, also with upper GI tract 
localization. This finding supports the evidence that the SLC22A4/5 variants are potential 
candidate genes for IBD susceptibility. However, due to the high degree of LD in the IBD5 
locus it remains to be seen whether SLC22A4/5  are responsible for CD susceptibility or that 
they are in strong LD with other truly causative genes.
The interaction of a member of the RUNX family and SCL22A4 in patients with RA is intrigu-
ing.17 Therefore, we also analyzed the previously described SNP disrupting the RUNX binding RUNX3, SLC22A4/5 and IBD
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site in SLC22A4. We did not find evidence for an association of this particular SNP. with CD 
or UC susceptibility. However, carriership of one of the risk associated alleles of RUNX3 in 
combination with one of the risk associated alleles of SLC22A4/5  showed an increased risk for 
having UC compared to CD (OR 3.83). Contrary to previous observations reporting epistasis for 
the 1p locus, where RUNX3 resides, and IBD1, the locus of CARD15, no interaction could be 
found of RUNX3 with CARD15.15  We did not find the previously described epistasis between 
SLC22A4/5 and CARD15.8
Transport proteins such as multidrug resistance protein 1 (MDR1) and OCTN have been impli-
cated in susceptibility to inflammatory bowel disease. Both MDR1 and SLC22A4 genes have 
RUNX binding sites in their promoter regions. An intronic SNP in a RUNX1 binding site of 
SLC22A4 resulted in a stronger suppression of OCTN expression.17 Furthermore, RUNX3 is ca-
pable of suppressing MDR-1 29 We showed a correlation between upregulated RUNX3 and 
downregulated OCTN in colonic but not in ileal tissue. In addition to mutations in SLC22A4 
and MDR1genes, RUNX mutations might further decrease tissue specific expression of these 
susceptibility genes indicating that a gene (SLC22A4/5, MDR1) with a susceptibility variant for 
IBD and a regulatory molecule (RUNX) with an allelic different binding for this susceptibility 
variant might further increase the risk of disease.
In summary, we provide evidence for the genetic association of RUNX3 with ulcerative colitis. 
Furthermore genetic association for Crohn’s Disease with SLC22A4/5 was confirmed, although 
this involved two other SNPs than previously described. An epistatic effect of RUNX3 and 
SLC22A4 was found with an increased risk for ulcerative colitis. Our data, combined with the 
increasingly recognized role of RUNX3 in autoimmunity, suggest an important role for RUNX3 
in UC susceptibility. Functional assays for RUNX3 activity are required to clarify the role of 
RUNX3 mutations in de development of UC.Chapter 5
Genetic susceptibility has a  
more important role in  
pediatric-onset than in adult-
onset Crohn’s disease
L. de Ridder, R.K. Weersma, G. Dijkstra, G. van der Steege,  
M.A. Benninga, I.M. Nolte, J.A.J.M. Taminiau, D.W. Hommes, 
P.C.F. Stokkers
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Abstract
Background: Genetic susceptibility may have a more important role in the etiology of early-, 
than of late-onset IBD and may have a higher frequency of gene mutations. We aimed to 
determine genotype and phenotype in pediatric-onset IBD, to compare these data with adult-
onset IBD and controls and to identify genotype-phenotype associations. 
Methods: Polymorphisms R702W, G908R and 3020insC of CARD15; Asp299Gly and Thr399Ile 
of  TLR4;  -207G→C,  1672C→T  (L503F),  rs3792876,  rs274551,  rs272893  and  rs273900  of 
SLC22A4/5; and 113G→A as well as rs2289311, rs1270912 and rs2165047 of DLG5 were as-
sessed in 103 pediatric-onset and 696 adult-onset IBD patients. Phenotypic classification was 
based on disease localization and behaviour. 
Results: Homozygosity for the 3020Cins mutation was significantly higher in pediatric-onset 
than in adult-onset CD (4.2% v 0.6%, 95% confidence interval (CI) 1.2-42.0). Homozygosity for 
the SLC22A4/5 rs3792876 SNP was significantly higher in pediatric-onset CD than in adult-
onset CD (6.1% v 1.1%, p=0.02). The 3020Cins mutation was associated with ileal involve-
ment (1.9% v 13.3%, CI 1.0-53.8) and a positive family history (6.1% v 20%, CI 1.2-9.0). DLG5 
rs2165047 was significantly associated with perianal disease (50% v 21.2%, CI 1.4-4).
Conclusions: 3020Cins in CARD15 and SLC22A4/5 rs3792876 mutations occurred statistically 
significant more often in pediatric-onset compared to adult-onset CD. 3020Cins (CARD15) and 
DLG5 rs2165047 mutations in this pediatric-onset CD cohort were associated with specific 
phenotypes. 5
67
Introduction 
Inflammatory Bowel Diseases (IBD) is a group of disorders marked by chronic inflammation 
of the intestinal tract. IBD comprehends two distinct disease entities, ulcerative colitis (UC) 
and Crohn’s disease (CD). These two groups are defined on clinical and histo-pathological 
features, but overlapping syndromes occur. As a multi-factorial disorder IBD is caused by a 
complex interaction of genetic, bacterial and immunological factors. The disease presents 
before the age of 20 years in 20-25% of patients. The incidence of pediatric IBD (under the 
age of 18 years) in the Netherlands is recently assessed and concerns 5.2/100.000 children.1 
This is comparable to data from other European countries.2 3
Genetic risk factors for IBD have been extensively studied in the last decades. Through fine 
mapping of genome wide scans and linkage studies the CARD15 gene on chromosome 16 
has been identified as a susceptibility gene for IBD.4-6 The polymorphisms R702W, G908R and 
3020Cins in the CARD15 gene are independently associated with an increased risk of suscepti-
bility for Crohn’s disease in Caucasian patients. Mutations of the CARD15 gene are associated 
with ileal disease activity, the presence of disease at a younger age, more frequent formation 
of granulomas and the occurrence of penetrating or stricturing phenotypes.7-11 These can be 
demonstrated in 5-15% of the Caucasian patients.12 A high diversity of these mutations exists 
in different (healthy) European populations. In a mixed European population the 3 mutations 
R702W, G908R and 3020Cins are found in 4.0, 1.0 and 1.9%, respectively while in a Dutch 
population the mutations G908R and 3020Cins are found in 3.0 and 1.0%, respectively.10,13
The NOD2 proteins and the Toll-like receptors (TLR’s) are pattern recognition receptors that 
signal presence of bacterial antigens, and play a key role in the innate immunity system. 
NOD2 is located intracellular, whereas TLR’s are extracellular proteins. Both NOD2 and the 
TLR’s are activated by pathogen-associated molecular patterns (PAMP) such as endotoxins. 
Recent studies indicate that members of the TLR family may also increase IBD susceptibility.14 
The Asp299Gly polymorphism in TLR4 was associated with CD and UC.15Another TLR4 muta-
tion, Thr399Ile was associated with UC.16
Of late, 2 novel IBD susceptibility genes have been identified, being SLC22A4/5 and DLG5. 
Within the IBD5 locus, a 250 kb risk haplotype on chromosome 5q31 has been associated 
with CD in different cohorts.17-19 However, the causative gene has not been clearly recognized 
due to a high degree of linkage disequilibrium (LD) in this region. Peltekova et al. identified 
2 functionally relevant mutations in the carnitine/organic cation transporter (OCTN) genes on 
the IBD5 locus being responsible for the IBD5 association. These mutations concern variants 
of SLC22A4 and SLC22A5 encoding OCTN1 and OCTN2.20 The T substitution of C1672 in exon 
9 of the SLC22A4 gene encodes for OCTN1 and a G to C substitution at position -207 in the 
promoter region of SLC22A5 gene encodes for OCTN2. Together these polymorphisms form 
a 2 allele risk haplotype associated with CD susceptibility. Interaction of this haplotype with 
mutations in the CARD15 gene is suggested.21 Other studies could not confirm this association 
of the 2 allele risk haplotype of SLC22A4/5 and CD, though in one study an increased risk in a 
subgroup with perianal CD has been found.22 23
Recently Stoll et al. identified an association between genetic variations in DLG5 (Drosophila 
Discs Large Homologue 5) on chromosome 10q23 and the risk of developing IBD.(24) DLG5 Gene panel in pediatric-onset IBD
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is important in maintaining the epithelial structure and genetic variants could result in im-
paired intestinal permeability. Two haplotypes were involved in IBD and CD susceptibility. A 
SNP 113G→A, resulting in an amino acid substitution R30Q, was positively associated with 
IBD and CD patients. A second haplotype identified by 8 other tagging SNPs was protective 
for IBD. Gene-gene interaction with CARD15 in CD was detected by a significant difference in 
association of the 113A variant in patients carrying the risk alleles for CARD15 compared to 
patients not carrying these alleles. However several subsequent studies failed to show any 
association for DLG5 with IBD.25-29
Genetic susceptibility may have a more important role in the etiology of early-, than of late-
onset IBD. After all, early-onset IBD patients were less exposed to environmental factors than 
late-onset IBD patients. If so, a higher frequency of the gene mutations can be expected in 
pediatric IBD patients. The purpose of our study was to determine the frequency of CARD15, 
TLR4, SLC22A4/5 and DLG5 mutations in pediatric-onset IBD, compare these data with adult-
onset IBD and to identify genotype-phenotype associations. 
Methods
Study patients
From November 1st 2003 to February 1st 2006, 103 pediatric-onset (under the age of 19) 
IBD patients agreed to participate in this genetic study performed in the Emma Children’s 
Hospital/Academic Medical Center. From January 1st 1997 to April 1st 2005, in the Academic 
Medical Center, 696 adult-onset (from the age of 19) IBD patients agreed to participate in this 
study. IBD was diagnosed based on clinical, endoscopic, radiological and histological criteria 
of Lennard-Jones.30 Patients with indeterminate colitis were excluded. Of all patients, written 
informed consent was obtained, and the study protocol was approved by the institutional 
review board of the Emma Children’s Hospital/Academic Medical Center, Amsterdam. Haplo-
types of spouses of IBD patients from the University Medical Center Groningen were taken as 
controls. Adult controls were considered adequate since genetic profiles do not change once a 
child has become an adult. Most of them were already used for genotype-phenotype studies 
on CARD15 and TLR4.14 31
Phenotype analysis
Gender and age at diagnosis of all patients were assessed. Phenotypic classification was based 
on disease localization and behaviour. Localization was determined by endoscopic, histologi-
cal and/or radiological examination. Categories were made according to the Vienna classi-
fication: upper gastrointestinal tract (including jejunum or upper ileum), ileal, ileo-colonic 
(terminal ileum or terminal ileum and ascending colon), colonic (transverse colon, descend-
ing colon, sigmoid or rectum) and perianal disease. Behaviour was defined as uncomplicated 
(non-stricturing/non-penetrating), penetrating or stricturing. Extra-intestinal manifestations 
included eye, joint, skin and liver involvement. Surgical intervention was defined as any 
operative IBD-related procedure, such as gut resection or fistula correction. Family history 5
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was defined as positive if at least one first- or second-degree relative was diagnosed with 
IBD. Phenotypic assessment was mostly available by the IBD-database and completed by the 
treating pediatric gastroenterologists, the treating gastroenterologists and by chart review.
Genotype analysis
Venous blood samples (10 ml from each pediatric patient and 20 ml from each adult patient) 
were collected. DNA was extracted following standard procedures and was stored at -80 oC. 
Primers to amplify the polymorphic loci were selected using on-line Primer3 software. SNP 
genotyping was carried out by using TaqMan PCR primer/probe sets, designed through Ap-
plied Biosystems’ Assay by Design service (http://myscience.appliedbiosystems.com/, Foster 
City, USA). SNP assay reactions were performed in 5 μl volumes and contained 25 ng DNA, 
1x TaqMan Universal PCR Master Mix (Applied Biosystems), 100 nM of each primer and 900 
nM of each probe. Cycling conditions on the ABI prism 7900 HT (Applied Biosystems) were 2 
minutes 50°C, 10 minutes 95°C followed by 40 cycles of 15 seconds 92°C and 1 minute 60°C. 
End-point fluorescence was measured immediately after cycling. Alleles were assigned using 
SDS 2.0 software (Applied Biosystems).
DNA of the patients was screened for the R702W, G908R and 3020Cins of the CARD15 gene 
and the Asp299Gly and Thr399Ile polymorphisms of TLR4. For SLC22A4/5 the known poly-
morphisms -207G→C and 1672C→T (L503F) and 4 additional SNPs (rs3792876, rs274551, 
rs272893 and rs273900) were analyzed. These SNPs were selected as haplotype-tagging SNPs 
for the most common haplotypes covering the entire SLC22A4/5 gene region. For DLG5, the 
previously described 113G→A polymorphism was determined. SNP rs2289311 was used as 
a haplotype-tagging SNP for the undertransmitted DLG5_26 haplotype described by Stoll et 
al.(24) Two added SNPs (rs1270912 and rs2165047) were selected as haplotype-tagging SNPs 
to cover DLG5 based on information from the HAPMAP database (http://www.hapmap.org). 
Correlations
Genotype correlations between pediatric-onset IBD, adult-onset IBD and healthy control pop-
ulations were examined. Phenotype correlations in pediatric-onset and adult-onset IBD pop-
ulation were examined. Consequently, genotype-phenotype correlations in pediatric-onset 
IBD were examined and compared to genotype-phenotype correlations in adult-onset IBD. 
Statistics
The differences between the frequencies of the CARD15, TLR4, SLC22A4/5 and DLG5 polymor-
phisms in pediatric-onset patients were compared with adult-onset patients and healthy con-
trols using χ2, when valid, otherwise using Fisher’s exact tests. Genotypic association analysis 
of CD characteristics was also performed in subsets of CD patients stratified according to the 
Vienna classification and comparing them with controls. Gene-gene interactions (CARD15 
interaction with TLR4, SLC22A4/5 and DLG5) were tested by means of logistic regression in 
SPSS. A p-value of <0.05 was considered to be significant.Gene panel in pediatric-onset IBD
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Results
Phenotypes 
A total of 103 pediatric-onset IBD patients and 696 adult-onset IBD patients were included. 
Patient characteristics are described in Table 1a and 1b. 
Isolated ileal disease is more common in adult-onset CD when compared to pediatric-onset 
CD (p=0.0004). Pediatric-onset UC more often is a pancolitis when compared to adult disease 
(p<0.0001). Adult-onset CD patients more often have stricturing and/or penetrating disease 
behaviour and more frequently undergo surgery in comparison to pediatric-onset CD pa-
tients.
Table 1a. IBD patient characteristics.
Pediatric-onset IBD 
(n=103)
Adult-onset IBD (n=612)
Gender (male; female), n (%)  50; 53 (49; 51) 263; 349 (43.0; 57.0)
Age at diagnosis, mean (range in years)  12.0 (0.5-18) 35.3 (19-69)
Type of IBD (CD; UC), n (%) 72; 31 (69.9; 30.1) 386; 226 (63.1; 36.9)
Ethnicity (caucasian; negroid;  
asiatic), n (%)
88; 9; 6 (85.4; 8.7; 5.8) NA
Family history of IBD, n (%) 18 (17.5) NA
Localization UC (proctitis, left-sided, 
pancolitis), n (%) 
6; 6; 19 (19.4; 19.4; 61.3) # 60; 112; 54 (26.5; 49.6; 23.9)
Table 1b. CD patient characteristics.
Pediatric-onset CD 
(n=72)
Adult-onset CD (n=368)
Gender (male; female), n (%) 40; 32 (56; 44) 134; 252 (35; 65)
Age at diagnosis, mean (range in years) 14 (6-18) 42 (19-70)
Localization (ileal; colonic; ileo-colonic), 
n (%)
16; 26; 29 (22.2; 36.1; 40.3)$ 153; 100; 76; (41.6; 25.9; 
19.7) 
Localization upper; peri-anal, n (%) NA; 13 (NA; 18) 176; NA (45.6; NA)
Disease behaviour, n (%)  51, 10, 14 (70.8; 13.9; 19.4)
176; 81; 129 (45.6; 21.0; 
33.4)
   (nonstricturing/ nonpenetrating; 
structuring; penetrating)
Extraintestinal manifestations, n (%) 14 (19.4) 97 (25.1)
Operated patients, n (%) 17 (23.6) 173 (44.8)
# p<0.0001
$ p=0.0004
Abbreviations: IBD= Inflammatory Bowel Diseases; CD= Crohn’s disease; UC= ulcerative colitis5
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Association analyses
Genotype and allele frequencies for the CARD15 polymorphisms R702W, G908R and 3020Cins 
are detailed in table 2a. 
A statistical association for R702W was found with pediatric-onset CD (carriership in patients 
with CD 14 [19.5%] and in patients with pediatric-onset UC 7 [23.3%] versus controls 18 [6.6%]: 
CD p=0.0027, UC p=0.0063). For the 3020Cins SNP, a nearly statistical association was found 
with pediatric-onset CD (carriership of 3020Cins in patients with CD 10 [13.9%] versus controls 
20 [7.3%]: p=0.060). Homozygosity for the 3020Cins mutation was noted in 3 patients (4.2%) 
of the pediatric-onset CD cohort, whereas 2 out of 343 patients (0.7%) of the adult-onset CD 
patients were homozygous (p=0.04, relative risk [RR] 7.1 95% confidence interval [CI] 1.2-42.0). 
The prevalence of CARD15 mutant homozygotes and compound heterozygotes was higher in 
the pediatric cohort compared to adult-onset CD, but this did not reach statistical significance: 
8 out of 72 (11.1%) pediatric-onset CD patients and 21 out of 293 adult-onset CD patients (7.2%) 
were either compound heterozygous or homozygous for CARD15 mutations. It was however 
significantly increased compared to controls (8 [2.9%], p=0.005). The polymorphism R702W 
was significantly increased in adult-onset CD patients compared to controls (p=0.0006). The 
prevalence of CARD15 mutant homozygotes and compound heterozygotes also was increased 
in adult-onset CD patients versus controls (p=0.006, RR1.6 95% CI 1.2-2.0). 
For the Asp299Gly and Thr399Ile polymorphisms of TLR4 no significant associations were 
found between pediatric-onset IBD, CD or UC versus controls or versus adult-onset IBD, CD or 
UC patients (table 2b). 
However, both polymorphisms Asp299Gly and Thr399Ile were significantly increased in adult-
onset CD patients compared to controls (p=0.02 and p=0.01, respectively). The prevalence of 
TLR4 mutant homozygotes and compound heterozygotes also was increased in adult-onset 
CD patients versus controls (p=0.02; RR 1.28; 95% CI 1.1-1.5). The CARD15 and TLR Asp299Gly 
data of the adult-onset IBD patients partially overlap with the cohort analysed and described 
by Braat et al.32
For the SLC22A4/5 rs3792876 SNP a statistical association was found with pediatric-onset CD 
(p=0.009 versus controls and p=0.03 versus adult-onset CD) (table 2c). 
Homozygosity for the SLC22A4/5 rs3792876 SNP also appeared significantly increased in pe-
diatric-onset CD patients when compared to the adult-onset CD patients (4 [6.1%] versus 4 
[1.1%]; p=0.02). No association with SLC22A4/5 was found for the 2 previously described SNPs 
L503F and -207G→C and 3 other tagging SNPs with IBD, CD or UC. The SLC22A4/5 rs272893 
and rs273900 SNPs were significantly increased in adult-onset CD patients compared to con-
trols (p=0.04). The SLC22A4/5 rs274551 SNP was significantly decreased in adult-onset CD 
patients compared to controls (p=0.002). Ninety-three pediatric-onset IBD patients were 
genotyped for the DLG5 polymorphisms (table 2d). 
Carriership of mutations was equally divided between men and women. For DLG5, rs2165047 
tended to be differently distributed among pediatric-onset UC compared to controls, al-
though this was not statistically significant (p=0.088). No associations were found versus the 
adult-onset IBD population. In adult-onset CD and UC however, the different distribution of 
DLG5 rs2165047 did reach statistical significance compared to controls (p=0.04 and p=0.03 
respectively). Gene panel in pediatric-onset IBD
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Gene-gene interactions
No interactions of TLR4, SLC22A4/5 or DLG5 with CARD15 were detected. 
Genotype-phenotype correlations pediatric-onset CD patients
Genotype-phenotype correlations of the pediatric-onset CD patients are shown in table 3. 
The 3020Cins mutation was associated with ileal involvement (including ileocolonic localiza-
tion) (p=0.03; RR 7.2; 95% CI 1.0-53.8) and this was even more strongly associated with purely 
ileal disease (p<0.0001; RR 12.2; 95% CI 4.1-36.4). The 3020Cins mutation was suggestively as-
sociated with a positive family history (p=0.07).
DLG5 rs2165047 was significantly associated with perianal disease (p=0.003; RR 2.4; 95% CI 1.4-
4.0). Other genotype/phenotype correlations were not found in the pediatric-onset CD cohort.
Discussion
This is the first study to report the contribution of the CARD15, TLR4, SLC22A4/5 and DLG5 
genes in a pediatric-onset IBD population and compare these data to an adult-onset IBD 
population. 
CARD15 
Homozygosity for the 3020Cins NOD2 mutation was significantly more frequent in pediat-
ric-onset CD than in adult-onset CD. This finding confirms our hypothesis that this CARD15 
mutation predisposes for pediatric-onset CD. So far, reports in literature are conflicting. Fer-
raris et al. found a higher incidence of the 3 major CARD15 mutations in their Italian pedi-
atric vs. adult CD cohort (p=0.056).33 Weiss et al. demonstrated a higher prevalence of G908R 
mutation in 67 Jewish pediatric vs. adult CD patients, though this did not reach statistical 
significance (p=0.063).34 Others did not find any differences in the prevalence of the 3 major 
CARD15 mutations between a pediatric-onset and an adult-onset CD cohort.35 36
These conflicting results can be explained by large regional and ethnical differences in gen-
otypes, the broad spectrum of phenotypes within IBD and the relatively low numbers of 
patients included in these studies. A statistical association between R702W and a nearly sta-
tistical association between 3020Cins and CD was found. The genotype-phenotype analysis 
revealed a strong association between the 3020Cins mutation and CD localization in the 
terminal ileum. The association between CARD15 mutations and involvement of the ileum is 
well described, both in adult and pediatric populations.8 37-39 Furthermore, we found that the 
3020Cins mutation is suggestively associated with familial disease. This finding is confirmed 
by a meta-analysis of 42 studies (mainly adult patients), in which more familial disease in 
CARD15 mutation carriers was demonstrated.39
TLR4
No significant associations were found for the TLR4 polymorphisms in this pediatric-onset 
IBD cohort, comparable with the findings of Leshinsky-Silver et al.36 However, both Asp299Gly 5
79
and Thr399Ile polymorphisms were associated with CD in our adult-onset cohort. Moreover, 
these polymorphisms have been associated with CD and UC.15 40-42 In other studies, these as-
sociations were not confirmed.43 44 
SLC22A4/5
In our pediatric-onset CD cohort we cannot confirm the associations of the 2 variants in 
SLC22A4 and SLC22A5 that were reported by Peltekova et al. They found that the association 
with the IBD5 locus is strongest for CD patients diagnosed under 16 years of age and this 
finding was confirmed in another study.17 20 Nevertheless, Russell et al. reported that the 
SLC22A4/5 variants do not act independently of variants in the IBD5 locus.45 In our cohort, 
although numbers are small, SNP rs3792876 was statistically associated with pediatric-onset 
CD compared with healthy controls. This mutation was also more frequent in the pediatric-
onset CD patients when compared to the adult-onset CD patients. As far as we know, this find-
ing has not been reported before. Taken together, these data support the evidence that the 
SLC22A4/5 variants are genetic risk factors for CD susceptibility. However, due to the high de-
gree of LD in the IBD5 locus it remains to be seen whether SLC22A4/5 variants are responsible 
for CD susceptibility or that they are in strong LD with other true causative genetic variants.
Moreover, we observed a statistically significant higher frequency of the SLC22A4/5 rs3792876 
mutation in the pediatric-onset CD patients compared to the adult-onset CD patients. As far 
as we know, this comparison is not reported before. 
DLG5
We could not confirm the previously described association of DLG5 and IBD in our pediatric 
cohort. Interestingly, we did find that rs2165047 was significantly increased in both our adult-
onset CD and UC population. Several other studies failed to validate the significance of DLG5 
variants as important determinants in IBD susceptibility in adult-onset IBD.25 27-29 Friedrichs 
et al. recently demonstrated that carriership of DLG5 mutations was a susceptibility factor for 
CD in men but not in women as did Biank et al. in pediatric-onset CD cohort.46 47 However, 
DLG5 mutation carriership was equally divided among both sexes in both our pediatric-onset 
CD patients and the healthy control group. Associations with DLG5 mutation carriership were 
not found. 
DLG5 rs2165047 mutation carriership in our pediatric CD cohort was significantly associated 
with perianal disease. Larger studies are needed to confirm these data since the number of 
patients of this cohort is too small to infer any conclusions as yet. We don’t have data on 
ethnicity of the adult-onset population. However, it is expected to be the same in the pedi-
atric-onset as in the adult-onset population, as it concerns the same geographic area where 
the patients come from and referral is based on the same conditions. Calculations were also 
performed in an exclusively Caucasian pediatric-onset IBD cohort and no other statistical sig-
nificances were revealed compared with the entire cohort, although some became stronger 
(data not shown).
In conclusion, this study demonstrated that the R702W mutation in CARD15 is associated 
with CD in a Dutch pediatric-onset IBD cohort. Secondly, for SLC22A4/5, SNP rs3792876 is Gene panel in pediatric-onset IBD
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associated with pediatric-onset CD. Moreover, both 3020Cins and SLC22A4/5 rs3792876 muta-
tions occurred statistically significant more often in pediatric-onset compared to adult-on-
set CD. Since TLR4, SLC22A4/5 and DLG5 seem moderate risk alleles, more associations with 
pediatric-onset IBD cannot be excluded yet and larger pediatric-onset CD cohorts need to 
be examined. Genetic susceptibility has a more important role in the etiology of early- than 
of late-onset CD. Within pediatric-onset CD specific genotype-phenotype associations can be 
found. These data stress the importance of genetic susceptibility research in large pediatric-
onset IBD cohorts in order to find new genes and to establish the influence of these muta-
tions on disease behaviour. 
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Abstract
Background: Inflammatory bowel diseases (IBD) –Crohn’s disease (CD) and ulcerative coli-
tis (UC) – and celiac disease are intestinal inflammatory disorders with a complex genetic 
background. Recently, two novel genes were found to be associated with IBD susceptibility. 
One, an uncommon coding variant (rs11209026) in the gene encoding for the interleukin-23 
receptor(IL23R) conferred strong protection against CD. The other, rs2241880 in the autoph-
agy-related 16-like 1 gene(ATG16L1) was associated with CD. We performed a case-control 
study for association of IBD with IL23R and ATG16L1 in a Dutch cohort. We also looked at the 
association of IL23R and ATG16L1 with celiac disease.
Methods: 518 Dutch Caucasian IBD patients (311 CD and 207 UC, including 176 trios of pa-
tients with both parents), 508 celiac disease patients, and 893 healthy controls were studied 
for association to the rs11209026 (IL23R) and rs2241880 (ATG16L1) SNPs. 
Results: The rs11209026 SNP in IL23R had a protective effect for IBD in case-control analy-
sis (OR=0.19; 95% CI: 0.10–0.37; p=6.6E-09). Both CD (OR=0.14; CI: 0.06-0.37; p=3.9E-07) 
and UC (OR=0.33; CI: 0.15-0.73; p=1.4E-03) were associated with IL23R. For ATG16L1 the 
rs2241880 SNP was associated with CD susceptibility (OR=1.36; CI: 1.12-1.66; p=0.0017). The 
population attributable risk for carrying allele G is 0.24 and 0.19 for homozygosity for allele G 
in CD. No association was found between IL23R or ATG16L1 and celiac disease.
Conclusions: We confirmed the association of IL23R and ATG16L1 with CD susceptibility and 
also the association of IL23R with UC. We found IL23R and ATG16L1 were not associated with 
celiac disease susceptibility.6
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Introduction
Inflammatory bowel diseases (IBD) are a group of chronic inflammatory disorders of the 
gastrointestinal tract of unknown origin; there are two main types: Crohn’s disease (CD) and 
ulcerative colitis (UC).1  Celiac disease is another chronic inflammatory disorder of the gastro-
intestinal tract, although it is not usually included under IBD. The combined prevalence of 
CD and UC is estimated at 100–200/100,000 in developed countries.2 3 Concordance rates in 
twins and siblings suggest that a genetic predisposition contributes to the pathogenesis of 
IBD. 4 In addition to genetic factors, environmental factors and the enteric microbial flora are 
involved in the development of IBD. Nevertheless the aetiology remains largely unknown.
In 2001 the CARD15 gene on chromosome 16 was identified as the first susceptibility gene 
for CD.5 6 IBD shows a variation in the individual clinical presentation and outcome that is 
most likely due to differences in the genetic susceptibility, exposure to environmental fac-
tors, the commensal bacteria in the intestine, and the intestinal immune system. Apart from 
the CARD15 association, the organic cation transporters, encoded by the genes SLC22A4 and 
SLC22A5, have been reported to be associated with CD susceptibility.7 However, this associa-
tion is not independent from the IBD5 haplotype.8 Further associations have been found 
with polymorphisms in the genes encoding for Drosophila discs large homologue 5 (DLG5), 
multi-drug resistance gene (MDR1), Toll-like receptor 4 (TLR4), Caspase-activating recruit-
ment domain 4 (CARD4) and Tumour Necrosis Factor superfamily member 15 (TNFSF15). 
However, none of these associations has been as consistently replicated as the CARD15 as-
sociation. 9-13
Recently, two genome-wide association studies were performed in IBD and uncovered two 
novel genes involved in IBD susceptibility: the first study, by Duerr et al., identified the 
gene encoding a subunit for the interleukin 23 receptor (IL23R) on chromosome 1p31 as a 
susceptibility gene for CD in a population of patients with ileal CD of non-Jewish, European 
ancestry.14  An uncommon variant Arg381Gln was shown to have a strong protective effect 
for CD and other non-coding IL23R variants were independently associated. This association 
was confirmed in independent cohorts of non-Jewish CD and UC patients, not only for CD 
but also for UC. Since the proinflammatory cytokine IL23 is increasingly being recognized 
as involved in gut inflammation, this finding is of great importance.15 The second study, by 
Hampe et al., found a strong association between CD and the autophagy-related 16-like 1 
gene (ATG16L1) encoding a protein in the autophagosome pathway, which processes intra-
cellular bacteria.16 They performed a genome-wide association scan in 735 German patients 
with CD and 368 controls. Their analysis of the most informative SNPs in an independent 
cohort of CD patients and controls identified ATG16L1 as a CD susceptibility gene. Marker 
rs2241880, a coding SNP (Thr300Ala), was strongly associated with susceptibility for CD. The 
risk for CD was confined to individuals carrying susceptibility allele G at rs2241880. It was 
suggested that there might be an epistatic effect with one of the three risk alleles in CARD15 
associated with CD. 
Since it is of pivotal importance that genetic associations are confirmed in independent 
cohorts from different countries, we performed a replication study for the two most strongly 
associated SNPs in IL23R and ATG16L1 in a cohort of IBD patients from the northern part of ATG16L1, IL23R and IBD
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the Netherlands. We were also interested in discovering whether these two genes are more 
generally involved in other common chronic disorders of the gastrointestinal tract and we 
therefore included a cohort of celiac disease patients from the Netherlands. 
Methods 
Subjects
IBD: A cohort of 518 IBD patients (311 CD and 207 UC) from the University Medical Center 
Groningen was used.17 The diagnosis of CD or UC was based on accepted clinical, radiologic, 
endoscopic and histopathologic criteria.1 For 176 (103 CD and 73 UC) patients genotyping of 
both parents was also available. The clinical characteristics of patients with CD are given in 
table 1 and with UC in table 2.
Celiac disease: A cohort of 508 independent celiac patients of Dutch origin was included in 
the study. The diagnosis of CD was made according to the revised ESPGHAN criteria.18 In ad-
dition, the intestinal biopsies on which the initial diagnoses were based were re-evaluated 
for all these patients by one experienced pathologist, and only patients with a demonstrable 
villous atrophy and Marsh III lesions were included in this study.
The controls consisted of 893 healthy volunteers recruited from the University Medical Center 
Utrecht. Celiac cases and controls have been previously described.19 All the participants were 
of European Caucasian descent.
All patients gave informed consent and the study was approved by the ethics review com-
mittees of the participating hospitals. All DNA samples and data in this study were handled 
anonymously.
Genotyping and SNP selection
Genotyping assays for the rs11209026 and rs2241880 SNPs were designed for the Seque-
nom MassArray iPLEX platform using the Sequenom Assay Design software, version 3.0. The 
case and control samples, as well as 90 Centre d’Etude du Polymorphisme Humain  samples 
included in the International HapMap project were genotyped by primer extension of mul-
tiplex PCR products, followed by a chip-based matrix-assisted laser desorption ionization 
time-of-flight (MALDI-TOF).20 21 All genotyping was performed according to the manufacturer’s 
protocol at the Laboratory of Genetics and Genomic Medicine (www.inflammgen.org). The 
DNA samples were processed in 384 well-plates and each 384-plate with patient and control 
DNA contained 16 genotyping controls (4 duplicates of 4 CEU DNA). Both SNPs were validated 
and we obtained >99.9% concordance between our genotype data and the CEU data avail-
able from HapMap. Laboratory staff was blinded for disease status of each sample.
Statistical analysis
After genotyping the markers, we tested for Hardy-Weinberg equilibrium by comparing the 
expected and observed genotypes in 2 x 3 χ² tables. Both markers showed no deviation from 
Hardy-Weinberg equilibrium in controls (p-value >0.05). Differences in allele and genotype 6
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Table 1. Clinical characteristics of patients with Crohn’s disease. 
Total number        311
Sex (m/f)         106 / 205
Age at diagnosis (years)
  Mean (range)      31.3   (6.7 – 73.9)
  Median  27.7
  Under 40 yrs      227  (73.0%)
Follow up (years) 
  Mean (range)      11.8  (0.4 – 49.4)
  Median        8.8
Disease localization 
  Ileal         78  (25.1%)
  Colon        67   (21.5%)
  Ileocolon        166  (53.4%)
Disease behaviour
  Non-stricturing, non penetrating  101   (32.8%)
  Stricturing       76  (24.4%)
  Penetrating      133   (42.8%)
Upper GI tract        24  (7.7%)
Peri-anal          88  (28.3%)
Extra-intestinal manifestations      42   (13.5%) 
Family history of IBD      62  (19.9%)
History of surgical intervention      187  (60.1%)
Table 2. Clinical characteristics of patients with ulcerative colitis.
Total number        207
Sex (m/f)          109 / 98
Age at diagnosis (years)
  Mean (range)      32.9   (5.6 – 46.0)
  Median        31.4
  Under 40 yrs      146  (70.5%)
Follow up (years)
  Mean (range)      14.2   (2.5 – 48.9)
  Median        12.5
Disease localization ¶ *
  Proctitis        14  (6.8%)
  Left-sided        65   (31.4%)
  Pancolitis        99  (47.8%)
Extra-intestinal manifestations      34  (16.4%)
Family history of IBD      31  (15.0%)
History of surgical intervention      46  (22.2%)
¶ Defined as maximum disease extend found at endoscopy during follow up. 
* Data was unavailable for 29 (14.3%) patients.ATG16L1, IL23R and IBD
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distribution in the cases and controls were tested for significance by the chi-squared (χ²) 
test. In the trios we looked for association with the transmission disequilibrium test , us-
ing the transmission disequilibrium test  phase program of the UNPHASED package.22 Odds 
ratios were calculated and confidence intervals were approximated using Woolf’s method 
with Haldane’s correction. 23 Binary logistic regression was also used to determine gene-gene 
interaction effects. A significant threshold for p-values was determined at p<0.05.
Results
The IL23R rs11209026 SNP and the ATG16L1 rs2241880 SNP were genotyped in a group of 
518 IBD patients (311 CD and 207 UC), 508 celiac disease patients and 893 controls, all of 
European Caucasian descent. 
For the rs11209026 SNP in IL23R we observed a significant decrease of the rs11209026*A 
allele in the IBD group compared to controls (OR=0.19; 95% CI: 0.10–0.37; p= 6.6E-09) 
(Table 3). The overall genotype distribution of the rs11209026 SNP was also significantly 
different from the control cohort (p=5.3E-08) (Table 3). We investigated whether the pro-
tective effect of the rs11209026*A allele was different in the CD and UC patient groups. 
Both the CD and UC patients showed a much lower frequency of rs11209026*A allele com-
pared to controls (OR=0.14; CI: 0.06-0.37; p=3.9E-07 for CD and OR=0.33; CI: 0.15-0.73; 
p=1.4E-03 for UC) and in both groups the genotype distribution differed significantly from 
the controls (Table  3). Although the association of the rs11209026*A allele with CD was 
stronger than with UC (OR(CD)=0.14 vs. OR(UC)=0.33), this difference was not significant 
(data not shown).
For 176 IBD patients we also had the genotypes of both parents, allowing us to perform a 
transmission disequilibrium test analysis. Due to the low frequency of the rs11209026*A 
allele, only 6 families were informative: two showed transmission (T) and four showed non-
transmission (NT) of allele rs11209026*A to affected offspring. Although this observation 
was in agreement with a protective effect of the rs11209026*A allele, it was not statistically 
significant due to the small number of cases (data not shown). In celiac disease patients 
both allele and genotype frequency of the rs11209026 SNP was similar to controls (Table 
3).
For the ATG16L1 rs2241880 SNP we saw an increased frequency of allele G in IBD cases 
(63%) vs. controls (56.7%) (OR=1.30; CI: 1.10–1.53; p=0.0016) (Table 4);. The association 
to rs2241880 was mainly due to the CD subgroup (OR=1.36; CI: 1.12–1.66; p=0.0017) and 
was also significant on the genotype level (p=0.0052) (Table 4). The population attributable 
risk for carrying allele G in CD is 0.24 and for homozygosity for allele G is 0.19. The associa-
tion with IBD was confirmed by transmission disequilibrium testing as the rs2241880*G 
allele was preferentially transmitted to affected individuals (54.7% transmission, OR=1.59; 
p=0.007) (table 5). We could not find any specific genotype-phenotype associations for 
ATG16L1 with respect to disease localization, disease behaviour, need for surgery, occur-
rence of extraintestinal manifestations and age of onset for both CD and UC.6
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Table 3. Allele and genotype frequencies of the rs11209026 SNP (IL23R) in inflammatory bowel dis-
eases (IBD n=518), Crohn’s disease (CD n=311), ulcerative colitis (UC n=207), celiac disease (n=508) 
and controls (n=893).
IBD (%) CD (%) UC (%) Celiac (%) Controls
allele A 10 (1.2) 4 (0.8) 6 (1.9) 76 (7.8) 112 (6.5)
allele G 812 (98.8) 504 (99.2) 308 (98.1) 894 (92.2)
1624 
(93.5)
Odds ratio 
(OR)
0.19 0.14 0.33 1.24 1
95% CI 0.10 - 0.37 0.06 - 0.37 0.15 - 0.73 0.91 - 1.67 –
p-value 6.60E-09 3.90E-07 0.0014 0.17 ref
AA 0 (0) 0 (0) 0 (0) 3 (0.6) 4 (0.5)
AG 10 (2.4) 4 (1.6) 6 (3.8) 70 (14.4) 104 (12.0)
GG 401 (97.6) 250 (98.4) 151 (96.2) 412 (84.9) 760 (87.6)
0 107 57 50 23 25
p-value 5.30E-08 2.40E-06 0.0064 0.4 ref
Table 4. Allele and genotype frequencies of the rs2241880 SNP (ATG16L1) in inflammatory bowel 
diseases (IBD n=518), Crohn’s disease (CD n=311), ulcerative colitis (UC n=207), celiac disease 
(n=508) and controls (n=893).
IBD (%) CD (%) UC (%) Celiac (%) Controls
allele G 596 (63.0) 367 (64.2) 229 (61.2) 521 (53.7) 988 (56.7)
allele A 350 (37.0) 205 (35.8) 145 (38.8) 449 (46.3) 754 (43.3)
Odds ratio 
(OR)
1.30 1.36 1.20 0.89 1
95% CI 1.10 – 1.53 1.12 – 1.66 0.96 – 1.51 0.76 – 1.04 –
p-value 0.0016 0.0017 0.11 0.13 ref
GG 190 (40.2) 121 (42.3) 69 (36.9) 129 (26.6) 280 (32.1)
AG 216 (45.7) 125 (43.7) 91 (48.7) 263 (54.2) 428 (49.1)
AA 67 (14.2) 40 (14.0) 27 (14.4) 93 (19.2) 163 (18.7)
0 45 25 20 23 22
p-value 0.0063 0.0052 0.27 0.09 ref
Table 5. Transmission disequilibrium test results for rs2241880 in ATG16L1 in 230 IBD families 
(176 complete and 54 incomplete trios; CD=138 and UC=92).
allele T NT %T OR p-value
IBD (CD+UC)  G 180 149 54.7 1.59 0.007
CD G 109 92 54.2 1.53 0.057
UC G 71 57 55.4 1.69 0.055
T transmitted allele, NT non-transmitted allele, %T percentage of transmitted alleles. OR odds ratio. ATG16L1, IL23R and IBD
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In celiac patients we found no significant association with rs2241880*G,but we did observe 
a trend for a lower frequency of the rs2241880*G allele in the celiac disease group com-
pared to the controls (53.7% vs. 56.7%) (Table 4).
Discussion
In this study we have confirmed the association of both IL23R and ATG16L1 with CD suscep-
tibility in the Dutch population. We also replicated the association of IL23R with the UC phe-
notype. The two SNPs in IL23R and ATG16L1 did not show association to celiac disease. The 
rs11209026 SNP in IL23R is a non-synonymous SNP (1142G→A) resulting in an amino acid 
change, Arg381Gln, and the glutamine allele appears to protect against the development of 
CD. This protective effect has been replicated in an independent cohort very recently and 
was also confirmed in two independents studies in childhood onset inflammatory bowel 
diseases. 24-26 The rare A-allele was present in approximately 3% of IBD patients in contrast to 
6.0 % of the controls in these studies. In our study we found an even lower frequency of 1.2% 
in patients compared to 6.5% in controls IL23R resides on chromosome 1p31 and encodes a 
subunit of the proinflammatory cytokine IL23 receptor. IL23 is a heterodimeric cytokine con-
sisting of a p19 and a p40 unit.27 The finding of IL23R as an IBD susceptibility gene is intrigu-
ing, since several studies have highlighted the central role of IL23 in gut inflammation. It has 
been suggested that IL23 initiates and perpetuates both innate- and T-cell-mediated intesti-
nal inflammation.28 Interestingly, a double-blind controlled study with a human monoclonal 
antibody against interleukin-12 (IL12) showed a positive effect on induction of remission in 
patients with active CD. This antibody was directed against the p40 subunit of IL12, which 
is shared with IL23. Hence, it is tempting to speculate that the observed anti-inflammatory 
effect was (partly) caused by suppression of IL23 rather then IL12.29 However, it remains to be 
elucidated how genetic variants of IL23R are involved in IBD susceptibility. 
Hampe et al. described the association of ATG16L1 as a susceptibility gene for CD.16 In our 
study population we were able to confirm the association of ATG16L1 with CD. We found a 
population attributable risk for carrying allele G of 0.24 for IBD and 0.24 for CD, which are 
similar to the values observed in the original paper.16 We could not define specific genotype-
phenotype associations in our study population for both CD and UC, possibly due to the lack 
of power. In recent reports the association of ATG16L1 with CD has been consistently repli-
cated. A large genome wide association study identified the association with the rs2241880 
SNP and confirmed this in two independent replication studies.30 Furthermore, two other 
studies found similar results.31 32 In one of these studies a modest association was also found 
for ulcerative colitis. Although we did not observe a significant association with UC, the trend 
was the same as for CD, both in the case-control analysis and in the transmission disequilib-
rium test. Since our UC study group was relatively small (n=207) the association did not reach 
significant values.
Preliminary data provided by Hampe et al. showed expression of the ATG16L1 protein in 
the intestinal epithelium, but there was no difference in pattern or degree of expression 6
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in tissue from CD patients compared to controls. There was also no difference in protein or 
cDNA expression in patients carrying different genotypes for rs2241880. ATG16L1 is part of 
the autophagosome pathway. Autophagocytosis mediates the bulk degradation of cytoplas-
mic components to the lysosome/vacuole. The process is involved in protein turnover, the 
starvation response, cellular differentiation and cell death, but also in the processing of in-
tracellular bacteria.33 34 How this process is implicated in susceptibility for CD remains elusive, 
although it would support the concept of CD being an inflammatory barrier disorder.35 
Celiac disease and IBD might share some genetic components, since they share at least two 
linkage peaks that have been well established for both diseases – on chromosomes 5q31 
(CELIAC2, IBD5) and 19p13.1 (CELIAC4, IBD6).36 37 The discovery that the MYOB9B gene is as-
sociated with both celiac disease and IBD further suggests that these diseases share part of 
their genetic susceptibility. We investigated whether IL23R and ATG16L1 variants are common 
genetic risk factors for both IBD and celiac disease, but found no association of celiac disease 
with either IL23R or ATG16L1.
In conclusion, we confirm the genetic association of IL23R with both Crohn’s disease and 
ulcerative colitis, and for ATG16L1 with Crohn’s disease, in a Dutch cohort of Caucasian IBD 
patients. Larger studies are needed to define specific genotype-phenotype associations.ATG16L1, IL23R and IBD
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Abstract 
Background: Inflammatory bowel diseases –consisting of Crohn’s disease (CD) and ulcera-
tive colitis (UC)- have a complex genetic background. Several genes have been found to be 
associated with IBD susceptibility. We performed a large population based case-control study 
in well phenotyped patients, in order to have enough power to detect these low penetrant 
genes and to find associations with different subsets of IBD patients. Furthermore, we as-
sessed the risk for developing IBD when combining information from multiple genes.
Methods: 2937 patients with IBD (1696 CD, 1099 UC and 142 Indeterminate Colitis) and 1484 
controls from 7 University Medical Centres in the Netherlands were included. A set of 8 SNPs 
was used for SLC22A4/5, 4 SNPs for DLG5 and 1 SNP for ATG16L1. Phenotypic details were 
available for 2091 patients (1316 CD and 775 UC).
Results: SLC22A4/5 is associated with IBD but this was not independent from the IBD5 locus. 
The IBD5 locus was associated with CD with an early age of onset and a complicated disease 
course. DLG5 is associated with both CD and UC. ATG16L1 is associated with CD, specifically 
with ileal localization and stricturing behavior. Individuals carrying an increasing number of 
risk alleles were at increasing risk for CD. The progressive increase in Odds Ratios is consistent 
with an independent effects multiplicative model. CD patients with a more severe disease 
course or operations had significantly more risk alleles compared to patients without opera-
tions or non-stricturing, non-penetrating behavior.
Conclusion: We confirmed the association of the IBD5 locus, DLG5 and ATG16L1 with CD and 
identified specific phenotypes in the Dutch Caucasian population. DLG5 and the IBD5 locus 
are also associated with UC indicating that they are a risk factor for IBD in general. 
Combining information from the known common risk polymorphisms may enable clinicians 
to predict the disease course of inflammatory bowel disease patients in the future.7
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Introduction
Chronic inflammatory bowel diseases (IBD) comprising Crohn’s disease (CD) and ulcerative 
colitis (UC) are characterized by chronic relapsing inflammation of the gastrointestinal tract. 
The combined prevalence of CD and UC is estimated at 100 – 200 / 100.000 in developed 
countries.1 2 Concordance rates in twins and siblings suggest that a genetic predisposition, 
contributes to the pathogenesis of IBD.3 4  
In 2001 the CARD15 gene on chromosome 16 was identified as a susceptibility gene for IBD.5 6 
Three mutations (R702W, G908R, and 1007fsinsC) are independently associated with CD in 
Caucasian patients. IBD shows a variation in the individual clinical presentation and out-
come that is most likely due to differences in the genetic susceptibility in combination with 
exposure to environmental factors, the commensal bacteria in the intestine, and the intes-
tinal immune system. Since IBD are complex genetic diseases, multiple genes are probably 
involved in the pathogenesis, each with a small overall contribution to IBD susceptibility. 
Next to CARD15 several consecutive genes have been implied to be involved in IBD suscep-
tibility, although none of them has been as consistently replicated as CARD15. Three of the 
most promising genes to be truly associated are SLC22A4/5 within the IBD5 locus, DLG5 and 
ATG16L1.7-9
A genome wide screen in affected Canadian families identified linkage with a region at chro-
mosome 5q31-q33 (IBD5) with a length of approximately 250 kb conferring susceptibility 
for CD. 10  Identifying the causative gene(s) in the IBD5 locus has been hampered by the high 
extent of LD in the region. Nevertheless, two functionally relevant mutations (1672 C→T 
and -207G→C) in SLC22A4/5 encoding for the carnitine / organic cation transporter 1 and 2 
(OCTN1/2) on the IBD5 locus were associated with CD.7 Gene-gene interaction with CARD15 is 
suggested.11 Following studies showed contradictory results and the associations found were 
much weaker than in the original study.12-14   
By refining their previously defined linkage region on chromosome 10q23, Stoll et al. iden-
tified the Drosophila Discs Large Homologue 5 (DLG5) gene as a susceptibility gene for CD 
and IBD.8 SNP 113 G→A, resulting in an amino acid substitution R30Q, and a low frequent 
SNP 4136 C→A (P1371Q) were positively associated with IBD and CD. DLG5 is important in 
maintaining the epithelial structure and genetic variants could result in impaired intestinal 
permeability.15 One study has been able to reproduce these results but other studies from 
Europe and Japan failed to show any association for DLG5 with IBD.16-18
A recent study  found a strong association between CD and the autophagy-related 16-like 1 
gene (ATG16L1) encoding a protein in the autophagosome pathway, which processes intra-
cellular bacteria.9 A genome-wide association scan in 735 German patients with CD and 368 
controls was performed.  Analysis of the most informative SNPs in an independent cohort of 
CD patients and controls identified ATG16L1 as a CD susceptibility gene. Marker rs2241880, 
a coding SNP (Thr300Ala), was strongly associated with susceptibility for CD. It was suggested 
that there is an epistatic effect with one of the three CD associated alleles in CARD15. 
Many of the replication studies on SLC22A4/5 and DLG5 are hampered by the relatively small 
numbers. To detect low penetrant genes or to have enough power to find associations with 
different subsets of IBD patients, large population based case-control studies in well pheno-Predicting occurrence and severity of Crohn’s disease
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typed patients are needed. In this study we aimed to answer three important questions. First, 
we aimed to investigate whether the previously described associations with SLC22A4/5, DLG5 
and ATG16L1 are present in the Dutch Caucasian population. Second, we studied whether 
these associations were specific for different phenotypic subsets of IBD patients. Further-
more, we examined the risk for CD when combining information from these three genes.   
Therefore, we analyzed the association of SLC22A4/5, DLG5 and ATG16L1 with IBD, CD, UC 
and different subsets of CD and UC in a large nationwide case-control study including well 
phenotyped IBD-patients from seven University Hospitals in the Netherlands.
Methods
Patients and controls
The study population consisted of 2937 patients with IBD (1696 CD, 1099 UC and 142 Inde-
terminate Colitis) and 1484 controls from seven participating hospitals in the Netherlands: 
Academic Medical Center, Amsterdam (n=758), VU University Medical Center, Amsterdam 
(n=636), University Medical Center Groningen, Groningen (n=533), Leiden University Medi-
cal Center, Leiden (n=505), Erasmus Medical Center, Rotterdam(n=267), Radboud University 
Nijmegen Medical Center, Nijmegen (n=157), and University Medical Center Utrecht, Utre-
cht (n=81).19-24 Controls consisted of healthy volunteers from the University Medical Center 
Utrecht (n=868), University Medical Center Leiden (n=168) and from the University Medical 
Center of Nijmegen (n=139).19 23 24 The cohort of the University Medical Center Groningen 
included a large proportion of trios. When DNA of parents was available the non-transmitted 
haplotypes of each parent were used as a control. When DNA of a child and a spouse was 
available, both haplotypes of the spouse were regarded as a control (n=309).21 
Patients were diagnosed on accepted clinical, endoscopic, radiological and histological find-
ings.1 Almost all individuals studied were of European Caucasian descent. All patients gave 
informed consent and the study was approved by the institutional ethics review commit-
tee of each participating hospital. All DNA samples and data in this study were handled 
anonymously. For CD patients phenotypic details were registered according to the Vienna 
classification.25 For UC patients, phenotypes were described according to age of onset, extend 
of disease (proctitis, leftsided, or extended), necessity of colectomy and the occurrence of 
malignancy and extraintestinal manifestations. Phenotypic details were available for 2091 
patients (1316 CD and 775 UC) and are presented in table 1 and 2. 
Genotyping and SNP Selection 
DNA was extracted from 20 ml EDTA-blood following standard procedures and was stored at 
-80 oC. Primers to amplify the polymorphic loci were selected using Primer3 software.26 SNP 
genotyping was performed as described previously.21 A set of eight SNPs was analyzed for 
SLC22A4/5. This set included the two known risk-associated SNPs 1672 C→T (rs1050152),7
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Table 1.  Details of patients with Crohn’s Disease with phenotypic description available.
Total number        1316
Sex (m/f)         466 / 850
Age at diagnosis ¶
  < 40 yrs        1053     (80%)
  > 40 yrs        263    (20%)
Disease localisation ¶ †
  Ileal           319 / 1316    (24.3%)
  Colon          392 / 1316     (29.8%)  
  Ileocolon        561 / 1316     (42.7%)
  Upper GI tract         178 / 1316    (13.5%)
Disease behaviour ¶
  Non-stricturing, non penetraiting    529 / 1307    (40.5%)
  Stricturing        345 / 1307    (26.4%)
  Penetrating        433 / 1307    (33.1%)
Perianal Disease ¶        275 / 1031    (26.7%)
Extraintestinal Manifestations ¶      244 / 1196     (20.4%) 
Operation ¶        604 / 1196    (50.5%)
Family history of IBD ¶      183 / 1316    (13.9%)
¶   Data depicted as cases / total number of patients with specific phenotypic detail available.
†  Patients could be classified as having disease localization in the upper GI tract next to ileal, colonic or 
ileocolonic localization. 44 patients (3.3%) had disease localization in the upper GI tract exclusively.
Table 2.  Characteristics of patients with ulcerative colitis with phenotypic description available.
Total number        775
Sex (m/f)          416 / 359
Age at diagnosis (years) ¶
 < 40 yrs          545 /769    (70.9%)
  > 40 yrs        224 /769    (29.1%)
Disease localisation ¶
  Proctitis         115 / 754    (15.3%)
  Leftsided        299 / 754    (39.6%)  
  Extended        340 / 754    (45.1%)
Extraintestinal Manifestations ¶      95 / 520     (18.3%) 
Operation ¶        124 / 619    (20.0%)   
Development of malignancy ¶      6 / 619     (1.0%)
Family history of IBD ¶      101 / 775    (13.0%)
¶  Data depicted as cases / total number of patients with specific phenotypic detail available.Predicting occurrence and severity of Crohn’s disease
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-207G→C (rs2631367) and SNP (rs3792876) which was found to be strongly associated to pedi-
atric IBD in our institute.7 26 Additionally three tagging SNPs within the region were analyzed 
(rs272893, rs273900 and rs274551). Two markers located at the 3’ end (rs2522057) and 5’ end 
(rs7705189) were chosen to analyze linkage disequilibrium within the IBD5 region. Four SNPs 
were analyzed for DLG5 including the two risk associated SNPs 113 G→A (rs1248696, haplo-
type D) and 4136 C→A (rs2289310, haplotype C) from the original paper by Stoll et al.8 Two 
additional haplotype tagging SNPs were chosen to determine haplotype A (rs2289311) and 
haplotype B (rs2165047). The risk associated SNP rs2241880 was determined for ATG16L1.9 
Marker data for all analyzed SNPs are described in table 3.
Statistical methods
As samples from multiple centers were combined, we first tested for homogeneity of the 
genotype data between centers. Genotype frequencies were compared between the centers 
using a chi-square test separately for cases and controls. If no homogeneity was observed 
(p<0.05), samples from the center showing the most deviating genotyping frequencies were 
discarded. Hardy-Weinberg equilibrium was tested among the unrelated unaffected indi-
viduals using a chi-square test with 1 degree of freedom. If a marker showed deviation from 
Hardy-Weinberg equilibrium (p<0.05), the marker was discarded from further analyses. The 
allele and genotype frequencies of patients and controls were compared to test for associa-
tion using the chi-square test or the Fisher’s exact test when appropriate. 
Odds ratios (ORs) and 95% confidence intervals (CI) were estimated using binary logistic regres-
sion (SPSS 12). Binary logistic regression was also used to determine pairwise and three-way 
Table 3. Marker data for genetic analysis of SLC22A4/5, DLG5 and ATG16L1.
Marker  Type
SLC22A4/5
rs7705189 A→G 5’ end IBD5
rs3792876 C→T
rs272893 1082 C→T
rs1050152 1672 G→C F503L
rs273900 G→A
rs2631367 -207 G→C
rs274551 C→T
rs2522057 C→G 3’ end IBD5
DLG5
rs2165047 C→T Haplotype B
rs2289311 A→G Haplotype A
rs2289310 4136 C→A Haplotype C; P1371Q
rs1248696 113 G→A Haplotype D; R30Q
ATG16L1
rs2241880 G→A T300A7
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gene-gene interaction effects with inclusion of the main effects of each gene in the model. 
In addition, ORs for CD were calculated in a binary logistic regression analysis with number 
of risk alleles at IBD5 rs2522027, DLG5 rs2289310 and ATG16L1 rs2241880 as independent 
variable compared to controls with zero or one risk allele. Ordinal regression was performed 
to test whether a more complex course of CD was associated with an increased number of 
risk alleles. Linkage disequilibrium (LD) parameters D’ and r2 were calculated for all pairs of 
SNPs within the SLC22A4/5 gene region and within DLG5.
Since all three genes were already identified as candidate genes for IBD, CD and UC, no mul-
tiple testing correction is required for testing for susceptibility. Therefore, a multiple testing 
correction was only performed in the genotype-phenotype subgroup analyses for the number 
of complementary subgroups of patients using a Bonferroni correction. 
Results
Allelic associations for DLG5, SLC22A4/5 and ATG16L1 and IBD, CD and UC are summarized 
in table 4. 
SLC22A4/5 / IBD5
The previously described CD associated SNP rs1050152 (1672G→C) was associated with both 
CD (p=0.046) and UC (p=0.049).  Rs2631367 (-207G→C) was not associated with IBD, CD, UC or 
any subset. Nevertheless, the risk associated TC haplotype for these two SNPs combined was 
overrepresented in CD patients (41%) and UC patients (41.4%) compared to controls (34.6%). 
We also observed an association with rs2522057 at the 3’end of IBD5 (OR 1.15; CI 1.05-1.25; 
p=0.002) with IBD and CD (OR1.15; CI 1.04-1.27; p=0.003) and for rs7705189 at the 5’end of 
IBD5 with IBD (OR 1.10; CI 0.99-1.23, p=0.040). The association for rs2522057 was strongest 
for CD with perianal disease (OR 1.37; CI 1.00-1.86; p=0.048) and for carriage of the G-allele 
for SNP rs7705189 at the 5’end of IBD5 with the necessity of operation in CD (OR 1.32; CI 
1.02-1.70; p=0.035). SNP rs273900, which resides between SLC22A4 and SLC22A5, was associ-
ated with IBD (OR 1.11; CI 1.00-1.23; p=0.023). An increased risk was found for carriers of 
the A-allele of rs273900 for a complicated course of CD (penetrating and stricturing disease 
combined; OR 1.19; CI 1.01-1.41; p=0.039). Carriage of the C-allele for SNP rs3792876 was 
associated with CD with an early age of onset (OR 12.21; CI 1.27-117.89; p=0.009).
SNPs rs272893, rs273900 and rs274551 showed no homogeneity (p<0.05) and the control 
group of the University Medical Center Groningen was discarded for further analysis for these 
SNPs. In the remainder of the controls all SNPs satisfied the HWE criteria. All markers were 
in strong LD (figure 1).
DLG5
Allele C of SNP rs1248696 (R30Q, haplotype D) was associated with IBD (frequencies; OR 
1.20; CI 1.05-1.37; p=0.004). This association was present both for CD (OR 1.17; CI 1.01-1.37; 
p=0.019) and UC (OR 1.25; CI 1.05-1.49; p=0.006). The PAR for carrying allele C was 12.6% for Predicting occurrence and severity of Crohn’s disease
106
T
a
b
l
e
 
4
.
 
A
l
l
e
l
i
c
 
A
s
s
o
c
i
a
t
i
o
n
 
A
n
a
l
y
s
i
s
 
f
o
r
 
S
L
C
2
2
A
4
/
5
,
 
D
L
G
5
 
a
n
d
 
A
T
G
1
6
L
1
 
f
o
r
 
I
n
fl
a
m
m
a
t
o
r
y
 
B
o
w
e
l
 
D
i
s
e
a
s
e
s
 
(
I
B
D
,
 
n
=
2
9
3
7
)
,
 
C
r
o
h
n
’
s
 
d
i
s
e
a
s
e
 
(
C
D
,
 
n
=
1
6
9
6
)
 
a
n
d
 
 
u
l
c
e
r
a
t
i
v
e
 
c
o
l
i
t
i
s
 
(
U
C
,
 
n
=
1
0
9
9
)
.
 
 
C
o
n
t
r
o
l
s
I
B
D
 
C
D
 
 
U
C
 
S
N
P
 
I
D
A
l
l
e
l
e
C
o
n
t
r
o
l
/
T
o
t
a
l
 
(
%
)
C
a
s
e
/
T
o
t
a
l
 
(
%
)
P
 
v
a
l
u
e
*
C
a
s
e
/
T
o
t
a
l
 
(
%
)
P
 
v
a
l
u
e
*
C
a
s
e
/
T
o
t
a
l
 
(
%
)
P
 
v
a
l
u
e
*
S
L
C
2
2
A
4
/
5
 
 
 
 
 
 
 
r
s
7
7
0
5
1
8
9
G
8
1
8
/
1
8
0
4
 
(
4
5
,
3
%
)
2
4
6
3
/
5
1
6
0
 
(
4
7
,
7
%
)
0
,
0
4
0
1
4
7
1
/
3
0
9
8
 
(
4
7
,
5
%
)
0
,
0
7
4
8
8
2
/
1
8
4
2
 
(
4
7
,
8
%
)
0
,
0
6
2
r
s
3
7
9
2
8
7
6
C
2
4
0
4
/
2
6
2
2
 
(
9
1
,
6
%
)
5
3
9
3
/
5
8
3
4
 
(
9
2
,
4
%
)
0
,
1
1
5
3
0
6
8
/
3
3
4
0
 
(
9
1
,
8
%
)
0
,
4
0
6
2
0
0
9
/
2
1
6
2
 
(
9
2
,
9
%
)
0
,
0
5
6
r
s
2
7
2
8
9
3
C
1
3
3
0
/
2
1
4
0
 
(
6
2
,
1
%
)
3
7
0
2
/
5
7
3
4
 
(
6
4
,
6
%
)
0
,
0
2
4
2
1
1
0
/
3
3
6
0
 
(
6
3
,
9
%
)
0
,
0
9
1
1
3
8
0
/
2
1
1
8
 
(
6
5
,
1
%
)
0
,
0
2
1
r
s
1
0
5
0
1
5
2
C
1
6
6
3
/
2
8
8
8
 
(
5
7
,
6
%
)
3
2
5
4
/
5
8
6
4
 
(
5
5
,
5
%
)
0
,
0
3
0
1
8
6
7
/
3
3
6
6
 
(
5
5
,
5
%
)
0
,
0
4
6
1
1
9
9
/
2
1
7
0
 
(
5
5
,
3
%
)
0
,
0
4
9
r
s
2
7
3
9
0
0
C
1
3
1
3
/
2
1
5
2
 
(
6
1
,
0
)
3
5
3
8
/
5
5
7
4
 
(
6
3
,
4
%
)
0
,
0
2
3
2
0
1
3
/
3
1
8
6
 
(
6
3
,
2
%
)
0
,
0
5
5
1
3
2
3
/
2
0
7
4
 
(
6
3
,
8
%
)
0
,
0
3
1
r
s
2
6
3
1
3
6
7
C
1
2
1
4
/
2
5
7
8
 
(
4
7
,
0
%
)
2
3
0
4
/
4
7
1
0
 
(
4
8
,
9
%
)
0
,
0
6
8
1
3
5
9
/
2
7
7
2
 
(
4
9
,
0
%
)
0
,
0
7
9
8
4
4
/
1
7
3
0
 
(
4
8
,
7
%
)
0
,
1
3
8
r
s
2
7
4
5
5
1
C
1
8
4
6
/
2
2
0
4
 
(
8
3
,
7
%
)
4
7
7
6
/
5
6
9
0
 
(
8
3
,
9
%
)
0
,
4
2
3
2
7
5
5
/
3
2
5
4
 
(
8
4
,
7
%
)
0
,
1
8
3
1
7
6
1
/
2
1
1
0
 
(
8
3
,
5
%
)
0
,
3
9
5
r
s
2
5
2
2
0
5
7
C
1
1
9
7
/
2
9
0
4
 
(
4
1
,
2
%
)
2
6
1
8
/
5
8
7
8
 
(
4
4
,
5
%
)
0
,
0
0
2
1
5
0
1
/
3
3
6
2
 
(
4
4
,
6
%
)
0
,
0
0
3
9
7
6
/
2
1
8
0
 
(
4
4
,
7
%
)
0
,
0
0
6
D
L
G
5
 
 
 
 
 
 
 
r
s
1
2
4
8
6
9
6
G
2
5
0
1
/
2
8
8
0
 
(
8
6
,
8
%
)
5
1
8
2
/
5
8
3
6
 
(
8
8
,
7
%
)
0
,
0
0
4
2
9
6
9
/
3
3
5
2
 
(
8
8
,
6
%
)
0
,
0
1
9
1
9
2
3
/
2
1
5
6
 
(
8
9
,
2
%
)
0
,
0
0
6
r
s
2
2
8
9
3
1
0
C
2
4
7
9
/
2
6
1
8
 
(
9
4
,
6
%
)
5
5
2
9
/
5
7
7
6
 
(
9
5
,
7
%
)
0
,
0
1
8
3
2
0
6
/
3
3
4
0
 
(
9
6
,
0
%
)
0
,
0
0
9
2
0
0
1
/
2
1
0
2
 
(
9
5
,
2
%
)
0
,
2
1
5
r
s
2
2
8
9
3
1
1
G
6
7
5
/
1
0
5
4
 
(
6
4
,
0
%
)
1
7
6
4
/
2
7
6
2
 
(
6
3
,
9
%
)
0
,
4
6
0
1
0
4
7
/
1
6
2
8
 
(
6
4
,
3
%
)
0
,
4
4
4
5
8
1
/
9
3
0
 
(
6
2
,
5
%
)
0
,
2
3
5
r
s
2
1
6
5
0
4
7
C
2
1
5
9
/
2
8
8
2
 
(
7
4
,
9
%
)
4
2
1
7
/
5
8
5
4
 
(
7
2
,
0
%
)
0
,
0
0
2
2
4
0
1
/
3
3
5
2
 
(
7
1
,
6
%
)
0
,
0
0
2
1
5
7
7
/
2
1
6
6
 
(
7
2
,
8
%
)
0
,
0
4
6
A
T
G
1
6
L
1
 
 
 
 
 
 
 
r
s
2
2
4
1
8
8
0
G
1
5
1
5
/
2
6
6
4
 
(
5
6
,
8
%
)
3
3
4
3
/
5
6
8
4
 
(
5
8
,
8
%
)
0
,
0
4
5
1
9
7
5
/
3
2
3
2
 
(
6
1
,
1
%
)
0
,
0
0
0
5
1
1
8
2
/
2
1
2
6
 
(
5
5
,
6
%
)
0
,
1
8
5
*
 
o
n
e
-
s
i
d
e
d
 
p
-
v
a
l
u
e7
107
IBD, 6.5% for CD and 22.1% for UC.  The association with UC was strongest for patients with 
leftsided and extensive colitis combined (OR 1.69; CI 1.10-2.61; p=0.014). We did observe an 
association of SNP rs2289310 (P1371Q, haplotype C) with IBD (OR 1.26;CI 1.01-1.55; p= 0.018) 
and CD (OR 1.34; CI 1.05-1.71; p=0.009).  We found a significant difference in SNP rs2165047 
minor allele T frequency (haplotype B) for IBD (OR 0.72; CI 0.56-0.92; p=0.002) and for CD 
(OR 0.70; CI 0.53-0.91; p=0.002). SNP rs2289311 (haplotype A) was not associated with IBD, 
CD, UC or any subset.
SNP rs2289310 in the controls from the Radboud University Medical Center, Nijmegen and 
SNP 2289311 in the cases from the Academic Medical Center, Amsterdam showed deviating 
genotype frequencies (homogeneity p<0.05) and these specific groups were discarded for 
further analysis for. All markers were in LD. (figure 2).
ATG16L1
For the ATG16L1 rs2241880 SNP we observed an increased frequency of allele G in CD cases 
(61.1%) vs controls (56.8%) (OR=1.19; CI: 1.07–1.32; p=0.0005). The association was also 
significant on the genotype level (OR=1.46; CI: 1.18-1.81; p=0.0025). The PAR for carrying 
allele G in CD is 11.6% and for homozygosity for allele G 11.9%. With respect to phenotypic 
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Figure 1. 
Linkage disequilibrium 
(LD) across SLC22A4/5 
and the flanking genomic 
region of the IBD5 locus. 
D’ values for LD are 
shown for each pair of 
markers. All markers are 
in strong LD.
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Figure 2.
Linkage  disequilibrium  (LD)  across  DLG5. 
D’ values for LD are shown for each pair of 
markers. All markers are in LD.Predicting occurrence and severity of Crohn’s disease
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subgroups we found an allelic association with stricturing behavior of CD (OR=1.27; CI 1.0-
1.55; p=0.018) and a tendency to association for carriership of the G-allele with operated CD 
(OR1.40; CI 1.01-1.95; p=0.067). The rs2241880*G allele was underrepresented in the group 
with CD with colonic localization and therefore overpresented in the ileocolonic and ileal 
localized CD groups combined (OR1.20; CI 1.01-1.45; p=0.05)
The rs2241880 showed homogeneous genotype frequencies among the different centers and 
was in HWE in the combined control group. 
Interaction of  DLG5, ATG16L1 and IBD5 for Crohn’s disease susceptibility
Interaction analysis was performed for the following three CD associated risk genotypes: car-
riage of the rs2522027*C allele for IBD5, carriage of the rs2241880*G allele for ATG16L1 and 
homozygosity for the rs2289310*C allele for DLG5. Pairwise and three-way gene-gene interac-
tion analysis did not show any evidence for statistical interaction on top of the main effects 
of the individual genes.
Individuals carrying an increasing number of risk alleles were at increasing risk for CD com-
pared to the 9.5% of the controls carrying zero or one risk alleles (Figure 3). This reference 
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Figure 3.
Odds Ratios (OR) and confidence intervals (CI) for patients carrying increasing numbers of risk alleles 
for developing Crohn’s disease. The risk alleles are IBD5 (the rs2522027*C allele), DLG5 (homozygosity 
for the rs2289310*C allele) and ATG16L1 (the rs2241880*G allele). The reference group consists of 
individuals with zero or one risk allele. The progressive increase in ORs is consistent with an independ-
ent effects multiplicative model.7
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group was chosen because only 0.5% of the controls carried zero risk alleles.  In this figure the 
risk “allele” for DLG5 rs2289310 is the second C allele because the AC genotype was considered 
the reference genotype due to the low prevalence of the AA genotype. It is shown that with 
an increasing number of risk alleles the OR for CD susceptibility increases. The progressive 
increase in ORs is consistent with an independent effects multiplicative model. Next, we used 
ordinal regression to determine whether an increasing number of risk alleles were associated 
with a more severe disease course. We found that operated CD patients had significantly 
more risk alleles compared to patients who were not operated (p=0.0049). Likewise, patients 
with a more severe disease course (stricturing or penetrating behavior) had more risk alleles 
compared to patients with non-stricturing, non-penetrating behavior (p=0.0097). 
Discussion
It is of utmost importance that previously found genetic associations for IBD are confirmed 
in independent cohorts with enough power to detect specific genotype-phenotype interac-
tions.28  To our knowledge, this is the largest replication study that has been performed for 
the association of SLC22A4/5, DLG5 and ATG16L1 with IBD.  Furthermore this is the first study 
to look at the combined impact of three genetic variants associated with CD susceptibility. 
We showed that the relative risk for CD increases with an increasing number of risk alleles, 
consistent with an independent effects multiplicative model. 
First, we confirmed the association for CD with the IBD5 haplotype. There have been several 
studies that confirmed the association of the IBD5 haplotype with CD, but identifying the 
true causal genes has been hampered by the high extend of LD in the region. Peltekova et al. 
found a two locus risk haplotype (“TC haplotype”) in SLC22A4 and SLC22A5 to be associated 
independently of the background risk haplotype of IBD5. 7 Although the previously described 
TC haplotype in SLC22A4/5 was overrepresented in IBD patients compared to the controls in 
our study, this effect was not independent of the IBD5 haplotype. For the individual SNPs 
at these loci we did find an association for rs1050152 (1672G→C)  but not for rs2631367 (-
207G→C). Our study was sufficiently powered (80% power; p=0.05 in a multiplicative model) 
to detect an association for these two SNPs in SLC22A4/5 with an OR of 1.148. Besides this 
we did find an association for (subsets of) CD with markers at the 5’ and 3’ end of the IBD5 
locus and with a marker in between SLC22A4 and SLC22A5. This indicates that SLC22A4/5 are 
associated with CD but that this is not independent from the IBD5 locus. Despite the fact that 
the true causal gene within the IBD5 locus is not identified yet, many studies have analyzed 
specific genotype-phenotype associations for IBD5. We observed an association with an early 
age of onset and a complicated course of CD with specific SNPs in the region. This is in line 
with several previously published studies reviewed by Reinhard et al.29
Multiple studies have been performed with conflicting results, regarding the association 
of the R30Q variant (SNP rs1248696) within DLG5 with IBD and CD (reviewed by Friedrichs 
et al.)30 In our study we did find an association for IBD, but surprisingly this risk was higher 
for UC than for CD, in particular with for UC with an extensive phenotype (e.g. leftsided and Predicting occurrence and severity of Crohn’s disease
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extensive colitis combined). Moreover, this association was observed with the major allele C 
instead of the minor allele as described by Stoll et al.8 This is a novel finding as none of the 
previously published studies have found an association for the R30Q variant with UC.30 There 
is substantial heterogeneity for the R30Q variant among different populations, even within 
Europe, which may be responsible for negative results in previous studies. Furthermore, we 
did confirm the association of P1371Q (SNP rs2289310) with CD, but could not confirm the 
protective effect of the haplotype A tagging SNP (rs2289311) as observed in the original paper.8   
Interestingly, we did find a protective effect for both CD and UC for the haplotype B tagging 
SNP rs2165047, which has not been found to be associated with IBD before. There were no 
gender-specific effects for DLG5 in our population as has been observed before.30 Our results 
regarding DLG5 and IBD susceptibility show that there is an association with IBD but this 
effect is not exclusive for CD. This indicates that DLG5 is not disease specific but a risk factor 
for IBD in general. 
Furthermore, we could confirm the association of ATG16L1 with CD. In an initial analysis of 
the cohort of the University Medical Center Groningen (this thesis, chapter 6), we found a 
population attributable risk for carrying allele G of 0.24 for CD, which is similar to the value 
observed in the original paper.9  When we analyzed the association in the total cohort it still 
was significantly associated but the PAR fell to 0.116. This is in line with other genetic associa-
tion studies, where the first study often suggests a stronger effect than is found by subsequent 
studies.31  This might be due to bias or due to genuine population diversity. We found the as-
sociation in particular with CD with ileal or ileocolonic localization, stricturing behavior and 
a history of surgical intervention. As stricturing behavior is mostly confined to localization in 
the ileum which frequently results in the necessity of surgery, this is an expected combina-
tion. This is the first report of an association of ATG16L1 with a specific phenotype of CD.  We 
could not find any other associations with UC or any specific subsets, 
In this study we show that when combining the information from ATG16L1, DLG5 and the 
IBD5 region the risk for developing CD increases. There is no specific gene-gene interaction 
between these three genes but the risk increases with an increasing number of risk alleles. 
This is the first time that this effect is reported for CD. It is consistent with the idea that mul-
tiple genes are involved in CD susceptibility, each with a small overall contribution. We dem-
onstrated that it is possible to combine information from multiple common low-penetrance 
variants to predict the susceptibility for a complex disease. Moreover, an increasing number 
of risk alleles was not only associated with CD susceptibility but also with a more complex 
disease course. Patients with more risk alleles or genotypes had a more severe disease behav-
ior and were more frequently operated. This is an important finding because this emphasizes 
the fact that it might be possible in the near future to create a genetic risk-profile for a patient 
to predict the disease course. 
In conclusion, we performed the largest case control study for genetic variants in DLG5, SL-
C22A4/5 and ATG16L1 and IBD susceptibility to date. In the Dutch Caucasian population we 
confirmed the association of ATG16L1 with Crohn’s disease specifically with stricturing behav-
iour. Secondly, we confirmed the association of DLG5 with inflammatory bowel diseases, not 
only with Crohn’s disease but also with ulcerative colitis. This indicates that DLG5 is a risk fac-
tor for both phenotypes of inflammatory bowel disease. Thirdly, we found an association of 7
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the IBD5 locus with Crohn’s disease which was not independent of the SLC22A4/5 genes. Most 
importantly, we showed that when combining the risk-associated variants the relative risk for 
developing Crohn’s disease increases with an increasing number of risk alleles or genotypes 
consistent with an independent effects multiplicative model. Furthermore, an increase in 
risk-alleles was associated with a more complex disease course. This finding may enable clini-
cians to predict the disease course of inflammatory bowel disease patients in the future.Predicting occurrence and severity of Crohn’s disease
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Abstract
Background: Azathioprine is widely used in Crohn’s disease. A major drawback is the oc-
currence of side effects, especially acute pancreatitis. Acute pancreatitis is rarely seen when 
azathioprine is used for other diseases than Crohn’s disease. 
Methods: The study is a retrospective case note survey of side effects of azathioprine after 
liver or renal transplantation, for systemic lupus erythemathosis, Wegener’s granulomatosis, 
autoimmune hepatitis, rheumatoid arthritis, ulcerative colitis or Crohn’s disease. A comput-
erized search using the term “azathioprine” or “imuran” was done on the Hospital Informa-
tion System of the university hospital Groningen, resulting in 1564 patients matching our 
criteria. 
Results: Eleven of 224 patients with Crohn’s disease experienced acute pancreatitis (4,9%) 
compared to 2/129 (1,5%) with autoimmune hepatitis, 2/388 (0,5%) after renal transplanta-
tion, 1/254 (0,4%) after liver transplantation. Acute pancreatitis was more prevalent in Crohn’s 
disease compared to any other disease. Azathioprine-toxicity necessitating withdrawal oc-
curred significantly (p<0,05) more in rheumatoid arthritis (78/317), ulcerative colitis (20/94) 
and Crohn’s disease (52/224) compared to systemic lupus erythemathosis (5/73), Wegener’s 
granulomatosis (6/85), autoimmune hepatitis (8/129), after liver transplantation (17/254) and 
after renal transplantation (22/388). 
Conclusions: Acute pancreatitis is strongly associated with Crohn’s disease and rarely occurs 
with other underlying conditions. Overall azathioprine-induced toxicity and the necessity 
of withdrawal is more common in inflammatory bowel diseases and rheumatoid arthritis 
compared to other diseases. 8
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Introduction
Azathioprine is a purine analogue that competitively inhibits the biosynthesis of purine nu-
cleotides. After absorption it is metabolized to 6-mercaptopurine and 6-methyl-mercaptopu-
rine by thiopurinemethyltransferase (TPMT). Azathioprine is widely used in the treatment of 
inflammatory bowel disease. The occurrence of side effects, however, is a major drawback in 
the use of azathioprine. Two types of side effects have been reported: the “allergic” non-dose 
related side effects that include pancreatitis, fever, rash, malaise, hepatitis, nausea and vomit-
ing and the “non-allergic” and dose related side effects as myelosuppression. The genotype of 
TPMT is an important determinant in the latter type.1 2   
One of the side effects of azathioprine is acute pancreatitis that usually follows a mild course 
and occurs in the first 3 to 4 weeks after initiation of treatment. The pathogenesis of azathio-
prine-induced acute pancreatitis is unknown. It is dose-independent and there is no correla-
tion with myelosuppression, suggesting it is independent of TPMT-levels. A recent popula-
tion-based case-control study in Denmark found an increased relative risk for pancreatitis in 
all users of azathioprine.3 In Crohn’s disease this incidence varies between 1,4% and 5% of all 
patients treated with azathioprine 4-8
 and is 3,3% in patients treated with 6-mercaptopurine.9
 
Azathioprine is used in a number of diseases other than inflammatory bowel disease and in 
transplantation medicine. Surprisingly, acute pancreatitis is rarely seen when azathioprine 
is used for other diseases than Crohn’s disease. In patients with renal transplantation acute 
pancreatitis is seen in two out of 161 patients treated with azathioprine in one study. 10 Never-
theless, there are a lack of association between the use of azathioprine and acute pancreatitis 
in renal transplantation patients. Usually, other factors are identified to be responsible for the 
development of acute pancreatitis.11 12
In patients with rheumatoid arthritis, azathioprine is used as a disease-modifying drug. In 
large studies, no reports have been made of acute pancreatitis as a side effect.13 14 In patients 
with autoimmune hepatitis, azathioprine-induced pancreatitis is mentioned very infrequently 
and the incidence is not exactly known.15 16 Reviewing studies on systemic lupus erythematosis 
and lupus nephritis, no cases of pancreatitis were documented in two studies.17 18 Also, in a 
recent study with patients with vasculitis associated with antineutrophil cytoplasmic autoanti-
bodies treated with azathioprine, pancreatitis is not mentioned as an adverse event.19
In this study we evaluated the occurrence of azathioprine-induced acute pancreatitis in pa-
tients with Crohn’s disease and compared this to the incidence of acute pancreatitis in other 
diseases for which azathioprine is indicated. Secondly we evaluated the overall toxicity of 
azathioprine in Crohn’s disease compared to other diseases.Azathioprine induced pancreatitis in Crohn’s disease
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Methods
Patient Selection
The study was performed in a university hospital. It is a retrospective analysis of patient 
records of patients using azathioprine (Imuran®) for one of the following indications: for 
rheumatoid arthritis, systemic lupus erythemathosis, Wegener’s granulomatosis, autoim-
mune hepatitis, Crohn’s disease, ulcerative colitis, renal transplantation or liver transplantation. 
Patients used azathioprine on at least two consecutive visits. Patients with an indeterminate 
diagnosis, more than one diagnosis or with only one visit in the outpatient facility, were 
excluded. Patients using azathioprine for other indications (e.g.: polymyositis, idiopathic 
thrombocytopenic purpura, after lung or heart transplantation) were excluded. Data from 
patients with ulcerative colitis or Crohn’s disease from a gastroenterological unit from a com-
munity hospital were also separately collected.
Data Collection
Patient data in the University Hospital Groningen were retrieved from the electronic Hospital 
Information System (HIS). Patient’s documents are generated on a word processing system 
that is used hospital wide. Data are subsequently imported into the DoCma System, which 
is a permanent data archive, where patient identification is added. A query consisting of 
the keywords “azathioprine” or “Imuran” was done on the full text of the data stored in the 
subset internal medicine, using the glimpse tool (http://glimpse.cs. arizona.edu). The query 
was done on the 29th of August 2002 searching 475.032 documents of 78.906 patients. The 
specified period was from the 1st of January 1995 till the 31st of July 2002. 2654 patients with 
charts matching the query were identified. Before inclusion, each patient record was care-
fully reviewed for the use, or previous use of azathioprine. 67 Patients with Crohn’s disease 
or ulcerative colitis who were using azathioprine from a gastroenterological unit of a com-
munity hospital were analyzed separately.
The dosage of azathioprine, occurrence and type of side effects, severe enough to withdraw 
azathioprine, were noted for all patients. In the case of suspected azathioprine-induced acute 
pancreatitis, subsequent data were collected. The diagnosis of acute pancreatitis was establis-
hed by the treating physician at the time. Criteria that were used were elevated amylase in 
combination of symptoms of upper abdominal or radiating pain, or nausea and vomiting. An 
asymptomatic rise in amylase levels was not considered an acute pancreatitis. Charts were re-
viewed on the time of use of azathioprine to onset of symptoms, the need for hospitalization, 
laboratory data, clinical symptoms of acute pancreatitis, co-medication and other alternative 
etiologies for acute pancreatitis.
Statistical Analysis
To compare proportions of occurrence of side effects and necessity to withdraw azathio-
prine in different treatment groups, a chi square test was used with a p<0,05 considered 
as significant. 8
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Results
In the University Hospital the records of 2654 patients matching the query were reviewed. 
Finally 1564 patients were included. All patients who were treated with Azathioprine in the 
specified period, for the specified diseases were included. Reasons for exclusion were: treat-
ment for other diseases, patient charts with only one visit to revise or, although azathioprine 
was mentioned in their charts, patients had not actually been using azathioprine. 
Numbers of patients, treated in the university hospital, in each group were: 388 patients 
after renal transplantation, 317 patients with rheumatoid arthritis, 254 patients after liver 
patients transplantation, 224 with Crohn’s disease, 129 patients with autoimmune hepatitis, 
85 patients with Wegener’s granulomatosis, 73 patients with systemic lupus erythemathosis, 
90 patients with ulcerative colitis and four patients with indeterminate colitis, who were 
combined with the ulcerative colitis group. Mean dosage and sex distribution are depicted 
in table 1.
Acute Pancreatitis
In the university hospital acute pancreatitis occurred in eleven of 224 patients with Crohn’s 
disease (4,9%), in two of 129 (1,5%) with autoimmune hepatitis, in two of 388 patients (0,5%) 
after renal transplantation and in one of 254 patients after liver transplantation (0,4%). Aza-
thioprine-induced pancreatitis was not seen in patients with systemic lupus erythemathosis, 
Wegener’s granulomatosis or rheumatoid arthritis. Acute pancreatitis occurred more in pa-
tients with Crohn’s disease than in any other treatment group (p<0,05). Only in the compari-
son with autoimmune hepatitis the difference did not reach a statistical significance (p=0.11). 
In the community hospital azathioprine-induced pancreatitis occurred in 2/41 patients (4.9%) 
with Crohn’s disease and in 1/26 patients (3.8%) with ulcerative colitis.
Characteristics of patients with azathioprine-induced pancreatitis in the university hospital 
and the community hospital combined, are shown in table 2. In all patients the treating phy-
sician diagnosed azathioprine-induced pancreatitis according to the rapid onset of symptoms 
and at least a 3-fold rise in serum amylase after initialising azathioprine. Symptoms resolved 
in all patients after withdrawal of azathioprine.  
Table 1. Patient Characteristics - University Hospital.
    RA SLE AIH WG UC CD RT LT
    n=317 n=73 n=129 n=85 n=94 n=224 n=388 n=254
Dosage   Mean (mg) 116 118 68 90 83 123 83 113
     
Sex         Male (n) 85 8 27 33 49 79 198 109
               Female (n) 232 65 102 52 45 145 190 145
RA=rheumatoid Arthritis, SLE=Systemic Lupus Erythematosis, AIH=Autoimmune Hepatitis, WG= 
Wegener’s  Granulomatosis, UC=Ulcerative Colitis, CD=Crohn’s Disease, RT= Renal Transplant 
LT=Liver Transplant Azathioprine induced pancreatitis in Crohn’s disease
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Mean amylase level in all 13 patients with Crohn’s disease was 1505 U/l and mean CRP 
level was 75. Lipase levels are not routinely measured in both hospitals. Mean dosage of 
azathioprine was 123 mg (1.75 mg / kg). Only one of 13 patients used alcohol in an amount 
of 2 units a day. In 8 of 13 patients a biliary origin of the pancreatitis was actively excluded 
by ultrasonography. Since in all 13 patients symptoms resolved soon after withdrawal of 
azathioprine no further abdominal CT scans were deemed necessary by the treating physi-
cian at time of diagnosis.
None of the 13 patients experienced an episode of pancreatitis before the treatment of 
azathioprine. None of the 13 patients used sulfasalazin. Six of 13 patients were using me-
salazine at the moment azathioprine was started. All six were using mesalazine for several 
years without symptoms of acute pancreatitis and continued to do so after withdrawal of 
azathioprine. 
For all 19 patients who developed pancreatitis, the mean time to onset of symptoms was 
21 days, excluding one patient after liver transplantation. In all patients symptoms resolved 
after withdrawing azathioprine.  Fifteen of nineteen patients required hospitalization. No 
patient experienced a rash or raised eosinophil count. None of the patients developed leu-
copenia
Table 3. Side-effects of Azathioprine in IBD; university vs community hospital.
  University Hospital
Community Hos-
pital
Total  
  CD UC CD UC CD UC
  n=224 n=94 n=41 n=26 n=265 n=120
Side-effects (n)        
  nausea and vomiting 20 5 2 2 22 7
  abdominal pain 6 4 2   8 4
  diarrhea 1     1  
  fever 5 6 2   7 6
  rash 3     3  
  hepatitis 5 2 3 1 8 3
  myelosuppression 4 1      4 1
  arthralgia 8     8  
  general weakness 3     3  
  acute pancreatitis 11   2 1 13 1
  infections 1     1  
  other* 3 1      3 1
withdrawn(n) 52 20 9 4 61 24
withdrawn(%) 23,2 21,3 22,0 15,4 23,0 20,0
Denotates all side-effects necessitating withdrawal. One patient can have more then one 
side-effect. CD=Crohn’s Disease; UC=Ulcerative Colitis Azathioprine induced pancreatitis in Crohn’s disease
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Only two patients were rechallenged with azathioprine. One patient with Crohn’s disease 
developed symptoms of acute pancreatitis after two days and one patient with renal trans-
plant and presumed azathioprine-induced pancreatitis developed no symptoms and toler-
ated azathioprine after rechallenge. 
Side effects other than acute pancreatitis
Frequency and type of side effects, severe enough to withdraw azathioprine, are shown in
table 3. One patient can have more than one type of side effect. The most common side 
effects of all patients combined were nausea and vomiting (4,1%), hepatitis (2,7%), myelosup-
pression (2,4 %), fever (1,7%), abdominal pain (1,2%) and acute pancreatitis (1,0%). 
Side effects depicted as “other” included: anxiety (one patient with rheumatoid arthritis), ver-
rucae (one patient with rheumatoid arthritis) macrocytosis (one after liver transplantation, 
one after renal transplantation), pulmonary embolism (one patient with ulcerative colitis), 
neuro-toxicity (two patients with Crohn’s disease), veno-occlusive disease (one patient after 
renal transplantation), weight loss (one patient with systemic lupus erythemathosis) and 
not specified (one rheumatoid arthritis, one Crohn’s disease, one autoimmune hepatitis 
and one patient after renal transplantation).
Withdrawal due to side effects occurred more often (p<0,05) in patients with inflamma-
tory bowel disease (Crohn’s disease 23,2% and ulcerative colitis 21,3%) and rheumatoid 
arthritis (24,6%) than in patients with systemic lupus erythemathosis (6,8%), autoimmune 
hepatitis (6,2%), Wegener’s granulomatosis (7,1%) after liver transplantation (6,7%) or renal 
transplantation (5,7%). 
Nausea and vomiting as a reason to discontinue azathioprine occurred more often in rheu-
matoid arthritis (10,4%), Crohn’s disease (8,9%) and ulcerative colitis (5,3%) compared to sys-
temic lupus erythemathosis (2,7%), Wegener’s granulomatosis (2,4%), autoimmune hepatitis 
(1,6) or after renal transplantation (0%) and liver transplantation (0%). Hepatitis during the 
use azathioprine, necessitating withdrawal occurred more often (p<0,05) in rheumatoid ar-
thritis (6.9%) than in  Crohn’s disease (2,2%), ulcerative colitis (2,1%), systemic lupus erythema-
thosis (1,4%), autoimmune hepatitis (0,8%) after renal transplantation (1,4%) or after liver 
transplantation (2,4%). Myelosuppression as the reason for withdrawal occurred more often 
in rheumatoid arthritis (3,5%) systemic lupus erythemathosis (4,1%), after liver transplanta-
tion (3,1%) or after renal transplantation (2,6%), compared to Crohn’s disease (1,8%), ulcera-
tive colitis (1,0%), autoimmune hepatitis (0,8%) and Wegener’s granulomatosis (0%).
In patients treated for inflammatory bowel diseases, there were no differences in the per-
centage of withdrawal between the University Hospital and the community hospital. In the 
University Hospital 52/224 (23.2%) patients treated for Crohn’s disease had to stop because of 
side effects versus 9/41 (22.0%) patients in the community hospital. For ulcerative colitis the 
numbers were 20/94 (21.3%) and 4/26 (15.4%) (Table 4).8
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Discussion
In this study 1564 patients treated with azathioprine were reviewed for the occurrence of 
acute pancreatitis and other side effects necessitating withdrawal. The retrospective nature of 
the data makes interpretation difficult, but to our knowledge this is the only comparison of 
the use of azathioprine in different diseases and secondly, it reflects the use of azathioprine 
in clinical practice.
In accordance with data from the literature, acute pancreatitis occurred significantly more 
often in patients with Crohn’s disease than in all other groups, suggesting a relation with the 
underlying condition. Frick et al. described a lack of association between azathioprine and 
Table 4. Characteristics of patients with azathioprine-induced acute pancreatitis university and com-
munity hospital combined.
  CD UC AIH RT LT
  n=13 n=1 n=2 n=2 n=1
patient     
  mean age (yrs) 39 64 62 44 40
  sex 10 f / 3 m 1 f  2 f 1 f / 1 m 1 f
  mean dosage (mg/day)  123  125 75 88 125
  time to onset (days) 25 14 14 9 2550
  hospitalisation  11/13 1/1 2/2 1/2 -*
  rechallenge (n) 1/13 0 0 1/2 0
    Recurrence of symptoms  yes - - no -
symptoms:    
  upper abdominal pain  11/13 1/1 2/2 1/2‡ ‡ 1/1
  nausea 10/13 1/1 0/1 1/2‡ ‡ ‡ 1/1
  vomiting  7/13 1/1 0 0/2‡ ‡ ‡ 1/1
  radiating pain  4/13 1/1 2/2 1/2‡ ‡ ‡ 0
  fever  4/13 1/1 0 1/2‡ ‡ ‡ 1/1
laboratory data    
  Mean CRP (mg/l)  75  181 10 136 -*
  Mean serum amylase (U/l)  1504  70 †  1937 1857 -*
Localisation (CD)    
  colon 13/13 - - - -
  term ileum  9/13 - - - -
  other  0/13 - - - -
* data not available; † urine amylase 1350 U/l ; ‡ ‡ ‡data not avalailable for second patient.
CD=Crohn’s Disease, UC=Ulcerative Colitis, AIH=Autoimmune Hepatitis, RT=Renal Transplant, 
LT=Liver Transplant, Azathioprine induced pancreatitis in Crohn’s disease
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pancreatitis in renal transplantation medicine.12 Also in our group of patients after renal 
transplantation, the presumed association was not evident. The first patient did not develop 
symptoms after rechallenge with azathioprine. The second patient experienced acute pan-
creatitis attributed to the use of tacrolimus, which was withdrawn. Symptoms of severe acute 
pancreatitis returned when azathioprine was started consecutively. These findings again sug-
gest that azathioprine is probably only a co-factor in inducing pancreatitis in renal transplan-
tation patients. Furthermore, symptoms of acute pancreatitis became apparent only after 
7 years in 1 patient with liver transplantation, which makes the relation with azathioprine 
highly unlikely in this patient.
Average duration of treatment in patients with Crohn’s disease and azathioprine-induced 
pancreatitis was 25 days, meaning a strong temporal relationship between the start of aza-
thioprine treatment and the emergence of symptoms of pancreatitis. Although patients in a 
University Hospital are highly selected, a selection bias because of referral doesn’t seem to 
be a good explanation of the high incidence of azathioprine induced pancreatitis in Crohn’s 
disease. All but one patients with pancreatitis started treatment with azathioprine in the uni-
versity hospital. Secondly the incidence is the same as in earlier studies. And finally, selection 
bias does not explain the difference in incidence of pancreatitis in comparison with the other 
disease populations, who were also treated in the University Hospital. 
Symptoms of acute pancreatitis required hospitalization in 78% of all cases, which was never 
necessary for the large group of patients with abdominal pain, nausea and vomiting due to 
azathioprine in the other treatment groups. Thus selection bias by gastroenterologists, who 
might consider acute pancreatitis earlier than other medical specialists, is unlikely. 
The use of aminosalicylates is also associated with acute pancreatitis and the simultane-
ous use of aminosalicylates and azathioprine is associated with an inhibition of TPMT activ-
ity resulting in an increased production of 6-thioguanine nucleotide, that could result in a 
higher risk of bone marrow suppression.20-22 Six patients were using mesalazine at the mo-
ment azathioprine was started. The simultaneous use of aminosalicylates cannot be ruled 
out to be a contributing factor to the occurrence of acute pancreatitis, although all six were 
using mesalazine for several years without symptoms of acute pancreatitis and continued to 
do so after withdrawal of azathioprine. None of the 6 patients using both drugs developed 
leucopenia.
The pathogenesis of azathioprine-induced acute pancreatitis is unknown. It is dose-inde-
pendent and there is no correlation with myelosuppression, suggesting it is independent of 
TPMT-levels. A delayed type II or IV allergic reaction has been suggested.5 The timing of symp-
toms is compatible with the development of antibodies. The recurrence of symptoms within 
several hours after rechallenge supports this idea. However our analysis suggests that there is 
a correlation with Crohn’s disease, which suggests a disease specific underlying mechanism. 
An immune mediated idiosyncratic drug reaction due to a genetic predisposition might be 
an explanation.
Circulating pancreatic antibodies (PAB) are found in approximately 30 % of patients with CD 
(table1). 23-25 PAB are not found in healthy controls, or in patients with other gastrointestinal 
diseases and in various autoimmune disorders (including autoimmune hepatitis, systemic 8
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lupus erythematosis and rheumatoid arthritis). Since PAB and azathioprine-induced pan-
creatitis are both specific for Crohn’s disease, an association or pathogenic role of PAB in 
azathioprine-induced pancreatitis can be hypothesized. One study suggests that patients with 
CD and pancreatic exocrine insufficiency were significantly more likely to be PAB positive 
than patients with CD without pancreatic insufficiency.26 The reason why CD patients have 
pancreatic insufficiency is unknown, but it might be due to a low-grade inflammation of the 
pancreas, possibly as an extraintestinal manifestation of CD. Furthermore, the use of azathio-
prine worsens the inflammation of the pancreas which was shown in an animal model of 
acute pancreatitis in rats.27 Extrapolating these findings one could suggest that adding aza-
thioprine to an already inflamed pancreas in PAB positive CD patients aggravates the inflam-
mation and leads to a clinical overt picture of acute pancreatitis. In addition to our retrospec-
tive case note survey we obtained eight samples of CD patients with azathioprine-induced 
pancreatitis and compared the occurrence of circulating PAB (determined by a standardized 
immunofluorescence assay) with 26 CD patients not using azathioprine.28  25% of identified 
patients with azathioprine induced pancreatitis had circulating PAB versus 8% of controls 
with CD. Although there was a difference, this was not statistically significant. PAB titers in the 
controls were very low, whereas PAB were detectable in high concentrations in the patients 
with pancreatitis. This may indicate that the presence of PAB at high titers increases the risk 
but is not a determining factor for developing pancreatitis.
Besides the occurrence of acute pancreatitis, the overall azathioprine-induced toxicity var-
ies between different diseases. In our study withdrawal due to side effects was significantly 
higher in patients with rheumatoid arthritis, Crohn’s disease and ulcerative colitis compared 
to systemic lupus erythemathosis, Wegener’s granulomatosis, autoimmune hepatitis, renal 
transplantation and liver transplantation. 
Difference in interpretation of symptoms and the experience with the use of azathioprine 
by different medical specialists may vary and might be an explanation for the disparity in 
withdrawal during the treatment of different diseases.  However, there is frequent commu-
nication between specialists in gastroenterology, hepatology, and transplantation medicine. 
Similarly, there is close contact between specialists in rheumatology, immunology and ne-
phrology. Furthermore, the percentage of withdrawal in patients with Crohn’s disease and 
ulcerative colitis did not differ between the university and the community hospital. There-
fore, differences in experience and interpretation of symptoms do not seem to be a satisfying 
explanation for the difference in appreciated adverse events.
Since our aim was to detect a difference in occurrence of azathioprine-induced acute pancre-
atitis, we did not collect data on medication used simultaneously at the time of occurrence of 
other side effects than pancreatitis. The concurrent use of steroids might be a contributing fac-
tor for the differences. However, there is a difference in percentage of withdrawal in systemic 
lupus erythemathosis, autoimmune hepatitis, ulcerative colitis, Crohn’s disease and Wegener’s 
granulomatosis, while most of these patients use steroids when azathioprine is started. 
In conclusion, there is a clear difference in percentage and severity of azathioprine-induced 
toxicity in different diseases. The occurrence of acute pancreatitis due to treatment with 
azathioprine is strongly associated with Crohn’s disease and rarely occurs in other diseases. Azathioprine induced pancreatitis in Crohn’s disease
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The reason for this is unknown but it is not associated with the occurrence of circulating pan-
creatic antibodies. An idiosyncratic drug reaction due to a genetic predisposition is supposed. 
The necessity to withdraw azathioprine is more frequent in inflammatory bowel diseases and 
rheumatoid arthritis compared to Wegener’s granulomatosis, systemic lupus erythemathosis, 
autoimmune hepatitis and after renal transplantation or liver transplantation. 8
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Summary
Chronic inflammatory bowel diseases (IBD) comprising Crohn’s disease (CD) and ulcerative coli-
tis (UC) are characterized by chronic relapsing inflammation of the gastrointestinal tract. The 
combined prevalence of CD and UC is estimated at 100 – 200 / 100.000 in developed countries. 
The pathogenesis of IBD is only partially understood but concordance rates in twins and sib-
lings suggest that a genetic predisposition, apart from environmental and immunological fac-
tors, contributes to the pathogenesis of IBD. In the past decade, tremendous progress has been 
achieved in unraveling the genetic etiology of IBD; several susceptibility loci for IBD have been 
identified and the CARD15 gene encoding for the NOD2 protein on chromosome 16 (IBD1) has 
been found to be strongly related to CD susceptibility.  NOD2 is part of the innate immune sys-
tem and recognizes specific bacterial membrane components. Two missense mutations (R702W 
and G908R) and one frameshift insertion mutation (L1007fsinsC) in the leucine rich repeat re-
gion of the protein are independently associated with ileal CD in caucasian patients, suggesting 
that a defect in bacterial recognition might be involved in CD.  Since CD and UC have many dif-
ferent phenotypic presentations and genome wide scans detected several linkage regions, IBD 
is considered a multigenic disease . Multiple low penetrance genes, each with a small overall 
contribution are probably associated with (different subsets of) UC and CD.  
For genetic research in complex genetic disorders as IBD it is important to have large homog-
enous cohorts of well described patients. In 2001 the CODE study (Chronische Ontsteking van 
de Darm en Erfelijkheid: Chronic Inflammation of the Gut and Inheritance) started in the Uni-
versity Medical Center Groningen. DNA has been, and is still being collected of a large cohort of 
mainly Caucasian patients and family members from the Northern part of the Netherlands. An 
important aspect in studying IBD genetics is the consequent description of disease phenotypes.   
Since IBD is considered a multigenic disorder, different genes are probably involved in different 
subsets of phenotypes. It is therefore mandatory to have internationally accepted classification 
systems for IBD. For the current thesis, the Vienna classification is used, an internationally ac-
cepted and frequently used system. 
Another research subject in IBD genetics is pharmacogenetics. There has been much inter-
est in the pharmacogenetics of azathioprine metabolism. Azathioprine is a purine analogue 
that is frequently used in the treatment of Crohn’s disease but its use is hampered by the 
frequent occurrence of side-effects. Polymorphisms in the thiopurinemethyltransferase (TPMT) 
gene, which metabolizes azathioprine to 6-mercaptopurine and 6-methyl-mercaptopurine, and 
inosine triphosphate pyrophospatase (ITP-ase) deficiency which leads to accumulation of the 
metabolite 6-thio-ITP, have been found to be responsible for a subset of the side-effects of 
azathioprine therapy.  
This thesis focuses on the genetic background of IBD. Our aim was to find specific genotype-
phenotype associations for previously identified genes and to find novel IBD associated 
genes. The first part explores the association of two novel genes with IBD. The middle part 
of the thesis consists of three studies replicating previously described associations in specific 
cohorts using different approaches and the last part focuses on azathioprine toxicity and 
specific diseases or phenotypes.9
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Chapter 1 starts with an introduction and describes the aims and outlines of the thesis.
 
This thesis focus on specific genetic associations with IBD. Therefore, a detailed review of 
the current literature on IBD genetics is given in Chapter 2. Tremendous progress has been 
achieved in unraveling the genetic etiology of IBD. It has led to the discovery of mutations in 
CARD15 encoding for NOD2, associated with ileal CD. However it is only partially understood 
how mutations in CARD15 lead to CD. Mouse models, in vitro data and studies in humans of-
fer conflicting data whether there is a loss or gain of function of NOD2 in CD. Current research 
on the role of mutations in CARD15 in the pathogenesis of IBD is reviewed. Since the discov-
ery of the association of CARD15 and CD, many additional genes have been studied. Several 
of these genes are potentially truly associated, but results have been conflicting for many of 
the associations found.  Promising candidate genes include Toll like receptor 4 (TLR4), Multi 
Drug Resistance 1 (MDR1), NOD1 (CARD4), HLA DRB1*103, DLG5 as well as the IBD5 locus on 
chromosome 5, including members of the organic cation transporter cluster 1 and 2. The cur-
rent literature for IBD associated genes is extensively reviewed. Furthermore, once a genetic 
association is established, it is important to identify specific phenotypes or subgroups that 
are associated with specific genetic variants. Therefore a uniform classification scheme like 
the Vienna classification (or its recent modification the Montreal Classification) is of utmost 
importance.
The first part of the thesis comprises two chapters studying the possible association between 
novel candidate genes and IBD susceptibility. We performed a case control study for the 
association of the gene encoding for the interleukin-receptor associated kinase-M (IRAK-
M) and IBD susceptibility in chapter 3. IRAK-M is a Nuclear Factor κB (NF-κB) dependent, 
negative regulator of Toll-like receptor signaling. Toll-like receptors (TLRs) are, like NOD2, 
important components of the innate immune system. TLRs have extracellular leucine-rich-
repeat domains that recognize pathogen associated molecular patterns (PAMPs) and activate 
adaptive immunity. Chronic repeated stimulation of TLRs by PAMPs causes an “endotoxin 
tolerance”. This process involves different mechanisms, including TLR4 downregulation and 
decreased NF- κB activation. In a previous study it was shown that genetically engineered 
IRAK-M knockout mice have an impaired endotoxin tolerance and show an increased inflam-
matory responses to bacterial infection. The function of IRAK-M as a negative regulator of 
TLR signaling, inducing an impaired endotoxin tolerance and an inflammatory response, in 
combination with its localization at an IBD susceptibility locus (IBD2)  makes IRAK-M a good 
candidate gene for susceptibility for inflammatory bowel diseases. Therefore, we studied the 
association of IRAK-M with IBD in a cohort of 542 patients with IBD (309 CD, 233 UC) and 305 
controls. Two exonic single nucleotide polymorphisms (SNPs) and six microsatellite markers 
were evaluated by allelic association analysis and the haplotype sharing statistics. Results 
were stratified for the three known CARD15 mutations R702W, G908R and 1007fsinsC. SNP 
genotyping was carried out by using TaqMan PCR primer/probe sets, designed through Ap-
plied Biosystems’ Assay by Design service by a standardized protocol. Similarly, a standard-
ized procedure was used for the microsatellite marker polymerase chain reactions.  
Power analysis showed that an association with an odds ratio (OR) of >1.75 should be de-Summary and future perspectives
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tected in our study population. However, we observed no significant differences in the dis-
tribution of IRAK-M allele frequencies between the patients with IBD, CD or UC and controls. 
Analysis of specific phenotypes of CD and UC did not reveal any significant differences either. 
Carriership of one or more of the three IBD associated mutations in CARD15 in combination 
with a specific microsattelite marker showed an increased risk for UC compared to patients 
not carrying a CARD15 mutation. Nevertheless, since CARD15 has not been shown to be in-
volved in UC susceptibility before, it is doubtful whether this is a true association or merely 
a false positive result.
In Chapter 4 the genetic association between RUNX3 and IBD is studied. RUNX3 is a member 
of the runt domain family of transcription factors which are increasingly being recognized 
to be involved in autoimmunity. Several reasons make RUNX3 a good candidate gene for 
IBD susceptibility. Firstly, loss of Runx3 function is associated with a spontaneous colitis in 
knockout mice. Secondly, RUNX3 is a member of the TGF- ß signaling pathway, which is 
a potent inhibitor of inflammation in IBD. Impaired activation of RUNX3 might result in 
decreased activity of the TGF- ß pathway and decreased inhibition of inflammation in IBD. 
Finally the gene encoding for RUNX3 resides on chromosome 1p36, which is a susceptibility 
locus for IBD. Four SNPs and four microsattelite markers were studied for RUNX3 in the CODE 
cohort. Furthermore, mutations in the genes SLC22A4 and 5 encoding for the organic cation 
transporters 1 and 2 (OCTN1/2) were found to be associated with CD in a previous publication. 
Another publication showed an association between polymorphisms in SLC22A4, resulting 
in a disrupted binding site for RUNX and rheumatoid arthritis. For that reason, six SNPs in 
SLC22A4/5 (including the known polymorphisms -207 G→C, 1672 C→G and the SNP disrupt-
ing the RUNX binding site in SLC22A4) were analyzed for association with IBD and interaction 
with RUNX3 was studied. All results were stratified for CARD15 status.  
We found a significant association between RUNX3-SNP rs2236851 and UC (OR 1.61; CI 1.11-
2.32, p=0.020). This association was confirmed by the Transmission Distortion Test (p=0.004) 
and Haplotype Sharing Statistics (p=0.012). Carriership of rs2236851 in UC was associated 
with pancolitis (OR 1.86; CI 1.08-3.21) and a tendency to association with an early age of 
onset (OR 1.59; CI 0.98-2.57). For a microsatellite marker in RUNX3, an association was found 
for colonic localization of CD (p=0.022). 
For SLC22A4/5 homozygosity for SNPs rs272893 and rs273900 was significantly associated with 
CD (OR 2.16; CI 1.21-3.59; p=0.008 and OR 2.40; CI 1.43-4.05 p=0.004 respectively) but not 
with UC. Both SNPs were associated with an age of onset >40 yrs (p=0.0016 and p=0.0007), 
ileocolonic localization (p=0.001 and p=0.002), non-stricturing non-penetrating behavior 
(p=0.020 and p=0.011), and extra-intestinal manifestations (p=0.001 and p<0.001). We did 
not find any association for the previously described SNPs rs2631367 (-207 G→C) and SNP 
rs1050152 (1672 C→G) with IBD, CD, UC or any subgroups.
Binary logistic regression analysis revealed an OR of 3.83 (CI 1.26-11.67; p=0.018) for UC pa-
tients with homozygosity for one or both associated SNPs rs272893 or rs273900 in SLC22A4, 
and carriership of rs2236851 in RUNX3. No evidence for epistasis of CARD15 with SLC22A4/5 
or for CARD15 with RUNX3 was found in IBD, UC or CD or in subsets of UC or CD patients.
Next we analyzed RUNX3 and OCTN1 mRNA expression in inflamed and non-inflamed ileal 9
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and colonic mucosal tissue samples from 30 IBD patients (16 CD and 14 UC) and 6 controls. 
In controls RUNX3 mRNA expression is evenly distributed throughout the colon and the il-
eum. OCTN1 expression is higher in the ileum compared to the colon (p<0.00001), while the 
expression level is constant throughout the colon. RUNX3 expression levels are increased in 
inflamed colonic mucosa compared to non-inflamed colonic mucosa in UC patients (p=0.01). 
OCTN1 expression is decreased in inflamed colonic mucosa compared to non-inflamed co-
lonic mucosa (p=0.08).
We conclude that we have provided evidence for the genetic association of RUNX3 with ul-
cerative colitis. Furthermore genetic association for Crohn’s Disease with SLC22A4/5 was con-
firmed, although this involved two other SNPs than previously described. An epistatic effect 
of RUNX3 and SLC22A4 was observed for susceptibility for ulcerative colitis. Our data, com-
bined with the increasingly recognized role of RUNX3 in autoimmunity, suggest an important 
role for RUNX3 in UC susceptibility.
The next part of the thesis consists of three studies replicating previously described associa-
tions in distinctive cohorts using different approaches.
In chapter 5, a comparison is made between adult-onset and pediatric-onset CD for genetic 
variants associated with CD susceptibility. Genetic susceptibility may have a more important 
role in the aetiology of early-, than of late-onset IBD. After all, early-onset IBD patients were 
less exposed to environmental factors than late-onset IBD patients. If so, a higher frequency 
of the gene mutations can be expected in pediatric IBD patients. Next to CARD15 and SL-
C22A4/5, associations have been found between DLG5 (Drosophila Discs Large Homologue 5) 
and the Toll-like receptor 4 (TLR4) and IBD. The purpose of this study was to determine the 
frequency of CARD15, TLR4, SLC22A4/5 and DLG5 mutations in pediatric-onset IBD, to com-
pare these data with adult-onset IBD and to identify genotype-phenotype associations. For 
CARD15, the three known risk-associated variants R702W, G908R and 3020insC and for TLR4 
Asp299Gly and Thr399Ile were determined. For SLC22A4/5 the 6 SNPs as described in chap-
ter 6 including SNPs -207G→C and 1672C→T were analyzed. Finally, 4 haplotype tagging 
SNPs in DLG5 including 113G→A were assessed in 103 pediatric-onset and 696 adult-onset 
IBD patients. Phenotypic classification was based on disease localization and behaviour. We 
observed that homozygosity for 3020insC in CARD15 was more prevalent in pediatric-onset 
than in adult-onset CD (4.2% v 0.6%, CI 1.2-42.0) and that homozygosity for SNP rs3792876 in 
SLC22A4/5 was significantly higher in pediatric-onset CD than in adult-onset CD (6.1% v 1.1%, 
p=0.02). For the other evaluated SNPs no difference in distribution between pediatric-onset 
and adult-onset IBD could be observed. On a phenotypic level we observed an association 
of 3020insC and ileal localization for both pediatric-onset and adult-onset groups. Although 
the numbers in the pediatric cohort were small, we concluded that genetic susceptibility has 
a more important role in the aetiology of early- than of late-onset CD and that within pedi-
atric-onset CD specific genotype-phenotype associations can be found. 
Recently, two novel IBD-associated genes were identified in two large genome-wide case-con-
trol analyses. One, an uncommon coding variant (rs11209026) in the gene encoding for the 
interleukin-23 receptor (IL23R) conferred strong protection against CD. It was also shown to 
be associated with UC in non-Jewish patients. The other, rs2241880 in the autophagy-related Summary and future perspectives
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16-like 1 gene (ATG16L1) was shown to be associated with CD. Since it is of pivotal importance 
that genetic associations are confirmed in independent cohorts from different countries, we 
performed a replication study in chapter 6 for the two most strongly associated SNPs in 
IL23R and ATG16L1 in 518 IBD patients (311 CD and 207 UC) and 893 healthy controls. We 
were also interested in discovering whether these two genes are more generally involved in 
other common chronic disorders of the gastrointestinal tract and we therefore included a 
cohort of 508 patients with celiac disease. The case and control samples, as well as 90 CEPH 
(Centre d’Etude du Polymorphisme Humain) samples included in the International HapMap 
project, were genotyped by primer extension of multiplex PCR products, followed by a chip-
based matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF). We found that 
the rs11209026 SNP in IL23R had a protective effect for IBD in case-control analysis (OR=0.19; 
95% CI: 0.10–0.37; p=6.6E-09). This was true for both CD (OR=0.14; CI: 0.06-0.37; p=3.9E-07) 
and UC (OR=0.33; CI: 0.15-0.73; p=1.4E-03). For ATG16L1 the rs2241880 SNP was associated 
with CD susceptibility (OR=1.36; CI: 1.12-1.66; p=0.0017). The population attributable risk 
for CD is 0.24 for carrying allele G and 0.19 for homozygosity for allele G. No association was 
found between IL23R or ATG16L1 and celiac disease. Our results confirm the genetic associa-
tion of IL23R with both Crohn’s disease and ulcerative colitis, and for ATG16L1 with Crohn’s 
disease.
It is not only mandatory that previously found associations are confirmed in independent co-
horts, these cohorts also need to have sufficient power to detect specific genotype-phenotype 
interactions. For genetic research in complex genetic disorders as IBD it is important to have 
large homogenous cohorts of well described and uniformly phenotyped patients. For that 
reason, on behalf of the Iniative on Crohn and Colitis (ICC), a large nationwide collaborative 
project was initiated. We performed an association analysis for DLG5, SLC22A4/5 and ATG16L1 
with IBD, CD, UC and different subsets of CD and UC. Furthermore we evaluated the interac-
tion between these genes. Results are described in chapter 7. 
DNA samples and phenotypic details of IBD patients from seven University Medical Centers 
in the Netherlands (University Medical Center Groningen; Academic Medical Center, Amster-
dam; VU University Medical Center, Amsterdam; Leiden University Medical Center; Radboud 
University Nijmegen Medical Center; Erasmus Medical Center, Rotterdam and the University 
Medical Center Utrecht) were collected. 2937 patients (1696 CD, 1099 UC and 142 with inde-
terminate colitis) and 1484 healthy controls were included. Phenotypic details were available 
for 2090 patients (1315 CD / 775 UC).  A set of eight SNPs was analyzed for SLC22A4/5. This 
set included, among others, the two known risk-associated SNPs and SNP rs3792876 which 
was found to be associated to pediatric IBD in chapter 7. Additionally, two markers located at 
the 3’ end and 5’ end were chosen to analyze linkage disequilibrium within the IBD5 region. 
Four SNPs were analyzed for DLG5. These SNPs were carefully chosen to identify the four 
different haplotypes described in the original article. The risk associated SNP rs2241880 was 
determined for ATG16L1. 
Firstly, we confirmed the association for CD with the IBD5 haplotype. However, this was not 
due to specific polymorphisms in the SLC22A4 and SLC22A5 genes. Our study was sufficiently 
powered to detect an association for SNPs rs2631367 (-207G→C) and rs1050152 (1672G→C) in 
SLC22A4/5 with an OR of 1.148. However we failed to show any association for these particu-9
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lar SNPs. We did, however find an association for (subsets of ) CD with markers at the 5’ and 
3’ end of the IBD5 locus and with a marker in between SLC22A4 and SLC22A5. This indicates 
that SLC22A4/5 are not the CD-associated genes in the IBD5 locus. We further observed an 
association with an early age of onset and a complicated course of CD with specific SNPs in 
the region. 
Secondly, we did find an association for DLG5 and IBD, but surprisingly this risk was higher 
for UC than for CD, in particular with for UC with an extensive phenotype (e.g. leftsided and 
extensive colitis combined: OR of 1.69). This is a novel finding as none of the previously pub-
lished studies have found an association with UC for the R30Q variant. Furthermore, we did 
confirm the association of P1371Q with CD, but could not confirm the protective effect of the 
haplotype A tagging SNP (rs2289311). However, we did find a protective effect for IBD and CD 
for the haplotype B tagging SNP. Our results regarding DLG5 and IBD susceptibility show that 
there is an association with IBD but this effect is not exclusive for CD. This indicates that DLG5 
is not disease specific but a risk factor for IBD in general.
Furthermore, we could confirm the association of ATG16L1 with CD. We found a population 
attributable risk for carrying allele of 0.116. We found the association in particular with CD 
with stricturing behavior and a history of surgical intervention and ileal or ileocolonic local-
ization..This is the first report of an association of ATG16L1 with a specific phenotype of CD. 
We could not find any other associations with UC or any specific subsets, neither on allelic 
nor on a genotypic level.Most importantly, we show that when combining the information 
from ATG16L1, DLG5 and the IBD5 haplotype the relative risk for developing CD increases. 
This risk increases with an increasing number of risk-alleles. This is the first time that this 
effect is reported for CD. It is consistent with the idea that multiple genes are involved in CD 
susceptibility, each with a small overall contribution. We demonstrate that it is possible to 
combine information from multiple common low-penetrance variants to predict the suscep-
tibility for a complex disease. Moreover, an increasing number of risk genotypes or risk alleles 
was not only associated with CD susceptibility but also with a more complex disease course. 
Patients with more risk alleles or genotypes had a more severe disease behavior and were 
more frequently operated. This is an important finding because this emphasizes the fact that 
it might be possible in the near future to create a genetic risk-profile for a patient to predict 
the disease course. 
The last part of the thesis focuses on azathioprine-toxicity in the treatment of IBD. 
Chapter 8 studies the occurrence of side-effects of azathioprine in different diseases. This 
chapter focuses mainly on acute pancreatitis, which is rarely seen when azathioprine is used 
for other diseases than Crohn’s disease. We performed a retrospective case note survey of 
1564 patients using azathioprine after liver or renal transplantation, for systemic lupus 
erythemathosis, Wegener’s granulomatosis, autoimmune hepatitis, rheumatoid arthritis, 
ulcerative colitis or Crohn’s disease. We observed that 11 of 224 patients with Crohn’s dis-
ease experienced acute pancreatitis (4.9%) compared to 2 / 129 (1.5%) with autoimmune 
hepatitis, 2 / 388 (0.5%) after renal transplantation, 1 / 254 (0.4%) after liver transplantation 
and none of the patients using azathioprine for Wegener’s granulomatosis (n=85), systemic 
lupus erythematosis (n=73), Rheumatoid arthritis (n=317) and ulcerative colitis (n=94). The 
prevalence of azathioprine-induced pancreatitis was higher in patients with Crohn’s disease Summary and future perspectives
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compared to any other disease (p<0.05). Furthermore we observed that azathioprine-toxic-
ity (all toxicity, including acute pancreatitis) necessitating withdrawal occurred significantly 
more in patients with rheumatoid arthritis (24.6%), ulcerative colitis (21.3%) and Crohn’s dis-
ease (23.2%) compared to the other patient groups (p<0,05). 
We conclude that acute pancreatitis is strongly associated with Crohn’s disease and rarely 
occurs with other underlying conditions and that overall azathioprine-induced toxicity and 
the necessity of withdrawal is more common in inflammatory bowel diseases and rheuma-
toid arthritis compared to other diseases. The pathogenesis of azathioprine-induced acute 
pancreatitis is unknown but our analysis suggests that there is a correlation with Crohn’s 
disease, which suggests a disease specific underlying mechanism. Circulating pancreatic an-
tibodies (PAB) have been found in approximately 30 % of patients with CD and were not 
found in healthy controls, or in patients with other gastrointestinal diseases and in various 
autoimmune disorders (including autoimmune hepatitis, systemic lupus erythematosis and 
rheumatoid arthritis). Since PAB and azathioprine-induced pancreatitis are both specific for 
Crohn’s disease, an association or pathogenic role of PAB in azathioprine-induced pancreati-
tis can be hypothesized. A pathogenic mechanism could be that azathioprine aggravates the 
inflammation in an already inflamed pancreas in Crohn’s disease in PAB positive patients. 
In addition to the case-note survey, we evaluated the occurrence of PAB in patients with 
azathioprine induced pancreatitis in Crohn’s disease and in controls with Crohn’s disease, 
hypothesizing that most or all patients with azathioprine-induced pancreatitis have circulat-
ing PAB. Two out of eight patients with AZA-AP were positive for PAB (25%), determined by 
a standardized immunofluorescence method. In the control group of 26 CD patients, two 
patients (7%) were positive for PAB in serum dilutions of 1:2. The difference in prevalence was 
not statistically significant. Therefore, although numbers are small, we could not confirm our 
hypothesis that most or all patients with AZA-AP were PAB positive. 9
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Future perspectives
The future of genetics in IBD research will focus on a number of questions. 
1.   How will novel IBD associated genes be identified? How will an association with a  
  specific phenotype be firmly established? 
2.  Once a genetic association is confirmed: how is a particular gene -and the 
  mutations found- involved in IBD susceptibility?
3.  How will these findings translate to the treatment of the patient? What will be the  
  role of “pharmacogenomics”?
4.  Will genetics be helpful in classifying IBD patients?
1. Future genetic studies in IBD
Numerous case-control studies have been performed concerning the association of a specific 
candidate gene with IBD. Many of these studies have resulted in positive results but only 
few of them have been consistently confirmed in independent cohorts. Considerable debate 
is going on about the appropriateness of applying a candidate-gene approach to complex 
genetic diseases as IBD.  It can be successful in identifying genes with high relative risks as 
CARD15. However, UC and CD and even different subsets of UC and CD have different aetio-
logical mechanisms therefore numerous genes, each with a small overall contribution and a 
small excessive risk can be involved. For that reason novel IBD associated genes are probably 
more difficult to identify then CARD15, and it is doubtful whether candidate gene studies in 
small local cohorts will be sufficiently powerful to find new associations. 
Next to hypothesis driven candidate gene approaches, genome wide linkage studies have 
been performed, using markers evenly spaced throughout the genome to identify linkage 
areas. These studies are obviously very costly. New sets with specific markers throughout the 
whole genome have been developed and recently the first genome wide case control studies 
have been performed, identifying two novel IBD associated genes. The gene encoding for the 
interleukin 23 receptor (IL23R) and the autophagy-related 16-like 1 gene were associated with 
CD and IL23R was also associated with UC. To have a homogenous cohort, specific subgroups 
of IBD -in the case of IL23R: CD with ileal localization- were initially studied and subsequently 
the most informative SNPs were confirmed in independent CD and UC cohorts. We were able 
to confirm these associations in the Dutch IBD population. Due to statistical deviation, which 
is invariably associated with this kind of studies, several truly associated genes will not be 
identified. Therefore, it is still worthwhile to perform a genome wide association study in an 
independent cohort using these sets of  markers. One approach will be to start off with a dif-
ferent subgroup of IBD with a specific unambiguous phenotype like ulcerative pancolitis. 
Another important issue is that most genetic research in IBD has been performed in Cauca-
sian patients. Although CARD15 has been confirmed in many different Caucasian popula-
tions, this association could not be found in a Japanese cohort. Probably different genes 
are involved in IBD susceptibility in different races. It is therefore necessary to generate IBD 
cohorts in different races to study IBD susceptibility. Summary and future perspectives
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To have enough power to detect the association of a specific gene with a particular pheno-
type, large cohorts need to be studied. These cohorts need to have an adequate uniform 
description of the clinical characteristics (e.g. the Vienna or Montreal classification). In this 
thesis we made an effort to establish a nationwide collaborative program for IBD and ge-
netics. On behalf of the Initiative on Crohn and Colitis (ICC) we were able to collect all DNA 
samples and phenotypic descriptions of patients from seven university medical centres in the 
Netherlands and set up a preliminary national database. A firm collaboration between all 
University Medical Centres in the Netherlands presently established for IBD research is.  
For future genetic research, whether it is to identify novel susceptibility genes or confirm pre-
viously found genes, it is mandatory to study large, well phenotyped, nationwide cohorts and 
even larger cohorts of matched controls. This requires a specific infrastructure and collabora-
tion between many research centres with sufficient funding and high-throughput molecular 
platforms. 
2. Genetics and Functional studies
Once a firm genetic association is established, the next question is, how a particular gene 
and the mutations found, are involved in IBD susceptibility. CARD15 encoding for NOD2 is 
strongly associated with CD with ileal localization. CD is characterized by an increased activity 
of NF-κB and NOD2 has been shown to have a role in the activation of NF-κB. However, the 
precise mechanism, how mutations in CARD15 and subsequently activation of NF-κB lead to 
susceptibility of IBD is still only partially understood. Mouse models, in vitro data and stud-
ies in humans offer conflicting data. Further studies are necessary and are currently being 
undertaken to identify how NOD2 variants are involved in IBD susceptibility. 
Since mutations in IL23R are protective for the development for CD and UC it is tempting to 
speculate that a defective receptor for IL23 blocks IL23-driven intestinal inflammation. How 
other associated genes like DLG5 and ATG16L1 are involved in IBD susceptibility is almost 
entirely unknown, and further studies are needed for this matter. 
Close collaboration between clinicians, basic scientist involved in IBD research and the ge-
neticists is necessary to proceed in studying functional implications of mutations in IBD as-
sociated genes.
3. Genetics and the Treatment of  IBD
IBD affect mainly young patients and can cause severe morbidity and have a marked impact 
on quality of life due to relapsing disease, interference with work and / or studies and so 
forth but also due to the use of medication and their side-effects. Up till now there is no cure 
available for IBD and treatment is focussed on the induction of remission and subsequently 
the maintenance of remission. 
Important immunomodulatory drugs, used for the maintenance of remission are the thi-
opurines, but their use is hampered by the frequent occurrence of side effects in IBD as is 
shown in this thesis. Polymorphisms in the genes encoding for Thiopurine Methyl Transferase 
(TPMT) and Inosine Triphosphate Pyrophospatase (ITP-ase) are responsible for a subset of 
side-effects. Future pharmacogenetic research in IBD will be focussed on identifying patients 
that are at risk for the development of side effects of thiopurine therapy. In addition phar-9
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macogenetic research might be able to identify patients that are more likely or less likely to 
respond to specific therapy (e.g. polymorphisms in glucocorticoid receptors, tumour necrosis 
factor-α receptors).
Nowadays many so called “biologicals” are being investigated as immunomodulatory medi-
cation. They are directed against different components of the inflammatory cascade involved 
in IBD pathogenesis. This stresses the fact that research in basic immunological and genetic 
mechanisms of IBD susceptibility is mandatory to clarify these underlying mechanisms. 
Moreover this highlights also the fact that clinical doctors treating patients have to be aware 
of these mechanisms, since biologicals will be the most important drugs in the treatment of 
IBD in the near future.
Although genetic research has not yet led to changes in the clinical management of patients, 
it will be helpful in selecting patients for a specific therapy and will provide important contri-
butions in the development of new therapeutic approaches.
4. Genetics and Patient classification
Next to genetic associations, an increasing number of serological markers like perinuclear 
antineutrophil cytoplasmic antibodies (pANCA), antibodies against Saccharomyces cerevisiae 
(ASCA), and Pancreatic antibodies are known to be associated with different subsets of IBD. 
Since the successful connection of CARD15 with ileal CD it is recognized that different pheno-
types of CD or UC are characterized by different genetic and serological markers. 
For future research, it is therefore of utmost importance that patients are accurately phe-
notyped according to a well defined clinical classification scheme. The Vienna classification, 
which is used in the current thesis, is frequently used for genetic studies in CD and includes 
age of onset (A), disease localisation (L) and diseases behaviour (B). A number of studies have 
validated this classification; however, several considerations have led to an update of the 
Vienna classification system during an expert meeting in Montreal in 2005. The main modifi-
cations were the introduction of an early age of onset category (< 16 years), the possibility of 
co-classification of upper gastrointestinal involvement and the inclusion of perianal disease 
as a disease modifier instead of being a form of penetrating disease. The latter is an impor-
tant modification because it is recognized that there is no clear association between perianal 
disease and intra-abdominal penetrating disease. 
The aim of rigorous phenotyping is to include serological and genetic markers into the clini-
cal classification system to stratify patients and eventually to predict disease course and re-
sponse to medical therapy. Chapter 10
Nederlandse samenvatting en 
toekomstperspectievenNederlandse samenvatting en toekomstperspectieven
144
Samenvatting 
De chronische inflammatoire darmziekten (inflammatory bowel diseases - IBD) bestaan uit 
colitis ulcerosa (CU) en de ziekte van Crohn (Morbus Crohn–MC). Beide zijn chronische ziek-
ten van het maagdarmkanaal die gekenmerkt worden door episodes van actieve ontsteking 
en episodes van rust. De prevalentie bedraagt 100-200 patiënten per 100.000 inwoners in 
de westerse wereld. De oorzaak van IBD is maar voor een deel bekend. Er is sprake van 
een dysregulatie van het immuunsysteem in respons op de normaal aanwezige bacteriën 
in de darm. Bepaalde omgevingsfactoren zoals roken spelen daar ook een rol bij. Epidemi-
ologische onderzoeken hebben aangetoond dat IBD vaker voorkomt binnen families en bij 
één- eiige tweelingen is er vaker concordantie van de ziekte dan bij twee-eiige tweelingen. 
Dit suggereert dat, naast de eerder genoemde factoren, ook een erfelijke factor van belang 
moet zijn. De ziekte heeft dan ook een multifactoriële achtergrond: de samenstelling van de 
bacteriën in de darm, de ontregeling van het immuunsysteem, omgevingsfactoren en dus 
een erfelijke component.
In de afgelopen 10 jaar is er een enorme vooruitgang geboekt in het ontrafelen van de ge-
netische achtergrond van IBD. Op het humane genoom zijn meerdere “risicogebieden” voor 
het verkrijgen van IBD geïdentificeerd. In 2001 is ontdekt dat mutaties in het gen CARD15, 
dat codeert voor het eiwit NOD2, zijn geassocieerd met het ontstaan van MC. NOD2 is een 
onderdeel van het aangeboren afweersysteem en herkent specifieke componenten in het 
membraan van bacteriën. Dit suggereert dat een defect in de herkenning van bacteriën 
een rol speelt bij het ontstaan van MC. Twee missense mutaties (R702W en G908R) en een 
frameshift mutatie (L1007fsinsC of 3020insC) zijn geassocieerd met MC met lokalisatie in het 
terminale ileum. 
Omdat er vele fenotypische presentaties zijn van IBD en omdat er meerdere “risicogebie-
den” zijn geïdentificeerd, worden MC en CU beschouwd als multigene ziekten. Waarschijnlijk 
zijn meerdere laagpenetrante genen, met elk apart een kleine bijdrage, geassocieerd met 
(verschillende fenotypes van) MC en CU. Voor genetisch onderzoek naar complexe geneti-
sche ziekten als IBD is het erg belangrijk om grote homogene cohorten van welomschreven 
patiënten te bestuderen. In 2001 is de CODE studie  (Chronische Ontsteking van de Darm en 
Erfelijkheid) gestart in het Universitair Medisch Centrum Groningen. Er is DNA verzameld 
van IBD patiënten van het Kaukasische ras en hun familieleden. Verder zijn alle patiënten 
fenotypisch beschreven volgens internationaal geaccepteerde classificatiesystemen zoals de 
Vienna classificatie voor MC. 
Een ander onderzoeksterrein binnen de IBD-genetica is de pharmacogenetica. Er is veel on-
derzoek gedaan naar het metabolisme van azathioprine. Azathioprine is een purine analoog, 
dat frequent gebruikt wordt in de behandeling van IBD. Het gebruik van azathioprine wordt 
echter ernstig beperkt door de bijwerkingen. Polymorfismen in de genen die coderen voor 
Thiopurinemethyltransferase (TPMT) en inosine triphosphatase (ITP-ase) zijn verantwoorde-
lijk voor een deel van de bijwerkingen van azathioprine. 
Dit proefschrift onderzoekt de genetische achtergrond van IBD. Het doel van het proefschrift 
is om specifieke genotype-fenotype associaties te vinden voor bekende genen en om nieuwe 
geassocieerde genen te ontdekken. In het eerste deel wordt de associatie voor twee nieuwe 1
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genen met IBD onderzocht. Het tweede deel bestaat uit drie studies waarin eerder gevonden 
associaties opnieuw worden belicht vanuit verschillende perspectieven. Het laatste deel richt 
zich op azathioprine therapie en toxiciteit bij IBD.
Hoofdstuk 1 is de introductie van dit proefschrift. De onderzoeksdoelen worden in dit hoofd-
stuk uiteengezet.
Het focus van dit proefschrift is gericht op specifieke genetische associaties met IBD. Daarom 
wordt er in hoofdstuk 2 eerst een uitgebreid overzicht gegeven van de recente literatuur 
over genetica en IBD. Ondanks veel onderzoek in muizenmodellen, patiënten en in vitro, is 
het nog steeds niet duidelijk hoe mutaties in CARD15 tot het ontstaan van MC lijden. Verder 
zijn er vele nieuwe kandidaat-genen ontdekt, waarvan sommige associaties werkelijk beves-
tigd zijn en er voor andere associaties veel conflicterende studies zijn.Veelbelovende genen 
zijn TLR4, MDR1, NOD1 (CARD4), DLG5 en het IBD5 locus op chromosoom 5 dat de genen 
SLC22A4/5 bevat. Verder wordt er in gegaan op het belang van een uniforme fenotypische 
classificatie en op de rol van pharmacogenetica in de behandeling van IBD. 
Het eerste deel van het proefschrift omvat twee studies die de associatie tussen twee nieuwe 
kandidaat genen en IBD onderzoeken. In Hoofdstuk 3 wordt er een case-control onderzoek 
verricht naar een associatie van het gen dat codeert voor de interleukin-receptor associated 
kinase-M (IRAK-M) en IBD. IRAK-M is een Nuclear Factor-κB (NF-κB) afhankelijke, negatieve 
regulator van Toll-like receptor signaaltransductie. Toll-like receptoren (TLRs) zijn, net als 
NOD2, een belangrijk onderdeel van het aangeboren afweersysteem. Eerdere studies toon-
den dat IRAK-M knock-out muizen een verminderde tolerantie hadden voor bacteriën en een 
verhoogde inflammatoire respons. Gezien de functie van IRAK-M als een negatieve regulator 
van de TLR-signaaltransductie en de lokalisatie van het gen in een IBD risicogebied op het 
genoom (IBD2) lijkt het een goede kandidaat voor associatie met IBD. We hebben 542 IBD 
patiënten (309 MC en 233 CU) en 305 controles bestudeerd. Twee single nucleotide polymor-
phisms (SNP’s) in exonen en 6 microsattelietmerkers werden geëvalueerd en de resultaten 
werden gestratificeerd voor de CARD15 status. SNP genotyperingen werden verricht middels 
Taqman PCR primer / probe sets volgens een gestandaardiseerd protocol. De PCR’s voor de 
microsatteliet markers  werden ook volgens een gestandaardiseerd protocol verricht. We von-
den geen verschil in distributie van de allelen tussen IBD-patiënten en controles. Wel vonden 
we dat dragerschap van een van de drie CARD15 mutaties in combinatie met een microsatte-
liet marker een verhoogd risico gaf op het ontstaan van CU. Gezien het feit dat er nooit eerder 
gevonden is dat CARD15 geassocieerd is met CU en de lage aantallen in deze subgroep is het 
de vraag of dit een echte associatie is of een vals positief resultaat.
In hoofdstuk 4 bestuderen we de genetische associatie voor RUNX3 met IBD. RUNX3 vormt 
samen met RUNX1 en RUNX2, de runt domain familie van transcriptiefactoren. Deze trans-
criptiefactoren worden in toenemende mate herkend als belangrijke factoren bij het ont-
staan van auto-immuunziekten. Er waren verschillende redenen om RUNX3 als kandidaat 
gen te onderzoeken. Ten eerste is het een belangrijke component van de TGF-β signaal-
route, welke een belangrijke anti-inflammatoire rol heeft bij IBD. Verder ontwikkelen Runx3 Nederlandse samenvatting en toekomstperspectieven
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knock-out muizen spontaan een colitis. En tenslotte ligt het coderende gen op chromosoom 
1p36, een risicogebied voor IBD, op het humane genoom. We bestudeerden 4 SNPs en 4 
microsattelietmerkers in en rond het gen RUNX3 in het CODE cohort. Daarnaast was uit een 
eerdere publicatie bekend dat de genen SLC22A4/5 in het IBD5 locus geassocieerd zijn met 
MC. Een ander artikel toonde dat een SNP die de bindingsplaats voor RUNX verstoort in 
SLC22A4 geassocieerd is met reumatoïde artritis. Daarom onderzochten we ook zes SNPs in 
en rond SLC22A4/5 en de interactie met RUNX3. We vonden een significante associatie voor 
RUNX3-SNP rs2236851 met CU (OR1.61; CI 1.11-2.32; p=0.020) en voornamelijk met panco-
litis ulcerosa (OR 1.86; CI 1.08-3.21). Deze associatie werd bevestigd door middel van TDT en 
haplotype sharing statistics. We vonden geen associatie voor de twee eerder beschreven SNPs 
-207G→C en 1672C→G in SLC22A4/5. Wel was er een associatie in geval van homozygotie 
voor SNPs rs272893 en rs273900 met MC ( OR respectievelijk 2.16; CI 1.21-3.59; p=0.008 en 
OR 2.40; CI 1.43-4.05; p=0.004). Binaire logistische regressieanalyse toonde een OR van 3.83 
(CI 1.26-11.67; p=0.018) voor CU wanneer een patiënt drager was van de risico SNP voor 
RUNX3 en homozygoot voor een van de twee risico SNP’s voor SLC22A4/5. 
Vervolgens hebben we de expressie van RUNX3 en OCTN mRNA (het eiwit waar SLC22A4 voor 
codeert) bepaald in ontstoken en niet ontstoken colon- en ileummucosa van 30 IBD patiën-
ten (16 MC en 14 CU) en 6 gezonde controles. Bij de controles is de expressie van RUNX3 
mRNA evenredig verdeeld in het colon en ileum en OCTN1 expressie is in het ileum hoger dan 
in het colon (p<0.00001). RUNX3 mRNA is toegenomen in ontstoken colon in vergelijking met 
niet ontstoken colon bij de CU patiënten (p=0.01). OCTN1 expressie lijkt lager in ontstoken 
colon in vergelijking met niet ontstoken colon (p=0.08) bij IBD. 
In dit hoofdstuk hebben we aangetoond dat RUNX3 betrokken is bij de pathogenese van CU. 
Een SNP in een intron van RUNX3 is genetisch geassocieerd met CU en RUNX3 mRNA is toe-
genomen in ontstoken colon in vergelijking met niet ontstoken colon. Verder vonden we een 
associatie voor SLC22A4/5 met IBD, alhoewel dit andere SNP’s betrof dan in eerdere publica-
ties gevonden werd. Verder lijkt er een epistatisch effect te zijn tussen RUNX3 en SLC22A4/5. 
Het volgende deel van het proefschrift bestaat uit drie studies die eerder beschreven geneti-
sche associaties voor IBD bestuderen en hiervoor verschillende benaderingen gebruiken.
In hoofdstuk 5 worden genetische varianten vergeleken tussen een groep volwassen MC 
patiënten (adult-onset) en een groep patiënten die MC ontwikkelden op de kinderleeftijd 
(pediatric-onset).  Op theoretische gronden kan gesteld worden dat genetische invloeden een 
belangrijkere rol spelen bij de ontwikkeling van MC op de kinderleeftijd dan bij het ontstaan 
van MC op de volwassen leeftijd. Pediatric-onset MC patiënten zijn minder lang blootgesteld 
aan omgevingsfactoren dan adult-onset MC patiënten en derhalve kan verondersteld worden 
dat MC-geassocieerde genetische varianten vaker voorkomen bij deze groep dan bij adult-
onset MC. Naast CARD15 en SLC22A4/5 zijn er ook associaties bekend voor DLG5 (Drosophila 
Discs Large Homologue 5) en de Toll-like receptor 4 (TLR4) en IBD. Het doel van de studie was 
om de frequentie van CARD15, TLR4, SLC22A4/5 en DLG5 varianten in pediatric-onset IBD te 
bepalen , deze data te vergelijken met adult-onset IBD en specifieke genotype-fenotype asso-
ciaties te analyseren. De drie bekende MC-geassocieerde mutaties in CARD15 (R702W, G908R 
en 3020insC) en Asp299Gly en Thr399Ile voor TLR4 werden bepaald. Verder werden 6 SNP’s in 1
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SLC22A4/5 (inclusief SNPs -207G→C en 1672C→T) en 4 haplotype-markerende SNP’s in DLG5 
(inclusief de eerder beschreven geassocieerde SNP 113G→A) bepaald in 103 pediatric-onset 
en 696 adult-onset IBD patiënten. 
Homozygotie voor 3020insC in CARD15 en homozygotie voor SNP rs3792876 in SLC22A4/5 
kwam significant vaker voor in pediatric-onset dan in adult-onset MC (respectievelijk 4.2% v 
0.6%; p= 0.04 en 6.1% v 1.1%; p=0.02). We vonden geen verschil in frequentie tussen beide 
groepen voor de andere SNPs. We vonden een associatie voor MC met lokalisatie in het ileum 
voor zowel de pediatric-onset als de adult-onset groep voor3020insC. Alhoewel de getallen 
in de pediatric-onset groep klein waren, is de conclusie dat de genetische component een 
belangrijkere rol speelt in het ontstaan van IBD bij pediatric-onset dan bij adult-onset MC. 
Recent zijn twee nieuwe MC-geassocieerde genen geïdentificeerd door middel van het gehele 
genoom overspannende case-control associatiestudies. De één is een zeldzame, coderende 
variant (rs11209026) in het gen dat codeert voor de interleukine-23 receptor (IL23R). Deze 
variant is geassocieerd met een sterk beschermend effect op het ontstaan van MC. Daarnaast 
bleek er ook een associatie te zijn met het ontstaan van CU bij niet-joodse patiënten. De an-
dere, rs2241880 in het autophagy-related 16-like 1 gen (ATG16L1) was geassocieerd met MC. 
Het is van enorm belang dat gevonden genetische associaties worden bevestigd in onafhan-
kelijke cohorten in andere landen. Daarom hebben we in hoofdstuk 6 een replicatiestudie 
verricht voor de twee sterkst geassocieerde SNPs in IL23R en ATG16L1 in 518 IBD patiënten 
(311 MC en 207 CU) en 893 gezonde controles. Daarnaast waren we geïnteresseerd of deze 
genen ook geassocieerd waren met andere chronische darmziekten. We hebben daarom een 
cohort van 508 patiënten met coeliakie geïncludeerd. DNA samples van de patiënten en de 
controles en 90 CEPH (Centre d’Etude du Polymorphisme Humain) samples vanuit het Inter-
nationale HapMap project werden gegenotypeerd middels matrix-assisted laser desorption 
ionization time-of-flight (MALDI-TOF).
SNP rs11209026 SNP in IL23R had een beschermend effect voor  IBD bij de  case-control ana-
lyse (OR=0.19; 95% CI: 0.10–0.37; p=6.6E-09). Dit gold zowel voor MC (OR=0.14; CI: 0.06-0.37; 
p=3.9E-07) als voor CU (OR=0.33; CI: 0.15-0.73; p=1.4E-03). Voor ATG16L1 was SNP rs2241880 
geassocieerd met MC (OR=1.36; CI: 1.12-1.66; p=0.0017). De population attributable risk voor 
MC is 0.24 wanneer er sprake is van dragerschap van het G-allel en 0.19 wanneer er sprake 
is van homozygotie is voor het G-allel. We vonden geen associatie voor IL23R of ATG16L1 met 
coeliakie. Onze resultaten bevestigen de genetische associatie voor IL23R met zowel MC als 
CU en voor ATG16L1 met MC.
Genetische associaties moeten niet alleen worden bevestigd in onafhankelijke cohorten, deze 
cohorten moeten ook voldoende power hebben om specifieke genotype-fenotype interacties 
te kunnen detecteren. Het is belangrijk om grote homogene cohorten met goede uniforme 
fenotypische beschrijvingen te hebben, om de genetische achtergrond te bestuderen van 
complexe ziekten als IBD. Er is daarom een groot nationaal samenwerkingsverband opge-
start vanuit de Initiative on Crohn and Colitis (ICC). Hierbij zijn al het beschikbare DNA en de 
fenotypische beschrijvingen van IBD patiënten uit zeven Universitaire Medische Centra in 
Nederland samengebracht. De resultaten van de associatie analyse voor DLG5, SLC22A4/5 en 
ATG16L1 met IBD, MC, CU en de verschillende fenotypes van MC en CU worden beschreven in 
hoofdstuk 7. Daarnaast wordt de interactie tussen deze genen bepaald. Nederlandse samenvatting en toekomstperspectieven
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2937 Patiënten (1696 MC, 1099 CU en 142 met indeterminate colitis) en 1484 gezonde con-
troles werden geïncludeerd. Fenotypische beschrijvingen waren beschikbaar voor 2090 pa-
tiënten (1315 MC / 775 CU). Er werden 8 SNP’s geanalyseerd voor SLC22A4/5. Deze set bevatte 
onder andere SNPs -207G→C en 1672C→T en SNP rs3792876 welke geassocieerd was met 
pediatric onset IBD in hoofdstuk 5. Daarnaast werden twee SNPs bepaald gelegen aan het 
3’ en het 5’ einde van het IBD5 locus om linkage disequilibrium met dit haplotype block te 
bepalen. Er werden 4 SNP’s bepaald voor DLG5 die dusdanig waren gekozen dat alle 4 ha-
plotypes uit het originele artikel konden worden geïdentificeerd. Verder werd SNP rs2241880 
bepaald voor ATG16L1.
Allereerst vonden we een associatie voor MC met het IBD5 haplotype. We vonden geen as-
sociatie met het de twee eerder beschreven SNPs 207G→C en 1672C→T. Wel vonden we dat 
SLC22A4/5 geassocieerd zijn met MC maar dat dit niet onafhankelijk was van het IBD5 locus. 
Er was sprake van een sterk linkage disequilibrium tussen alle SNPs in en rond SLC22A4/5. 
SLC22A4/5 kunnen dus wel de MC-geassocieerde genen zijn in het IBD5 locus, maar het is 
net zo waarschijnlijk dat andere genen in dit gebied de werkelijke MC-geassocieerde genen 
zijn. Verder vonden we dat het IBD5 locus geassocieerd is met het ontstaan van MC op jonge 
leeftijd en met een gecompliceerd ziektebeloop. 
Ten tweede vonden we een associatie voor de R30Q (rs1248696) variant in DLG5 en IBD. Ver-
rassend genoeg was de associatie sterker voor CU dan voor MC. Dit is een nieuwe bevinding, 
want in eerder publicaties worden er alleen associaties met MC beschreven.  Verder konden 
we de associatie voor P1371Q (rs2289310) met MC bevestigen, maar vonden we geen bescher-
mend effect voor de haplotype A markerende SNP. 
Ten derde konden we ook in dit cohort de associatie voor ATG16L1 met MC bevestigen.  De 
associatie werd met name gevonden voor MC met lokalisatie in het terminale ileum, met 
stricturerende ziekte en met chirurgische interventie. We vonden geen associatie met CU of 
met andere fenotypes. 
Vervolgens hebben we de interactie tussen de genen geanalyseerd, door gebruik te maken 
van de sterkst met MC-geassocieerde SNP’s in elk gen. We konden geen specifieke interactie 
vinden tussen de genen. MC patiënten hadden echter wel significant meer risicoallelen dan 
controles. Vervolgens konden we aantonen dat het risico op het ontstaan van MC toeneemt 
met het aantal risicoallelen. Dit is voor het eerst dat dit aangetoond is voor MC en past in het 
concept dat er meerder genen betrokken zijn bij het ontstaan van MC, die elk onafhankelijk 
bijdragen aan het ontstaan van de ziekte. Verder hebben we middels ordinale regressie ana-
lyse aangetoond dat een gecompliceerd beloop van de ziekte (stricturerende of penetrerende 
ziekte en chirurgische interventie) geassocieerd was met een toenemend aantal risicoallelen. 
Dit is een belangrijke bevinding omdat het in de toekomst mogelijk moet zijn om een gene-
tisch risicoprofiel van een MC patiënt te maken om het verloop van de ziekte te voorspellen.
Tenslotte bestuderen we in hoofdstuk 8 de incidentie van bijwerkingen van azathioprine in 
patiënten met  verschillenden ziekten. De studie is in het bijzonder gericht op het ontstaan 
van azathioprine- geïnduceerde pancreatitis, wat voorkomt bij de behandeling van MC, maar 
zelden of nooit wanneer azathioprine gebruikt wordt voor andere ziekten. We hebben een 
retrospectieve studie verricht van 1564 patiënten die azathioprine gebruikten na een lever 1
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of een niertransplantatie, voor systemische lupus erythematosis, Wegener’s granulomatosis, 
autoimmuun hepatitis, reumatoïde arthritis, CU of MC. We vonden dat acute pancreatitis ten 
gevolge van azathioprine bij 11 van de 224 (4.9%) patiënten met MC ontstond. Dit is significant 
(p<0.05) vaker dan bij autoimmuun hepatitis (2 / 129 - 1.5%), na niertransplantatie (2 / 388 
– 0.5%), na levertransplantatie (1 / 254 – 0.4%), bij systemische lupus erythematosis (0 / 73), 
Wegener’s granulomatosis (0 / 85) , reumatoïde artritis (0 / 317) en CU (0 / 94).  Verder moesten 
patiënten met MC (23.2%), CU (21.3%) en reumatoïde artritis (24.6%) vaker stoppen met azathi-
oprine ten gevolge van alle bijwerkingen dan de andere patiënten groepen (p<0.05).
De conclusie is dat azathioprine-geïnduceerde acute pancreatitis sterk geassocieerd is met 
MC en zelden ontstaat wanneer azathioprine gebruikt wordt voor andere ziekten en dat aza-
thioprine vaker gestopt wordt in verband met de bijwerkingen bij IBD en reumatoïde artritis 
dan bij andere ziekten.     
De oorzaak van azathioprine geïnduceerde acute pancreatitis is onbekend.Het feit dat  wij 
een sterke associatie vonden met MC suggereert een ziekte specifiek mechanisme. Circule-
rende antilichamen tegen het pancreas (Pancreatic antibodies – PAB) worden in ongeveer 
30% van alle MC patiënten gevonden en niet bij gezonde controles of patiënten met andere 
gastrointestinale aandoeningen. Aangezien zowel PAB als azathioprine geïnduceerde acute 
pancreatitis specifiek zijn voor MC, kan een associatie of pathogene rol worden veronder-
steld. Een mogelijkheid zou kunnen zijn dat azathioprine een acute verergering uitlokt van 
een al enigszins ontstoken pancreas bij PAB positieve MC patiënten. We onderzochten nog 
de aanwezigheid van PAB in acht MC patiënten met een azathioprine-geïnduceerde pancre-
atitis en in 26 controles met MC. We vonden geen verschil in prevalentie in beide groepen 
en konden derhalve onze hypothese niet bevestigen. Wel vonden we een lagere frequentie 
(12%) van PAB in vergelijking met eerdere studies bij MC.Nederlandse samenvatting en toekomstperspectieven
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Toekomstperspectieven
Er zijn verschillende vragen waarop het onderzoek naar de genetische achtergrond van IBD 
zich in de toekomst zal richten. 
1.  Op welke manier zullen nieuwe genetische associaties met IBD worden vast   
  gesteld? Hoe zullen associaties met specifieke fenotypes worden gevonden?
2.  Wanneer een genetische associatie gevonden en bevestigd is: Hoe is dit gen    
  – en de gevonden  mutaties - betrokken bij het ontstaan en het beloop van IBD?
3.  Hoe zullen deze bevindingen worden vertaald naar de behandeling van de    
  patiënt? Wat zal de rol zijn van “pharmacogenetics” bij de behandeling van IBD?
4.  Zal de genetische achtergrond een rol spelen in het classificeren van IBD patiënten?
1. Toekomstige studies naar nieuwe IBD-geassocieerde genen 
In de afgelopen jaren zijn er zeer veel kandidaat-gen studies verricht, waarin de associatie 
met een specifiek gen met IBD werd onderzocht. Veel van deze studies hebben positieve 
resultaten opgeleverd, maar er zijn maar weinig van deze associaties bevestigd in onaf-
hankelijke cohorten. Derhalve is er ook veel discussie over de waarde van kandidaat-gen 
studies in complexe ziekten als IBD. Genen met een hoog relatief risico zoals CARD15 zullen 
worden geïdentificeerd. Echter, niet alleen tussen MC en UC, maar vrijwel zeker ook binnen 
de twee aandoeningen zijn er belangrijke verschillen in de pathogenese. Dit komt waar-
schijnlijk omdat meerdere genen elk met een lage penetrantie en kleine bijdrage aan de 
pathogenese betrokken zijn bij het ontstaan van verschillende fenotypes van IBD. Nieuwe 
genetische associaties zullen dan ook moeilijker te vinden zijn dan CARD15 en het is dan 
ook te betwijfelen of kandidaat-gen studies in kleine lokale cohorten genoeg power hebben 
om deze te vinden.
Recent zijn de resultaten van de eerste het gehele genoom omvattende case-control analyses 
bij IBD gedaan waarbij 100.000 tot 500.000 geselecteerde SNP’s verspreid over het genoom 
werden geanalyseerd. Deze SNP’s werden bepaald in een homogeen cohort IBD patiënten (in 
het geval van IL23R bij MC patiënten met lokalisatie in het terminale ileum). De gevonden 
associaties werden vervolgens bevestigd in onafhankelijke MC en CU cohorten. Ook wij kon-
den deze associaties bevestigen in ons cohort. Ten gevolge van de enorme hoeveelheid SNP’s 
en de daaraan inherente statistische deviaties, zullen er altijd nog werkelijk geassocieerde 
genen onontdekt blijven met deze benadering. Het is daarom zeker nog zinvol om dergelijke 
genoom omspannende associatie-analyses te verrichten in onafhankelijke cohorten. Dit zou 
bijvoorbeeld gedaan kunnen worden in een andere subgroep van IBD met een welomschre-
ven fenotype, zoals pancolitis ulcerosa. 
Een ander belangrijk aspect is dat alle gevonden genetische associaties bestudeerd zijn 
bij IBD patiënten van het Kaukasische ras. CARD15 blijkt bijvoorbeeld niet geassocieerd te 
zijn met IBD in de Aziatische populatie. Waarschijnlijk zijn bij verschillende rassen andere 
genen betrokken bij het ontstaan van IBD. In de toekomst zullen er dan ook goede studies 
moeten worden verricht in cohorten IBD patiënten van verschillende rassen.1
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Om specifieke genotype-fenotype associaties te vinden moeten grote cohorten worden be-
studeerd. Daarom hebben we binnen de Initiative on Crohn and Colitis (ICC), een landelijk 
samenwerkingsverband tussen alle Universitair Medische Centra in Nederland, een project 
opgestart op het gebied van IBD-genetica. We hebben hierbij alle DNA samples van zeven uni-
versitair medische centra verzameld en een nationale DNA database opgezet. Van een groot 
deel van deze patiënten zijn adequate uniforme fenotypische beschrijvingen beschikbaar. 
Voor studies naar de genetische achtergronden van IBD zijn grote samenwerkingsverbanden 
noodzakelijk met specifieke infrastructuren, voldoende financiële ondersteuning en zoge-
naamde “high throughput” platformen die grote hoeveelheden SNPs kunnen analyseren.
2. Genetica en functionele studies
Wanneer een genetische associatie bij herhaling bevestigd is in onafhankelijke cohorten, is 
de volgende vraag hoe een specifiek gen en de gevonden mutaties betrokken zijn bij de pa-
thogenese van IBD. In het geval van CARD15 zijn er, ondanks veel onderzoek, tegenstrijdige 
bevindingen in de literatuur. De vraag of er sprake is van een toename of een afname van de 
functie van NOD2 is tot op heden maar gedeeltelijk beantwoord. Voor bijvoorbeeld mutaties 
in IL23-R, die een beschermend effect hebben op het ontstaan van IBD, is het te verwachten 
dat een defecte IL23 receptor de IL23 gedreven intestinale ontsteking onderdrukt. Op dit mo-
ment worden er verschillende studies naar dit onderwerp gedaan. Voor andere geassocieerde 
genen zoals ATG16L1 en DLG5 is er nauwelijks informatie beschikbaar over hun rol in de 
pathogenese van IBD. Basale wetenschappers, genetici en clinici zullen nauw moeten samen-
werken om de functionele implicaties van gevonden genetische associaties te bestuderen. 
3. Genetica en de behandeling van IBD
IBD komt voornamelijk voor bij jonge mensen en kan tot ernstige morbiditeit leiden. De 
ziekte kan grote invloed hebben op de kwaliteit van leven ten gevolge van de ziekteactiviteit 
maar ook ten gevolge van operaties en bijwerkingen van medicijnen. 
Er zijn genetische polymorfismen bekend die verantwoordelijk zijn voor bijvoorbeeld een 
deel van de bijwerkingen van azathioprine. Pharmacogenetisch onderzoek zal er op gericht 
zijn om patiënten te identificeren die wel of geen bijwerkingen op specifieke medicamenten 
zullen ontwikkelen. Daarnaast zal het in de toekomst misschien ook mogelijk zijn om patiën-
ten te identificeren die in meer of mindere mate zullen responderen op specifieke medicatie 
(bijvoorbeeld door het bepalen van polymorfismen in glucocorticoïd receptoren of tumor 
necrosis-α receptoren.)
Tegenwoordig worden er veel zogenaamde “biologicals” onderzocht voor de behandeling 
van IBD. De meeste van deze “biologicals” zijn gehumaniseerde antilichamen of fragmen-
ten daarvan. Deze antilichamen zijn gericht tegen specifieke componenten van de inflam-
matoire cascade van IBD. Dit onderstreept nogmaals het feit dat basaal immunologisch en 
genetisch onderzoek noodzakelijk is om deze inflammatoire mechanismen te doorgronden. 
Daarnaast dient ook de maag-darm-leverarts die patiënten behandelt, kennis te hebben van 
deze mechanismen, omdat de “biologicals” waarschijnlijk de belangrijkste componenten zul-
len zijn voor de behandeling van IBD in de nabije toekomst.Nederlandse samenvatting en toekomstperspectieven
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4. Genetica en de classificatie van patiënten
Voor wetenschappelijk onderzoek naar IBD, dienen patiënten uniform en volgens interna-
tionaal geaccepteerde classificatiesystemen te worden beschreven. Recent is er een update 
verschenen van de Vienna classificatie: de Montreal classificatie die goed bruikbaar lijkt voor 
zowel MC als CU. Naast genetische associaties zijn er ook in toenemende mate circulerende 
antilichamen (Antineutrophil cytoplasmic antibodies - ANCA, antibodies against Saccharomy-
ces cerevisiae – ASCA etc ) geïdentificeerd die met specifieke fenotypes van IBD zijn geassoci-
eerd. Het doel is om tot een classificatieschema te komen waarin de klinische (fenotypische) 
beschrijving, de circulerende antilichamen en de genetische polymorfismen in kunnen wor-
den geïncorporeerd. Dit kan clinici helpen om het toekomstige ziekteverloop van een patiënt 
te voorspellen en het beleid daarop aan te passen.155
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